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Abstract 
 
The Far-UpStream Element (FUSE) regulatory system tightly controls             
the expression of c-myc proto-oncogene – a master regulator of cellular proliferation 
and differentiation. The FUSE mechanism relies on the inter-molecular interactions 
between a DNA regulatory sequence – the FUSE, a transcriptional activator – FUSE-
Binding Protein (FBP) and a transcriptional repressor – FBP-Interacting Repressor 
(FIR). The FUSE DNA element serves as a sensor of the level of ongoing c-myc 
transcription. The FBP and FIR proteins bind sequentially to the FUSE, first to rapidly 
increase the expression (FBP) and then to cease it (FIR). Crucial for the regulation is     
a FBP – FIR interaction that acts as a transcriptional on/off switch. 
In my thesis, I used Nuclear Magnetic Resonance (NMR) Spectroscopy             
to determine a high resolution structure of the first two RNA Recognition Motifs 
(RRMs) of FIR (FIR RRM1-RRM2) alone and in the complex with an Nbox peptide 
derived from the FBP protein. The structural details provided explain how a low affinity 
but specific interaction between FBP and FIR is achieved. Further studies, using NMR 
and BioLayer Interferometry (BLI), explored the interplay between the three 
components in the FUSE regulatory system. The results show that FIR RRM1-RRM2 
provides independent binding sites for the FUSE and FBP protein and that both FBP 
and FIR proteins are able to bind simultaneously to the DNA. Furthermore, FBP protein 
tethers FIR to the DNA, thereby contributing to the control of the transcriptional switch. 
In summary, these data extend our understanding of the c-myc proto-oncogene 
regulation and suggest a strategy for controlling c-myc expression in cancerous cells. 
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1.1 Physiological role of the c-MYC protein 
 
The myc oncogene was identified in 1978 as a transforming sequence of the M29 
avian tumour virus, an infectious agent of myelocytomatosis (myc) (Sheiness et al., 
1978). Soon afterwards cellular homologues of myc (c-myc) were discovered in birds 
(Sheiness and Bishop, 1979) and in humans (Collins and Groudine, 1982). In the past 
30 years the transforming potential of c-myc has led to a sustained effort to understand 
its role in cell growth and proliferation, and in cancer. However, c-myc biology is very 
complex and many questions still remain unanswered (Meyer and Penn, 2008). 
c-MYC is a member of the human MYC protein family (together with L-MYC 
(small cell lung cancer-related MYC (Nau et al., 1985)) and N-MYC (neuroblastoma-
related MYC (Schwab et al., 1983)). The protein has a broad spectrum of functions – it 
stimulates cell cycle progression, enables cell growth, blocks differentiation, induces 
apoptosis, activates angiogenesis, induces genome instability and causes transformation 
(Figure 1A) (Oster et al., 2002). c-MYC regulates transcription of 10-15% of human 
genes comprising transcription factors, mRNA metabolism proteins, cell cycle proteins, 
mitochondrial proteins, DNA repair factors, telomerases and cytokines (Dang et al., 
2006; Eilers and Eisenman, 2008; Levens, 2002; Wierstra and Alves, 2008). It also 
affects transcription of many non-coding RNAs, including tRNAs, rRNAs and miRNAs 
(Kenneth and White, 2009). Recently c-MYC has been implicated in a direct 
(transcription-independent) regulation of global chromatin structure, translation and 
DNA replication (Figure 1B) (Cole and Cowling, 2008; Herold et al., 2009; Knoepfler, 
2007). 
c-MYC functions as an activator and as a repressor and its effect on                 
the expression of any single gene is relatively modest (Knoepfler, 2007; Oster et al., 
2002). The activation function of c-MYC is linked to the MYC/MAX/MAD system 
(Wierstra and Alves, 2008). c-MYC and MAX dimerisation protein (MAD) are short 
lived and they regulate target genes antagonistically (Wierstra and Alves, 2008). Both  
c-MYC and MAD proteins heterodimerise with a ubiquitous and stable MYC-
associated factor-X (MAX) via a common basic-helix-loop-helix/leucine zipper 
(bHLHLZ) dimerisation domain and, as a heterodimer, bind to E-box (5’-CACGTG-3’) 
sequences in the promoters of regulated genes (Nair and Burley, 2006; Oster et al., 
2002; Wierstra and Alves, 2008). The MYC/MAX heterodimer can activate expression 
19 
 
Figure 1 c-MYC has multiple functions in the cell. A) A summary of processes 
controlled by c-MYC. B) The different modes of action of c-MYC. 
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via at least three different mechanisms: 1) recruitment of histone acetyltransferase 
(HAT) complexes to the promoter, 2) recruitment of ATP-dependent chromatin 
remodelling complexes to the promoter and 3) induction of promoter clearance of       
the RNA polymerase II at the target promoter (Oster et al., 2002). The MAD/MAX 
heterodimer represses expression of target genes by recruiting histone deacetylase 
(HDAC) complexes to the promoter (Wierstra and Alves, 2008). 
c-MYC-mediated repression does not involve direct binding of the protein to 
DNA (Oster et al., 2002). Instead, c-MYC interferes with the function of different 
activatory factors that act via initiator elements (Inr) (e.g. YY1, TFII-I, Miz-1) or other 
DNA regulatory sequences (e.g. NF-Y, Sp1/Sp3) present in the regulated promoters 
(Oster et al., 2002). 
The global chromatin remodelling function of c-MYC is based on                    
the recognition of target sequences in the DNA and a balance between c-MYC/MAX 
heterodimers, which recruit HAT complexes, and MAX/MAD heterodimers, which 
recruit HDAC complexes (Knoepfler, 2007). Unlike in transcriptional regulation        
the target DNA sequences are both genic and intergenic and this allows extensive 
modification of the balance between euchromatin and heterochromatin (Knoepfler, 
2007). 
c-MYC also increases translation of specific mRNAs (e.g. cyclin T1, CDK9) by 
enhancing recruitment of cap RNA methyltransferase and promoting 5’ mRNA guanine 
methylation, which is essential for protein-coding gene expression (Cole and Cowling, 
2008). 
Finally, c-MYC localises to the early sites of DNA replication and interacts with 
numerous components of the pre-replicative complex, probably playing a role in origin 
selection (Cole and Cowling, 2008; Herold et al., 2009). 
 
 
 
1.2 c-MYC and cancer 
 
Because c-MYC has so many important physiological roles the deregulation of   
c-myc expression is likely to be detrimental for the cell (Vita and Henriksson, 2006). 
Indeed, since its discovery c-MYC has been shown to be a very strong activator of 
21 
carcinogenesis and has been linked to a broad range of cancer pathologies, including 
Burkitt’s and non-Burkitt’s lymphomas, breast cancer, prostate cancer, gastrointestinal 
cancer, melanoma, multiple myeloma and myeloid leukaemia (Nesbit et al., 1999; Oster 
et al., 2002; Vita and Henriksson, 2006). The vital role of c-MYC as a regulator of     
the cell’s destiny is emphasised by the fact that it is one of the four transcription factors 
that together reprogram somatic cells to induced pluripotent stem (iPS) cells (Eilers and 
Eisenman, 2008; Takahashi and Yamanaka, 2006). Although c-MYC is not necessary 
for the generation of iPS, it substantially increases the efficiency of this process 
(Nakagawa et al., 2008). 
In spite of the clear transforming potential of c-MYC initial studies failed to 
identify mutations in the coding sequence of the gene in transformed cells (Meyer and 
Penn, 2008). However, subsequent studies linked c-MYC function in tumorigenesis to 
three types of large genome rearrangements at the c-myc locus: 1) insertional 
mutagenesis, 2) chromosomal translocation, and 3) amplification (Meyer and Penn, 
2008). Insertional mutagenesis relies on insertion of viral sequences into the c-myc 
locus that enhance gene expression (Meyer and Penn, 2008). Chromosomal 
translocations result in juxtaposition of the c-myc gene to potent activatory elements,   
as in Burkitt’s lymphoma where an immunoglobulin enhancer drives a high level of     
c-myc production (Meyer and Penn, 2008; Nesbit et al., 1999; Vita and Henriksson, 
2006; Wierstra and Alves, 2008). Finally, gene amplification increases gene dosage in 
the cell and leads to increased c-MYC activity (Meyer and Penn, 2008; Nesbit et al., 
1999). 
Further studies have shown that c-MYC can be deregulated not only by genome 
rearrangements but also by a broad spectrum of direct and indirect mechanisms that 
target its expression and/or activity, including an activated upstream signalling cascade, 
point mutations within coding and non-coding c-myc sequences, enhanced translation 
and increased protein stability (Meyer and Penn, 2008; Nesbit et al., 1999; Oster et al., 
2002; Vita and Henriksson, 2006). Two well studied examples are point mutation of 
T58 in c-MYC (observed in Burkitt’s lymphomas) (Oster et al., 2002) and increased 
stability of β-catenin, a co-activator for the TCF-4 transcription factor (observed in 
gastrointestinal cancers) (Nesbit et al., 1999; Oster et al., 2002). Mutation of T58 
abolishes phosphorylation at this residue – this leads to inefficient ubiquitination and 
stabilisation of the c-MYC protein (Oster et al., 2002). β-catenin is usually sequestered 
in the cytoplasm by the APC protein, which promotes its degradation (Nesbit et al., 
22 
1999). Mutations that disrupt protein–protein interactions (either in β-catenin or in 
APC) have been found in cancers with increased c-MYC production (Nesbit et al., 
1999). The stabilised β-catenin enters the nucleus and enhances a function of the TCF-4 
transcription factor that targets the c-myc proto-oncogene (Nesbit et al., 1999). 
No single function of c-MYC has been correlated with its transforming potential 
and it is generally accepted that tumorigenesis is a result of global deregulation of      
the cell cycle, differentiation, cell growth, genome instability and angiogenesis (Meyer 
and Penn, 2008). Importantly, c-MYC also activates apoptosis, which serves as a safety 
valve to eliminate the cells with misregulated c-myc (Meyer and Penn, 2008; Wierstra 
and Alves, 2008). In cancerous cells c-myc deregulation is always accompanied by 
disruptions of the apoptotic pathways that immortalise the cells (Meyer and Penn, 
2008). Concurrently, resurrecting apoptotic mechanisms in c-MYC-driven tumours 
leads to increased mortality of transformed cells (Goga et al., 2007). 
Various anti-cancer strategies have been developed to target c-MYC either by 
decreasing its level (e.g. by blockage of c-myc expression at the DNA, mRNA or 
protein level, or by promotion of c-MYC protein degradation) or by modulating c-MYC 
function (e.g. by disruption of the c-MYC/MAX interaction, or by inhibition of          
the expression of c-MYC target genes) (Vita and Henriksson, 2006). However, only 
recently a direct evidence that c-MYC inhibition could be an efficient therapy was 
demonstrated in a mouse model (Soucek et al., 2008). 
 
 
 
1.3 Regulation of c-myc expression 
 
c-myc expression is strictly correlated with cellular proliferation (Figure 2) 
(Wierstra and Alves, 2008). In quiescent cells c-MYC is practically absent – one 
transcript and 500 protein molecules per resting fibroblast (Chung and Levens, 2005; 
Wierstra and Alves, 2008). Upon mitogen stimulation the protein is immediately and 
robustly produced and this drives the cell into the G1 phase (Wierstra and Alves, 2008). 
The peak of expression (measured by the mRNA level) is observed 2 h post-stimulation 
and results in a 10- to 40-fold increase in the amount of protein that quickly drops to     
a lower level that is kept steady in proliferating cells – as long as growth factors are 
23 
 
Figure 2 c-myc expression throughout the cell cycle (adapted from Wierstra and Alves, 
2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 
present (Liu et al., 2006; Wierstra and Alves, 2008). Anti-proliferation, differentiation 
or starvation signalling results in a rapid decline in c-myc expression (Wierstra and 
Alves, 2008). 
The rapid regulation of c-MYC concentration in response to signalling relies on 
a fast turnover of the protein in the cell (Chung and Levens, 2005; Wierstra and Alves, 
2008). Low abundance and short half-lives (20-30 min.) of c-MYC mRNA and protein 
are important factors that allow a rapid switch in the activation of the c-myc (Chung and 
Levens, 2005; Wierstra and Alves, 2008). Furthermore, the multiple levels at which     
c-myc expression is regulated potentiate the possibilities for efficient up- and down-
regulation during the cell cycle (Wierstra and Alves, 2008). However, at the same time 
the proto-oncogene has to be tightly controlled to protect the cells from the deleterious 
effect of its over-expression (Chung and Levens, 2005). The necessity to combine these 
two conflicting requirements makes the regulatory network of c-myc expression very 
complex (Chung and Levens, 2005; Meyer and Penn, 2008; Wierstra and Alves, 2008). 
The sophisticated post-transcriptional regulation of c-myc ensures rapid 
clearance of c-MYC mRNA and protein in the absence of pro-proliferating signalling 
(Chung and Levens, 2005; Wierstra and Alves, 2008). The c-MYC mRNA has two 
independent instability determinants: 1) the coding region determinant (CRD) located in 
the sequence corresponding to the C-terminal domain of the protein and 2) the adenine- 
uracil-rich element (ARE) located in the 3’ untranslated region (3’-UTR) (Meyer and 
Penn, 2008). CRD is specifically recognised by a CRD-binding protein (CRD-BP) that 
protects c-MYC mRNA against endonucleolytic cleavage (Bernstein et al., 1992; 
Prokipcak et al., 1994; Sparanese and Lee, 2007). Normally CRD-BP is expressed only 
in foetal tissues but it has also been detected in cancerous cells (Ioannidis et al., 2003). 
AREs are recruiting elements for ARE-binding proteins (ABPs), trans-acting factors 
that regulate the rate of c-myc mRNA decay via deadenylation, decapping and then    
the exosome-mediated 3’-5’ degradation pathway (Barreau et al., 2005). 
The fast turnover of c-MYC protein relies on proteasomal degradation and is 
driven by at least two ubiquitin ligases that act in phosphorylation dependent (FBW7) 
and independent (SKP2) ways (Amati, 2004; Eilers and Eisenman, 2008). The two 
ligases recognise different regions of c-MYC and have different biological roles – as 
tumour suppressor (FBW7) and as proto-oncogene (SKP2) (Amati, 2004). 
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1.4 Complexity of c-myc proto-oncogene transcription 
 
 c-myc proto-oncogene is located in the human chromosome 8 (Wierstra and 
Alves, 2008). The locus is extensively regulated via chromatin remodelling and          
the methylation and acetylation state of histones correlates with c-myc transcription 
activity and cellular proliferation (Wierstra and Alves, 2008). The gene has four distinct 
transcription start sites (P0, P1, P2 and P3) and two polyadenylation sites, which are 
utilised with different frequencies (Wierstra and Alves, 2008). The role of these 
alternative transcripts is not clear, but it has been observed, for example, that the ratio of 
P1 : P2 transcription start sites usage is increased from 1 : 10 – 1 : 5 in normal cells to   
1 : 1 and higher in abnormal cells (Wierstra and Alves, 2008). 
 No single regulatory pathway is alone responsible for the physiological 
activation of the c-myc promoter. Instead, the promoter is responsive to multiple inputs 
from over 30 different transcription factors that bind to distinct cis regulatory sequences 
spread over a DNA region some 3 kbp in length (Wierstra and Alves, 2008). These 
transcription factors are the effectors of different signalling pathways which are in turn 
activated by a range of extracellular signals including growth factors (e.g. PDGF, EGF), 
mitogens (e.g. LPS, anti-CD3), hormones (e.g. glucocorticoids, testosterone), vitamins 
(e.g. vitamin A and D) and cytokines (e.g. TNF, IL-1) (Wierstra and Alves, 2008). 
Furthermore, the c-MYC protein directly and indirectly affects the c-myc expression 
level (Wierstra and Alves, 2008). The direct regulation is a typical negative feedback 
loop where c-MYC dimerises with MAX and interferes with activation driven by      
Inr-binding and E2F transcription factors (Wierstra and Alves, 2008). The indirect 
mechanisms can provide both positive and negative inputs to the c-myc promoter 
because c-MYC acts as an activator/repressor of its own activators/repressors (Wierstra 
and Alves, 2008). 
 The large number of inputs of similar importance minimises transcriptional 
noise and therefore the risk of unwanted c-myc expression (Chung and Levens, 2005). 
This guarantees tight control of c-myc, but could hinder effective (rapid) activation as 
many different transcription factors would have to act concurrently to significantly 
increase the level of transcription (Chung and Levens, 2005). A rapid response is 
possible because 1) there is a paused polymerase II complex at the promoter that simply 
has to be released, saving the time that would be required for assembly of the whole 
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complex, and 2) an additional regulatory mechanism, called FUSE–FBP–FIR, provides 
a positive feedback loop regulation (Chung and Levens, 2005; Liu et al., 2006; Nechaev 
and Adelman, 2008; Wierstra and Alves, 2008). 
 
 
 
1.5 The FUSE–FBP–FIR regulatory system 
 
The FUSE–FBP–FIR system is designed to assure a rapid regulation of c-myc 
transcription in proliferating cells, accurately shaping the peak of c-myc expression 
(Chung and Levens, 2005; Liu et al., 2006; Wierstra and Alves, 2008). The FUSE 
mechanism rapidly up- and down-regulates the expression of c-myc in response to its 
own transcription and therefore c-myc transcription regulation may be considered as      
a two-step regulation (Liu et al., 2006; Wierstra and Alves, 2008). First, in response to 
multiple inputs at the promoter a decision is made to initiate c-myc expression by 
increasing the escape of the paused polymerase (Liu et al., 2006; Wierstra and Alves, 
2008). Then the regulation of the transcription is taken over by the FUSE–FBP–FIR 
mechanism that further drives the expression of the gene (Liu et al., 2006; Wierstra and 
Alves, 2008). 
The FUSE mechanism is based on a cis DNA regulatory element called far-
upstream element (FUSE) and two trans-acting proteins – the FUSE-binding protein 
(FBP) and the FBP-interacting repressor (FIR) (Liu et al., 2006). The FUSE is             
an AT-rich element located 1.7 kbp upstream of the c-myc P2 transcription start site 
(Avigan et al., 1990). The actively transcribing RNA polymerase II is one of the most 
potent generators of torsional stress and introduces an overtwisting in the DNA helix 
downstream of the polymerase (positive torsional stress) and an undertwisting in        
the DNA helix upstream of the polymerase (negative torsional stress) (Kouzine and 
Levens, 2007). The force generated upstream of the promoter during transcription is 
sufficient to melt the double-stranded FUSE DNA regulatory element that is indeed 
found in a single-stranded conformation in proliferating cells (Bazar et al., 1995; 
Duncan et al., 1994; He et al., 2000; Kouzine et al., 2004; Kouzine et al., 2008; 
Michelotti et al., 1996). The FBP and FIR proteins both bind to the single non-coding 
strand of the FUSE (ssFUSE) and act respectively as an activator and a repressor 
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(Avigan et al., 1990; Duncan et al., 1994; He et al., 2000; Liu et al., 2000; Liu et al., 
2006; Michelotti et al., 1996). The FUSE DNA works as a sensor that detects a low 
level of c-myc transcription initiated by multiple inputs into the promoter and switches 
on the FUSE–FBP–FIR regulatory system to rapidly up-regulate c-myc expression (Liu 
et al., 2006). 
Liu et al. have proposed a model of the FUSE–FBP–FIR mechanism that can be 
summarised as three steps: 1) initiation of c-myc transcription in response to 
environmental signals that leads to the melting of FUSE; 2) a boost in transcription 
caused by the FBP protein and 3) shut off of the transcription by the FIR protein  
(Figure 3) (Liu et al., 2006). In resting cells the c-myc proto-oncogene is silent:           
the FUSE element is masked by a nucleosome and there is a paused pre-promoter 
escape complex at the P2 transcription start site (Liu et al., 2006; Michelotti et al., 
1996). Upon activation, which can be triggered by many concurrently and/or 
sequentially acting factors, the rate of escape of the paused polymerase is augmented 
and this leads to an increase in transcription (Liu et al., 2006). Simultaneously, 
chromatin remodelling proteins are recruited to unmask the FUSE element (Liu et al., 
2006; Michelotti et al., 1996). The ongoing transcription causes an accumulation of 
negative torsional stress upstream of the c-myc proto-oncogene, which melts the FUSE 
DNA and makes it single-stranded (Kouzine et al., 2004; Kouzine et al., 2008; Liu et 
al., 2006). Only then is the FBP protein recruited – it interacts with transcription factor 
TFIIH and establishes a loop with the transcriptional machinery (He et al., 2000; Liu et 
al., 2001; Liu et al., 2006). FBP increases the 3’-5’ helicase activity of the XPB subunit 
of TFIIH boosting c-myc transcription (Liu et al., 2001; Liu et al., 2006). FBP-mediated 
stimulation may be a more complex process as TFIIH acts at multiple steps during 
transcription initiation and elongation (Weber et al., 2005). The increase in productive 
transcription mediated by FBP binding to TFIIH introduces additional twists into        
the DNA, increasing the negative torsional stress and melting a larger section of         
the FUSE (Liu et al., 2006). Subsequently, the FIR protein is recruited to the FBP–
FUSE complex (Liu et al., 2006). FIR also interacts with the XPB subunit of TFIIH and 
suppresses its 3’-5’ helicase activity, slowing down the transcription (Liu et al., 2000; 
Liu et al., 2006). The torsional stress is gradually dissipated by topoisomerases and this 
leads to re-annealing of the FUSE sequence and dissociation of the FBP (Liu et al., 
2006). Dissociation of the activator leads to a further decrease of transcription, ejection 
of FIR and complete re-annealing of the FUSE (Liu et al., 2006). The FUSE again  
28 
Figure 3 Proposed model of FUSE–FBP–FIR regulation of c-myc proto-oncogene 
(adapted from Liu et al., 2006). A) In non-proliferating cells, the FUSE is masked by    
a nucleosome while a pre-promoter escape complex (PPC) is paused at the P2 c-myc 
promoter. B) A stimulating event converts PPC into an elongation complex (EC) and 
causes chromatin remodelling, which unmasks the FUSE. C) The resulting transcription 
creates negative supercoiling upstream of c-myc that melts the FUSE element, which 
then recruits the FBP. FBP contacts the TFIIH at the c-myc promoter and boosts 
transcription to create a peak in expression. D) As transcription proceeds                     
the topologically closed FBP–TFIIH loop accumulates negative supercoiling leading to 
further melting of the FUSE. This causes FIR to be recruited via interactions with       
the ssFUSE DNA and FBP and TFIIH proteins. E) FIR represses transcription, 
decreasing the dynamic stress. This leads to FBP ejection. A) The low level of 
transcription causes dissociation of the polymerase from the PPC complex. Finally, 
without activation, the torsional stress is dissipated, FIR dissociates and the c-myc 
promoter becomes silent. 
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becomes masked by a nucleosome and the promoter is again silent (Liu et al., 2006). 
This complex mechanism allows the rapid up- and down-regulation of c-myc 
expression, creating a peak in the mRNA level that reaches a maximum at ~ 2 h post-
stimulation and ends within the following ~ 4 h (Liu et al., 2006). This model is 
supported by two observations: 1) a mutation in TFIIH that abolishes the creation of the 
loop between FUSE and the transcription start site changes the expression profile of     
c-myc and 2) the same mechanism can be employed to reprogram expression from an 
unrelated promoter if a FUSE element is inserted in the appropriate place (Liu et al., 
2006). 
 
 
 
1.6 The FBP family 
 
 The human FBP protein family comprises the FBP, FBP2 and FBP3 proteins 
(Davis-Smyth et al., 1996). All three proteins were initially identified in connection 
with the FUSE DNA regulatory mechanism and were shown to bind a non-coding 
strand of FUSE and to activate gene transcription (Davis-Smyth et al., 1996; Duncan et 
al., 1994). FBP proteins share a very similar domain organisation with three 
functionally distinct segments: an N-terminal domain, a central nucleic acid binding 
domain and a C-terminal activation domain (Figure 4A) (Davis-Smyth et al., 1996; 
Duncan et al., 1994). The N-termini of FBP and FBP2 are involved in transcription 
repression (Chung et al., 2006; Duncan et al., 1996). Originally this activity was 
mapped to the first 107 residues of FBP but further analysis highlighted the importance 
of a short sequence (Nbox) within this region, which was proposed to form                  
an amphipathic α-helix (Chung et al., 2006; Duncan et al., 1996). Interestingly           
the Nbox sequence of FBP3, which does not repress transcription, is the most divergent 
of the three sequences (Chung et al., 2006). The central parts of the FBPs contain four 
K-homology motifs (KH motifs), a fold originally identified as an RNA recognition 
domain in the hnRNP K protein and later found to be common in proteins engaged in 
ssDNA and ssRNA recognition (Davis-Smyth et al., 1996; Duncan et al., 1994; Siomi et 
al., 1993; Valverde et al., 2008). The C-termini of the FBP proteins contain 2-4 repeats 
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Figure 4 Domain organisation of the FBP and FIR proteins and a summary of inter-
molecular interactions in the FUSE–FBP–FIR system. A) Domain organisation of FBP 
protein. FBP2 and FBP3 are very similar but they contain respectively four and two    
Y-motifs instead of the three found in FBP. B) FIR comprises three RRM domains.     
C) Schematic representation of inter-molecular contacts between the three components 
of the system. The regions of proteins involved in protein–nucleic acid and protein–
protein interactions are boxed in yellow and red respectively. 
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of Y-motifs (AW(A/E)(A/E)YY) that are engaged in transcriptional enhancement 
(Davis-Smyth et al., 1996; Duncan et al., 1996). 
In spite of the similar domain organisation of the FBP proteins, siRNA 
experiments revealed that they regulate only partially overlapped subsets of genes and 
therefore are not functionally redundant (Chung et al., 2006). The diverse roles played 
by the proteins are further emphasised by their different distribution in different cell 
types – the FBP proteins are expressed in a broad range of tissues – and by additional 
functions performed by only some of the family members (Davis-Smyth et al., 1996; 
Wang et al., 1998). The FBP2 protein and its homologues have been implicated in 
splicing, miRNA processing, cellular localisation and mRNA degradation (Briata et al., 
2005; Gherzi et al., 2004; Kroll et al., 2002; Min et al., 1997; Rehbein et al., 2002; 
Trabucchi et al., 2009), whilst the FBP protein has been found in large RNA-containing 
complexes (Rothe et al., 2006). The FBP proteins occupy the FUSE regulatory sequence 
of the c-myc proto-oncogene at different times during transcription regulation, but      
the individual functions of each protein have not been studied in detail (Chung et al., 
2006). Interestingly overexpression of FBP and FBP3 has been correlated with high     
c-myc expression and high proliferation in renal cancer (Weber et al., 2008). 
 
 
 
1.7 The FIR protein 
 
 FIR acts both as a transcriptional repressor of the c-myc proto-oncogene and     
as a splicing factor (Liu et al., 2000; Page-McCaw et al., 1999). The protein is encoded 
by a gene with two alternatively spliced exons and the absence of one of them has been 
connected with tumorigenesis (Matsushita et al., 2006). FIR comprises three RNA 
recognition motifs (RRM) – a common ssDNA and ssRNA binding module (Figure 4B) 
(Clery et al., 2008). The first two RRMs (RRM1 and RRM2) are canonical nucleic acid 
binding domains that display the highly conserved aromatic residues necessary for DNA 
and RNA binding (Clery et al., 2008). The third RRM domain (RRM3) belongs to      
the U2AF homology motif (UHM) RRM protein-interacting subfamily and interacts 
with several protein partners containing short peptide UHM ligand motifs (ULM) 
(Corsini et al., 2009; Kielkopf et al., 2004). 
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 The FIR protein is localised mainly in the nucleus and is expressed in different 
amounts depending on the cell and tissue type (Liu et al., 2000; Page-McCaw et al., 
1999). The transcriptional repression activity of FIR has been mapped to                     
the N-terminal, unstructured region of the protein, that is involved in a direct interaction 
with TFIIH (Liu et al., 2000). It has recently been shown that expression of FIR by      
an adenovirus vector has an anti-tumour effect on human cancer cells both in vitro and 
in vivo (Matsushita et al., 2009). 
 
 
 
1.8 Interactions between FUSE, FBP and FIR 
 
 The comprehensive understanding of FUSE-mediated regulation of c-myc 
requires full characterisation of inter-molecular contacts in the FUSE–FBP–FIR system 
and currently available data are summarised in this section. 
The FBP and FIR FUSE binding activity was originally mapped to the KH 
domains of FBP and to the first two RRM domains of FIR (Figure 4C) (Chung et al., 
2006; Davis-Smyth et al., 1996; Duncan et al., 1994). Furthermore, the solution 
structure of KH3 and KH4 of FBP bound to a FUSE-derived sequence revealed that   
the ssDNA is recognised in an extended conformation and interacts with the canonical 
nucleic acid binding surfaces of the KH domains (Braddock et al., 2002). FBP binds 
preferentially to T- and G-rich sequences but this preference is not stringent and         
the binding is context-dependent (Benjamin et al., 2008; Braddock et al., 2002).          
An X-ray structure of the first two RRM domains (RRM1-RRM2) of FIR bound to        
a FUSE-derived sequence showed that the ssDNA recognition occurs via the β-sheet 
surface of RRM1, which is a canonical nucleic acid binding surface of an RRM domain 
(Clery et al., 2008; Crichlow et al., 2008). Interestingly RRM2 of FIR is not involved in 
the interaction, despite possessing conserved aromatic residues usually engaged in 
nucleic acid recognition (Clery et al., 2008; Crichlow et al., 2008). Instead, the β-sheet 
surface of RRM2 interacts with α-helices of RRM1 to form a hydrophobic inter-domain 
interface (Crichlow et al., 2008). Furthermore, it was found that two FIR RRM1-RRM2 
molecules dimerise upon binding to ssDNA (Crichlow et al., 2008). The dimerisation 
surface spans both RRMs and is favoured due to a fixed inter-domain orientation 
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between RRM1 and RRM2 within a monomer (Crichlow et al., 2008). The protein–
protein interaction is weak because it occurs only after the two FIR RRM1-RRM2 
molecules are bound to the ssDNA and the dissociation constants (Kd) for the two 
binding sites on the FUSE-derived sequence are ~ 2 µM and ~ 75 µM (Crichlow et al., 
2008). Although FIR RRM1-RRM2 was crystallised in the complex with FUSE-derived 
ssDNA only single nucleotides (C or A) were modelled in both binding sites of           
the dimer due to a poor electron density (Crichlow et al., 2008). These two identified 
nucleotides are not in agreement with the T-rich sequence preference of FIR observed  
in missing-base interference analysis (Benjamin et al., 2008). 
 Protein–protein interactions between FBP and FIR were studied with the yeast-
two hybrid assay (Chung et al., 2006). These experiments showed that RRM1-RRM2  
of FIR interact with a construct of FBP that contains an Nbox sequence and KH 
domains (Chung et al., 2006). Mutational analysis of the Nbox and chimeric constructs 
of different FBP proteins suggested that the Nbox is the determinant for FIR RRM1-
RRM2 interaction with FBP and that several hydrophobic residues in this putative       
α-helix are crucial for the binding (Figure 4C) (Chung et al., 2006). KH domains of 
FBP contribute to FIR–FBP interaction in the presence of FUSE-derived ssDNA 
because they bind to the ssDNA molecule, the same molecule FIR binds to, increasing 
the local concentration of the Nbox (Chung et al., 2006). Furthermore, the inter-protein 
recognition may modify the position of the two proteins on the FUSE element 
(Benjamin et al., 2008). 
FBP and FIR both interact with the XPB subunit of TFIIH that is important for 
the transcriptional regulatory function of both proteins (Liu et al., 2001; Liu et al., 
2000). Immunoprecipitation and pull-down assays mapped these interactions to          
the N-terminal repression domain of FIR and to the C-terminal activation domain of 
FBP (Liu et al., 2001; Liu et al., 2000). 
 
 
 
1.9 Rationale for the project 
 
The molecular interactions within the FUSE–FBP–FIR system have been only 
partially characterised. Although a qualitative description of the interactions and 
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information on the structure of several components are available (and discussed above) 
a coherent description of the system from a structural and biophysical point of view is 
missing. Lack of this information severely limits the molecular understanding of FUSE-
mediated regulation and therefore our ability to interfere with it. 
The FUSE mechanism is based on a single activator (FBP) and a single repressor 
(FIR). Central to FUSE regulation is the FIR–FBP interaction that mediates FIR 
recruitment and transcriptional shut-off, thereby defining the length and size of the peak 
of c-myc transcription. Therefore structural and quantitative characterisation of           
the RRM1-RRM2 of FIR and its interactions with FBP and the non-coding strand of 
FUSE (henceforth referred to as ssFUSE) is of particular importance. Furthermore, to 
accurately describe models for FBP and FIR recruitment to and ejection from ssFUSE it 
is necessary to quantify the strength of the FIR–FUSE interaction and to compare it 
with the FBP–FUSE interaction. 
The information available on the FUSE–FBP–FIR system suggests that              
the complex undergoes significant intra- and inter-molecular motions to manage         
the appropriate contacts both in space and in time. To dissect this flexible and dynamic 
mechanism we need to provide a structural description of different, often weak 
complexes. Nuclear magnetic resonance (NMR) spectroscopy is one of two techniques 
(the other one being X-ray crystallography) that allows one to determine the structure of 
macromolecules with atomic resolution. Importantly, NMR spectroscopy has specific 
features that make it particularly useful for the study of the mechanism of FUSE-
mediated c-myc regulation. Among them are: the possibility of studying the sample in 
solution, the ability to study flexibility, conformational changes and inter-molecular 
interactions within the same experimental framework and the incremental nature of    
the information obtained during an NMR study that allows one to obtain data on folding 
states and binding affinities prior to the availability of a high resolution structure. 
Moreover, previous studies on the identification of protein and DNA regions involved 
in the interactions (see section 1.8 Interactions between FUSE, FBP and FIR) allow me 
to reduce the system under study to a size amenable to NMR spectroscopy.                
The information obtained can be subsequently expanded to larger and more complex 
systems with the help of a complementary technique. 
Biolayer interferometry (BLI) is a useful method for the study of interactions 
between large molecules because its optical-based detection does not impose an upper 
limit on the size of the system being studied. On the contrary, the larger the molecules 
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being investigated, the larger is the shift of the interference signal (the BLI observable). 
BLI allows one to test different experimental set-ups quickly and with a small amount 
of material (typically nM to µM concentrations in 200 µl wells). Furthermore,            
the ability to use low concentrations expands the measurable Kd range towards tighter 
interactions compared to the range accessible by NMR. This is because dissociation 
constants can be accurately measured in direct assays (in contrast to competition ones) 
only at concentrations of studied molecules that are comparable to the Kd and             
the sensitivity limitations of NMR impose a Kd > ~ 1 µM limit on studied complexes. 
In summary, NMR and BLI complement each other in the study of 
macromolecular interactions in general and in the particular for the FUSE–FBP–FIR 
system. 
 Misregulation of c-myc expression has been associated with many cancers and it 
has been shown that c-myc can drive carcinogenesis (Nesbit et al., 1999; Oster et al., 
2002; Vita and Henriksson, 2006). Further studies proved that c-myc is a potential target 
in an anti-cancer therapy (Soucek et al., 2008; Vita and Henriksson, 2006). Nevertheless 
the complexity of c-myc regulation hinders development of efficient and safe therapies. 
FUSE–FBP–FIR is a very attractive option for medical treatment as it is able to rapidly 
stop the c-myc transcription initiated by different signalling pathways (Wierstra and 
Alves, 2008). However, a full understanding of this transcription-responsive mechanism 
is a necessary prerequisite to design the treatment strategies based on manipulation of 
the FUSE–FBP–FIR system. 
 The aim of this thesis is to provide a more accurate molecular picture of          
the FUSE–FBP–FIR system. It focuses on the switch between activation by FBP protein 
and repression by FIR protein that is central to the c-myc transcription regulation.      
The work includes the high resolution structure of the first two RRM domains of FIR 
(FIR RRM1-RRM2), the complex between FIR RRM1-RRM2 and an amphipathic      
α-helix of FBP protein (Nbox) and the qualitative and quantitative description of        
the interactions in the FUSE–FBP–FIR system. 
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2.1 Protein structure determination by NMR 
 
This section focuses on the well-established methodologies of protein structure 
determination by NMR that I have used during my thesis. 
NMR spectroscopy can be employed to study the structure, dynamics and 
interactions of biological macromolecules. In NMR, magnetically active nuclei provide 
information on their local chemical environment and therefore on the structure and 
motions of the molecule. A major limitation of NMR is its sensitivity to the size of     
the system to be studied – with standard methodologies ~ 50 – 100 kDa molecules/ 
complexes represent a challenge. However, the possibility of studying the systems in 
solution, of performing time-resolved analysis and of investigating dynamic systems 
justifies the importance of NMR in the study of biologically relevant questions. 
Standard NMR high resolution protein structure determination can be 
summarised in four steps (Linge et al., 2001; Markley et al., 2003) (Figure 5). First, 
sequential assignment of the protein backbone resonances is achieved by analysing        
a number of 3-dimensional (3D) NMR through-bond experiments which correlate intra-
residual and sequential 15N, 1HN, 13Cα, 13Cβ and 13C′ resonances. Then, the amino acid 
spin systems are assigned to identify the remaining 13C, 1H and 15N frequencies. 
Subsequently, distance and angle restraints are obtained from NMR observables        
(i.e. nuclear Overhauser effect (NOE) correlations, exchange experiments, J couplings, 
chemical shift patterns and residual dipolar couplings). Finally, these restraints are 
inserted into a molecular dynamics protocol to calculate a family of structures that 
satisfy both the chemical geometry and the provided NMR restraints. 
 
 
 
2.1.1 Backbone assignment 
 
The first step towards structure determination is an assignment of different 
nuclear magnetic resonances observed in the spectra to a specific nucleus of the protein. 
Initially, the 1HN, 15N, 13Cα, 13C′ backbone and 13Cβ resonances (Figure 6A) of each 
residue are identified and sequentially connected using triple-resonance experiments.   
In the recorded spectra, 1HN and 15N resonances of a residue are correlated to the 13Cα, 
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Figure 5 Flow-chart of a standard NMR structure determination protocol. 
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Figure 6 Backbone NMR experiments used in this study. A) Nomenclature.                
B) Backbone experiments used in my thesis for the assignment. The atoms correlated by 
the different backbone NMR experiments are marked with red circles. Dashed lines 
separate the individual residues. 
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13Cβ and/or 13C′ resonances of the same and/or preceding residue. The most 
information-dense experiment for backbone assignment is the 3D HNCACB        
(Figure 6B). However, this experiment is also the most sensitive to an increase of       
the molecular weight. The data from the other 3D NMR backbone experiments 
(HN(CO)CACB, CBCA(CO)NH, HNCA and HN(CO)CA) (Figure 6B) complement  
the HNCACB data and fill the gaps existing for the fastest relaxing and the overlapped 
resonances. Where the information obtained from backbone experiments is ambiguous 
or incomplete, through-space 3D NOE spectroscopy (NOESY) experiments, that are 
less sensitive to molecular weight and connect a wider range of resonances, can help to 
identify the missing sequential connections (Cavanagh, 2007). The stretches of 
sequentially assigned resonances are then matched to unique positions within              
the primary protein sequence. The process relies on the characteristic distribution of 13C 
chemical shifts in peptidic chains, that restrict the possibilities of matching with          
the protein sequence (particularly distinctive are 13Cα of glycines and 13Cβ of alanines, 
serines and threonines) (Wishart et al., 1995). 
For a small well-behaved protein, triple-resonance backbone NMR experiments 
make sequential assignment of spin systems straightforward. However, the performance 
of these experiments is strongly dependent on the size and aggregation state of            
the investigated molecules. In the case of FIR RRM1-RRM2, a moderate molecular 
weight (~ 20 – 25 kDa) and a transient aggregation experienced at higher concentrations 
of the protein (> 0.5 mM) significantly affected signal-to-noise (S/N) ratio of              
the recorded spectra and hindered the assignment process. The NOESY experiments 
turned out to be an invaluable help to resolve any ambiguities and complete some 
missing assignments. Nevertheless, not all resonances were identified and 
unambiguously assigned, especially in loop regions, where internal mobility of           
the protein may lead to exchange broadening of the resonances and where dispersion of 
observed chemical shifts is low. 
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2.1.2 Side-chain assignment 
 
 Side-chain assignment is routinely achieved by combining 3D through-bond and 
through-space NMR experiments (Cavanagh, 2007). The former are 3D HCCH total 
correlated spectroscopy (TOCSY) and 3D 15N TOCSY experiments that correlate all 
13C-attached intra-residual protons to each other or to backbone amides, respectively. 
The latter are 3D 15N NOESY and 3D 13C NOESY experiments that correlate              
an individual 1H to other 15N- (15N NOESY) or 13C-attached (13C NOESY) protons 
within ~ 6 Å distance. The sequential assignment of backbone resonances facilitates   
the assignment of side-chains, because amino acid spin system correlations can be 
found starting from the backbone resonances and then the assigned chemical shifts can 
be validated against the tabulated values for each amino acid type (Wishart et al., 1995).  
In theory, the through-bond experiments could provide a complete side-chain 
assignment, as they correlate all protons and heteronuclei (13C and 15N) within            
the protein. However, there are two difficulties when working on larger proteins          
(> 10 kDa). Firstly, the increased overall rotational correlation time (τc) results in broad 
peaks and a rapid relaxation of the magnetisation. To increase the sensitivity shorter 
TOCSY mixing periods are used that often eliminate the correlations between distant 1H 
in the side-chains (e.g. K 1HN – 1Hε2/ε3, I 1Hα – Qδ1). Secondly, the larger proteins have 
more residues of the same type increasing the spectra overlap. This is especially 
apparent in the methylene and methyl regions of the spectra. Fortunately,                    
the information obtained from TOCSY experiments can be completed and validated 
with through-space NOESY experiments, which rely on the dipolar couplings between 
the two spins and are not as sensitive as through-bond scalar coupling interactions to  
the increase of the τc of the molecule. In the NOESY spectra, both intra- and inter-
residual 1H-1H correlations are observed for nuclei separated by up to ~ 6 Å, depending 
on the relaxation properties of the resonances and the mixing times used. Importantly,  
at short mixing time the strongest cross-peaks are typically observed for intra-residual 
protons and a coherent pattern of correlations allows identification of individual spin 
systems. Regardless of the approach taken, the best measure of the validity of             
the assignment results is the self-consistency of all of the information derived from    
the chemical shift values, through-bond scalar coupling interactions and through-space 
dipolar coupling interactions. In the case of FIR RRM1-RRM2, the main source of 
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information for the side-chain assignment were the NOESY spectra, because of the long 
τc of FIR RRM1-RRM2 both in isolation and in the complex with the FBP Nbox 
peptide. 
 
 
 
2.1.3 NMR-derived structural restraints 
 
2.1.3.1 NOE distance restraints 
 
 The most important restraints used in NMR structure calculations are the inter-
proton distances derived from NOE-based experiments. In NOESY experiments,        
the NOE causes a change in the intensities of dipolar-coupled resonances. Thus,           
in a separate two-spin IS system, saturation of S resonance leads to the change in            
the intensity of I resonance, provided the inter-nuclear distance allows efficient dipolar 
cross-relaxation to occur. In such an ideal system, the maximum value of the NOE is 
independent of the inter-proton distance. However, the cross-relaxation rate constant 
σIS, that determines how quickly the NOE builds up, is inversely proportional to         
the sixth power of the inter-nuclear distance rIS: 
 
σ ~ r     
 
For practical reasons, the intensities of cross-peaks instead of cross-relaxation rate 
constants are used to derive inter-nuclear distances. This is possible because at            
the initial stage of the NOE build-up the size of the enhancement is controlled by the σIS 
(initial rate approximation) (Neuhaus and Williamson, 2000), and thus the NOE cross-
peak intensity fI after a certain time t is linearly correlated with σIS of the individual 
two-spin system: 
 
	
 ~ σ 
 
In principle, the inter-nuclear distance can be obtained by comparing σIS for the spin 
pair of interest (σ) with σIS for a spin pair with known inter-nuclear distance (σ) 
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(e.g. methylene or ortho aromatic protons) that acts as a reference (Neuhaus and 
Williamson, 2000): 
 
σσ 
	
	
  r

r
      r  r 	
	


 
 
However, the NOE-derived distances are intrinsically inaccurate (Neuhaus and 
Williamson, 2000) as: 
1. The two spins are never in isolation and an indirect effect via spin diffusion can lead 
to significant calibration errors. Thus, the NOE observed on spin B when irradiating 
spin A can derive both from a direct A-B coupling and from indirect A-C and C-B 
couplings. If the A-C and B-C distances are significantly shorter than the A-B 
distance the contribution of the indirect pathway is not negligible. 
2. The internal dynamics of macromolecules affects both cross-relaxation rate constants 
(σIS) and inter-nuclear distances (rIS). The σIS is dependent on correlation time, that 
may be different for two spin pairs with identical rIS. At the same time, the rIS varies 
with time due to internal motions and this leads to averaging of σIS over all 
conformers for individual two-spin systems. 
3. The reference distances are not accurate because they are also affected by internal 
mobility. Furthermore, they are significantly shorter than most of the unknown 
distances and therefore are not ideal for calibration. 
4. The integration of cross-peak volumes or the measurement of their intensities can be 
compromised by spectral overlap or poor baseline. 
Consequently, NOE-derived distances (rIS) are considered as semi-quantitative and are 
typically specified by lower (r) and upper (r) bounds: 
 
r  r  r 
 
In the structure calculations of FIR RRM1-RRM2 and FIR RRM1-RRM2 – FBP 
Nbox complex ~ 4500 NOE distance restraints were used, giving on the average          
20 restraints per residue. The distance calibration was performed with automatic 
procedure implemented into structure calculation protocols. The process was successful 
for FIR RRM1-RRM2 alone, but failed for the complex, so that a converged family of 
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structures could have not been obtained. This is likely due to an intermediate regime of 
the exchange process between the free and bound states of the interacting partners, that 
causes broadening of the resonances. Consequently, the calibrated distances are 
weighted towards longer-than-real distances. To overcome this inaccuracy a semi-
quantitative approach to distance calibration of inter-molecular restraints was applied. 
 
 
 
2.1.3.2 Hydrogen bond distance restraints 
 
H-bond distance restraints are powerful determinants of protein structure.       
The most common H-bond restraints used in protein structure determination are that 
between carbonyl (acceptor) and amide (donor) groups of the protein backbone.           
In α-helical regions, the H-bond occurs between an amide group of n residue and          
a carbonyl group of n-4 residue. In β-regions, the H-bond takes place between amide 
and carbonyl backbone groups in the adjacent β-strands within the β-sheet structure. 
NMR experiments that directly correlate H-bond donor and acceptor groups are of 
limited use in protein structure determination because of their low sensitivity due to   
the small coupling (1 – 2 Hz) (Grzesiek et al., 2001). A more widespread approach 
introduces H-bonds based on the initial rounds of structure calculations. This indirect 
identification is typically supported by information obtained from presence of donor and 
acceptor in regular secondary structure elements or, in the best case, from the protection 
of the amide donor protons against exchange with 2H2O. In a 2H2O exchange 
experiment, the sample is lyophilised and then resuspended in 2H2O, where the 
unprotected amide protons are rapidly exchanged with deuterons leading to a fast 
decrease of the intensity of the amide resonances in 1H-15N correlation spectra. The 
involvement of a 1H in an H-bond slows the exchange rate very significantly: 
 
 N  H ||||| O  C $  %   N  H       O  C $  %  N  D       O  C $ 
 
It is normally assumed, that if a resonance is visible in the 1H-15N correlation spectra, 
the amide proton must be hydrogen bonded. In reality, protection factors of amide 
protons are not linked only to their involvement in H-bonds (Polshakov et al., 2006), but 
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measurement of 2H2O exchange rates, when feasible, represents a straightforward 
method to validate H-bonds identified during structure calculations procedure.              
A limitation of the method is that, in small and not very stable domains or regions of 
particular domains, domain ‘opening’ (unfolding and refolding) can be too fast to 
observe the effect even for the protected resonances. 
In the structure calculations reported in this thesis H-bond distance restraints 
were applied, if an H-bond was observed in ≥ 50% of the structures obtained in          
the previous round of structure calculations and if the amide donor proton was protected 
against exchange with 2H2O. Interestingly, despite exchange experiments being 
performed at relatively high pH and temperature (pH 8.0, 37 °C), they showed            
the protection of ~ 80 HN groups in both FIR RRM1-RRM2 free and bound. However 
the indirect detection of H-bond acceptors did not allow me to identify unambiguously 
all of them. Most of the H-bonds identified using the method above are typical for       
α-helical and anti-parallel β-sheet structures. In the case of FBP Nbox peptide,           
the H-bonds restraints were introduced for the α-helical part of the peptide based on   
the NOE pattern and the values of dihedral angles. This is, because resonances of amide 
groups in all 1H-15N correlation spectra of the peptide (free and bound) at pH 8.0 and  
37 °C are significantly broadened due to an intermediate regime of the exchange 
process of protons with water molecules and therefore 2H2O exchange experiments are 
not a feasible option. 
 
 
 
2.1.3.3 Torsion angle restraints 
 
The geometry of protein backbone can be described by three torsion angles: φ, ψ 
and ω that represent rotations around N-Cα, Cα-C′ and C′-N bonds, respectively.       
The peptide bond (C′-N) in proteins is planar due to its partial double-bond character 
and in most cases (> 99%) the corresponding ω angle is in trans conformation (~ 180°) 
(Sheik et al., 2003; Stewart et al., 1990). The values of the other two torsion angles      
(φ and ψ), although limited by steric hindrance, can assume different values (Sheik et 
al., 2003). These values define the geometry of the protein backbone, which is very 
different in the different secondary structure elements (Neuhaus and Williamson, 2000). 
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The values of φ and ψ torsion angles can be estimated experimentally from 
measurements of one-, two-, three- and four-bond scalar couplings (Edison et al., 1994; 
Vuister and Bax, 1994), with the most popular being three-bond 1HN-1Hα scalar 
coupling for estimation of φ angle (Vuister and Bax, 1993). However, a more common 
approach takes advantage of the empirical correlation between the local geometry of  
the protein backbone and the chemical shift values of both backbone 1Hα, 13Cα, 13C′ and 
15N resonances and the side-chain 13Cβ resonances. An important advantage of this 
approach is that the information required (the backbone and 13Cβ chemical shifts) are 
obtained during the assignment process and no additional NMR experiments are 
needed. Different protocols have been developed to derive torsion angle restraints from 
the chemical shifts. The one used in my studies is implemented in the TALOS (torsion 
angle likelihood obtained from shifts and sequence similarities) software (Cornilescu et 
al., 1999). The protocol utilises both sequence and chemical shift homology to predict 
the most likely backbone angles for a given residue. To improve the reliability of 
predictions a stretch of three consecutive residues (XYZ) is used to derive φ and ψ 
torsion angles of the centrally located residue (Y). The query triplet is compared with all 
triplets within the database consisting of 176 proteins with known high-resolution X-ray 
structure and known 13Cα, 13Cβ, 13C′, 1Hα and 15N chemical shifts. The results are ranked 
according to the similarity in amino acid type and chemical shift values and then        
the prediction of the torsion angles is made based on the ten best matches. Importantly, 
if the torsion angles values are not consistent among the ten best scored triplets           
the prediction is discarded as unreliable. However good, TALOS is a database-based 
method and makes on the average ~ 3% of erroneous predictions and thus, care must be 
exerted when using the results obtained (Cornilescu et al., 1999). 
 TALOS protocol generated 236 angle predictions for FIR RRM1-RRM2 and 
250 for FIR RRM1-RRM2 bound to the FBP Nbox peptide. Furthermore, 30 torsion 
angles were predicted for the peptide in the complex. The incorporation of these 
restraints into structure calculations improved the quality of obtained structures, 
especially at the initial stage of the calculations, when many NOE distance restraints 
were not unambiguously assigned. 
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2.1.4 Structure calculations – ARIA workflow 
 
 Several computational packages have been developed to assist structure 
determination from NMR data. The Ambiguous Restraints for Iterative Assignment 
(ARIA) has been designed to speed up the process of structure determination as well as 
to optimise structure quality. ARIA combines three powerful ideas: automated NOE 
assignment, usage of ambiguous NOE distance restraints and automated structure 
calculations (Güntert, 2003; Habeck et al., 2004; Linge et al., 2001; Nilges, 1996; 
Nilges et al., 1997; Nilges and O'Donoghue, 1998; Williamson and Craven, 2009). 
Thus, ARIA uses unassigned or partially assigned NOE peak lists with their intensities, 
together with protein sequence and chemical shift list, to perform NOE assignment, 
distance calibration, structure calculations, violation analysis, structure refinement and 
analysis of structure quality practically without any external intervention. 
The principal aim of ARIA is to facilitate analysis of ambiguous NOEs and to 
incorporate this ambiguous data into automated structure calculations. The ambiguity of 
NOE cross-peaks is an inevitable consequence of increasing number of 1H in larger 
proteins that entails an increased probability of having two or more nuclei with identical 
or very similar chemical shifts. Thus, a single cross-peak in the NOESY spectra, based 
only on chemical shifts, may be assigned to several nuclei. Among possible assignments 
there are real ambiguous (i.e. the peak represents contributions from at least two 
different inter-proton distances) as well as false assignments, that cannot be eliminated 
without any additional information. One solution to the false assignment problem is to 
calculate a preliminary structure only with unambiguous restraints and then try to 
resolve ambiguities based on the result of the structure calculations. Such a strategy is 
used during the non-automated iterative procedure of structure calculations. However, 
this procedure still discards correlations that derive from multiple contributions and that 
in some cases may be powerful restraints. ARIA takes advantage of these ambiguous 
correlations by treating each peak as a sum of all possible assignments and therefore as 
a sum of restraints, each weighted by the inverse sixth power of the corresponding inter-
proton distance. Furthermore, an iterative protocol of ARIA for cross-peaks assignment, 
structure calculations and evaluation of assignment process allows elimination of 
incorrect assignments and thereby decreases the NOE ambiguity with each iteration step 
(Figure 7). 
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Figure 7 ARIA workflow. 
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ARIA uses as an input a protein sequence, a chemical shift assignment list and 
unassigned or partially assigned peak lists from NOESY spectra. In the first iteration 
(by convention called ‘iteration 0’), the assignment of peaks is performed exclusively 
based on the chemical shift list. The assigned restraints are subsequently calibrated by 
ARIA. To perform this calibration ARIA does not use reference distances r, but 
derives a calibration factor C from the equation using the experimental data: 
 
C  ' rV)*+,  
where: 
C calibration factor 
r inter-proton distance 
V observed NOE volume or intensity 
 
The sum runs over all experimentally measured NOEs for which rIS are shorter than       
a cut-off (6 Å). The ambiguous restraints are taken into account by replacing rIS with   
an effective distance (‘r summed distance’) that contains contributions from all 
possible assignments. The obtained calibration factor is subsequently used to calculate 
the observed distance: 
 
r-.  
CV ⁄  
 
Importantly, the performance of this calibration method is rapid and very effective even 
when distances are derived from an extended template conformation (in iteration 0) of 
the polypeptide chain. For reasons discussed before (see section 2.1.3.1 NOE distance 
restraints) the calibrated restraints are intrinsically approximate and in ARIA the error ∆ 
is estimated from an empirical equation: 
 
Δ   12r-.34           (typically 1 = 0.125 Å-1) 
 
 
Then the upper and lower bounds are defined by: 
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r  r-.  Δ r  r-. 5 Δ 
 
The restraints obtained are subsequently used to calculate structures. The aim of 
structure calculation protocols is to find a global minimum region of the total energy 
function Ehybrid of the system. This function, also called force field, combines the NMR 
experimental data and the information on covalent geometry (bonds, angles, planarity, 
chirality) and the non-bonded contacts (van der Waals force). The individual terms are 
represented as energy contributions and are accordingly weighted: 
 
678-9  ' :6  
where: 
Ei individual energy contributions 
wi weight factors for each energy term 
 
In ARIA, the global minimum of total energy function Ehybrid is calculated with 
the Crystallography and NMR System (CNS) (Brunger et al., 1998), that relies on 
molecular dynamics-based simulated annealing protocol. The molecular dynamics 
protocol calculates the trajectories of all atoms within the molecule using the equations 
of Newtonian mechanics and treating the molecule essentially as a sophisticated 
mechanical model. Initially, every atom obtains some kinetic energy in the form of      
an initial velocity in a random direction – this is done based on a Maxwellian 
distribution corresponding to a notional temperature for the molecule as a whole.      
The movement of every atom is affected by different forces that are represented in      
the force field. Considering these complex relations, the relative positions of atoms and 
their velocities are recalculated at very short time intervals (i.e. short relative to          
the highest frequency of motion in the system) simulating the movements of the atoms 
over time. The simulations are performed in the torsion angle space that significantly 
reduces the freedom of atoms, as the only degree of freedom are the torsion angles. 
Furthermore, the protocol includes a high-temperature search phase followed by a slow 
cooling phase, which slowly reduces the kinetic energy of the atoms. Such an approach 
minimise the problem of trapping in the local minimum of the Ehybrid function. 
Importantly, the ARIA protocols change some of the parameters during calculations in  
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a way that has been optimised to maximise the possibility of reaching a global 
minimum of the force field. 
Following structure calculations, violation analysis is performed to eliminate 
noise-derived and erroneously assigned peaks. Afterwards the next iteration starts, but 
this time assignment of ambiguous restraints is based on the best fraction of calculated 
structures in the preceding iteration. The whole procedure continues for several 
iterations (typically nine) during which parameters for assignment of ambiguous 
restraints and violation analysis are being tighten up to improve the quality of calculated 
structures. 
 In addition to NOE-derived distance restraints ARIA can use complementary 
experimental information such as hydrogen bonds, torsion angles, residual dipolar 
couplings and disulfide bridges. 
 Upon completion of the last iteration (typically iteration 8) the final structures 
are a subject to a short molecular dynamics refinement in explicit solvent with a full 
force field, including electrostatic and Lennard-Jones potentials. This step improves   
the quality of obtained structures as they often show artefacts due to simplified 
treatment of non-bonded forces and missing solvent contacts during structure 
calculations. 
Finally, ARIA generates many output files that report on performance of 
assignment and structure calculations procedures as well as on quality of the final 
conformers. 
 
 
 
2.1.5 Strategy for the structure determination of protein–protein 
complexes by NMR 
 
NMR spectroscopy is a powerful tool in the study of macromolecular 
interactions in solution and has been proved to be particularly useful for the structural 
investigation of transient complexes that are usually not amenable by X-ray techniques 
(Nietlispach et al., 2004). NMR-driven structure determination is limited by                
the molecular weight of the studied molecule/complex. Typically, complexes with 
molecular weight > 50 kDa have large rotational correlation time (τc) and thereby,      
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the sensitivity of most multi-dimensional NMR experiments is low. Furthermore,       
the large number of 1Hs in high molecular weight complexes results in the overlap of 
their resonances and hampers the assignment process. A common strategy to overcome 
this problem is to identify which parts/domains of the binding partners are involved in 
the interaction and to reduce the system under study to these regions (Nietlispach et al., 
2004). 
Ideally, two samples – each containing one of the components labelled and      
the other unlabelled – are used to complete the assignment of the complex. Two 
separate sets of experiments are recorded for the two samples. The comparison of these 
experiments allows one to identify intra- and inter-molecular restraints and                 
the assignment of inter-molecular restraints is then validated using filtered experiments 
(Nietlispach et al., 2004). In some cases, the small size of one of the two components 
allows for the structure determination of the complex without that component to be 
labelled (Nietlispach et al., 2004). 
In practice the strength of the inter-molecular interaction often defines             
the strategy used for the structure determination of the complex (Nietlispach et al., 
2004). Complexes with dissociation constants in the micromolar range, such as the one 
between FIR RRM1-RRM2 and FBP Nbox usually have resonances in the moderately 
fast exchange regime on a chemical shift time scale (depending on the changes in 
chemical shifts between the free and bound states). The ratio of the two components 
during experiments on the complex is chosen so that the observed component is nearly-
fully saturated, which typically requires an excess of the other component. Saturation of 
the observed component serves three purposes: firstly, it minimises broadening due to 
exchange between the free and bound conformation; secondly, it allows maximisation 
of the signal coming from the bound component and thirdly, it helps to maintain 
consistency in the chemical shift of references in the bound form. Interestingly, 
relatively weak binding can be of help during the assignment of the bound resonances 
because the shift of the well dispersed 1H, 13C and 15N resonances during titration with 
the other component can be used to transfer assignments from the free to the bound 
form, without having to undertake a full assignment procedure. It is also worth 
mentioning that complexes in very and moderately fast exchange regime are often 
difficult to crystallise. This makes NMR spectroscopy techniques especially useful in 
studies of such transient complexes. 
53 
Preliminary NMR experiments revealed that the FIR–FBP–FUSE system is 
indeed in the fast-to-intermediate exchange regime and that the affinity of FIR for 
ssFUSE and FBP Nbox is in the micromolar range. Furthermore, the previously 
performed studies (discussed in section 1.8 Interactions between FUSE, FBP and FIR) 
and my NMR experiments showed that it is possible to reduce the system under study to 
a size amenable for NMR for high resolution studies. Thus, NMR is the technique of 
choice to study the structure of these transient complexes. 
 
 
 
2.2 Circular Dichroism 
 
Circular dichroism (CD) is a spectroscopic technique that allows one to obtain 
low-resolution structural information about proteins and nucleic acids from small 
amounts of material (Martin and Schilstra, 2008). CD spectroscopy measures              
the difference in absorbance for left- and right-handed circularly polarised light.        
The CD signal derives from chromophores, the same as those that give rise to 
absorbance and fluorescence phenomena, but to observe the CD signal these 
chromophores have to be inherently chiral or to be located in a chiral environment 
(Martin and Schilstra, 2008). In proteins, chromophores are generally achiral and       
the observed signal is generated by the chiral environment of the protein.                      
In the near-UV CD spectra of proteins the signal originates from tryptophan, tyrosine, 
phenylalanine and cystine and reflects the tertiary, and sometimes quaternary, structure 
of the protein. In the case of the far-UV CD spectrum of proteins the absorbance 
phenomenon comes mainly from n → pi* (at ~ 220 nm) and pi → pi* (at ~ 190 nm) 
transitions within the peptide bond and reflects the secondary structure of the protein 
(Martin and Schilstra, 2008). 
The main advantages of CD are high sensitivity to changes in conformation,    
the possibility to study a broad range of solvent conditions and requirement for small 
amounts of the material (Martin and Schilstra, 2008). CD has been extensively used to 
1) estimate the secondary structure content of the proteins, 2) detect conformational 
changes within the macromolecules, 3) study folding, unfolding and stability of          
the macromolecules and 4) study inter-molecular interactions (Martin and Schilstra, 
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2008). In this thesis, CD was employed to evaluate the fold (from the far-UV CD 
spectrum) and stability (from the thermal denaturation experiment) of the FIR RRM1-
RRM2, and also to estimate the secondary structure content of the FBPs Nbox peptides. 
 
 
 
2.3 BioLayer Interferometry 
 
BLI is a label-free surface-based optical analytical technique to study inter-
molecular interactions. The detection is based on the interference of electromagnetic 
waves (from the visible light spectrum) that are partially reflected from an internal 
reference layer and from a layer of immobilised molecules (biolayer). The reflected 
waves encounter constructive or destructive interference, depending on the wavelength, 
and create a characteristic intensity pattern across the white light spectrum (Figure 8). 
When the thickness of the biolayer increases due to inter-molecular interactions on     
the biosensor surface a shift in the interference pattern is observed. 
BLI has been implemented in the Octet platform (ForteBio) that allows eight 
parallel binding assays being performed in a relatively short time (a few minutes to       
a few hours, depending on the set-up). The researcher’s intervention is limited to 
preparing solutions with the desired compositions in a 96-well plate, choosing            
the parameters of the assay and analysing the data. A “dip and read” technology 
eliminates problems of microfluidics becoming clogged and significantly reduces       
the necessary maintenance. Furthermore, disposable sensors eliminate the need for 
surface regeneration, significantly increasing throughput and allowing a quick test 
and/or optimisation of the assay conditions. 
In the course of a surface-based experiment (e.g. in the Octet platform) one of 
the interaction partners is immobilised on the surface of a tip (e.g. by streptavidin-biotin 
binding) which is then exposed to a solution containing the other interaction partner. 
Binding changes the thickness of the biolayer generating the detectable signal. The main 
pitfall of surface-based optical analytical techniques is the possibility of non-specific 
binding of the non-immobilised protein to the surface. This can be tested in a control 
experiment where the first component is not immobilised on the surface and the tip is 
exposed to the second component. Preliminary BLI experiments on FUSE–FBP–FIR 
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Figure 8 Physical background of BLI method (figure taken from 
http://www.fortebio.com/bli_technology.html). The detected signal originates from     
an interference between electromagnetic waves reflected from an internal reference 
surface and an immobilised-molecules surface. Upon inter-molecular interaction            
a distance between two reflecting surfaces increases causing a shift in an interference 
pattern that is a detected signal. 
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system, which were performed in the buffer used in the NMR titrations (10 mM Tris- 
HCl pH 7.4, 50 mM NaCl, 2 mM Tris(2-carboxyethyl) phosphine (TCEP)), showed that 
the FBP constructs bind non-specifically to the sensor surface in the absence of 
immobilised ssDNA. Thus, the experimental conditions were optimised and it was 
found that increasing the salt concentration (up to 150 mM) and including bovine serum 
albumin (BSA) (0.5 mg/ml) in the buffer eliminates these non-specific interactions. 
 
 
 
2.4 Experimental details 
 
2.4.1 Cloning 
 
The cDNA sequences encoding FIR RRM1, FIR RRM2 and FIR RRM1-RRM2 
(NP_055096) were PCR-amplified from the pCMV-rSiahBP plasmid (a gift of Dr. S. 
Kindler) using primers that introduced 5’ NcoI and 3’ HindIII restriction sites (Table 1). 
The original plasmid carries a sequence of rat homologue of FIR, rSiahBP (AF165892). 
However, the protein is very conserved and no differences exist in the region of interest 
(RRM1-RRM2) at the protein level (Appendix I). Thus, in this thesis, the numbering of 
protein residues is after the human FIR (NP_055096). The PCR products were cloned 
between NcoI and HindIII sites of the pETM-30 expression vector (EMBL-Heidelberg, 
Protein Expression Facility) generating plasmids, which encode four variants of FIR 
RRM1, FIR RRM2 and FIR RRM1-RRM2 (Table 2, see also Figure 10) with              
an N-terminal tobacco etch virus (TEV) protease-cleavable hexa-histidine tag (HisTag) 
glutathione-S-transferase (GST) fusion. 
The cloning of FBP constructs described below has been performed by David 
Hollingworth at the National Institute for Medical Research, London, UK. 
The cDNA sequence encoding full length FBP sequence was amplified and 
cloned from a cDNA library (MegaMan human transcriptome library, Stratagene) 
following the manufacturer’s instructions and using FBP-F and FBP-R primers     
(Table 1). FBP Nbox-KH1-KH4 (amino acids 27-455, NP_003893) and FBP KH1-KH4 
(amino acids 85-455, NP_003893) were PCR-amplified from the full-length clone using 
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Table 1 Primers used to clone FIR and FBP constructs. 
 
Name Sequence 
Forward
/Reverse 
Restriction 
site 
Nucleotidesa 
FIR 
F-RRM1-L 5'-AGA TCC ATG GCT CAG CGG CAG CGG GCA C-3' Forward NcoI 319-337 
F-RRM1-S 5'-AGA TCC ATG GCT ATC ATG TGC CGG GTG TAT G-3' Forward NcoI 340-361 
F-RRM2-L 5'-AGA TCC ATG GCT AGC AAC ATC GGA CAA GCC CA-3' Forward NcoI 578-599 
F-RRM2-S 5'-AGA TCC ATG GCT TTC AAC CGA ATA TAC GTG G-3' Forward NcoI 633-655 
R-RRM1-L 5'-A GAT AAG CTT TCA AGC CCT AGC CTC CTC AGC CA-3' Reverse HindIII 617-637 
R-RRM1-S 5'-A GAT AAG CTT TCA AGG TCT TCC CAC CTT GAT GTT C-3' Reverse HindIII 558-579 
R-RRM2-L 5'-A GAT AAG CTT TCA CGT GGC AGG TGT TAG CAG GG-3' Reverse HindIII 887-906 
R-RRM2-S 5'-A GAT AAG CTT TCA TGT GAC GGC CTT GCC CAC CC-3' Reverse HindIII 857-876 
FBP 
FBP-F 5’-CTT GTC TAG ATG GCA GAC TAT TCA ACA GTG CCT-3’ Forward XbaI 90-113 
FBP-R 5’-C TTG CTC GAG TTA TTG GCC CTG AGG TGC TGG AG-3’ Reverse XhoI 2002-2021 
FBP-F-Nbox 5’-CTT GCC ATG GGA GTT AAC GAC GCT TTC AAA GA-3’ Forward NcoI 165-187 
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Name Sequence 
Forward
/Reverse 
Restriction 
site 
Nucleotidesa 
FBP 
FBP-F-KH1 5’-CTT GCC ATG GGA TTT GGA ACA CAG TTA CCA CCG ATG CA-3’ Forward NcoI 342-367 
FBP-R-KH4 5’-CT TGA AGC TTA CCC TAA AGG ATT TAC TGG GCC A-3’ Reverse HindIII 1433-1454 
Nbox-F 
5’-GCA TCC ATG GGC TAT GTG AAC GAT GCG TTT AAA GAT GCG 
CTG CAG CGC GCG CGC CAG ATT GCG GCG AAA ATT GGC GGC GAT 
GCG GGC ACC AGC TAA GCT TAT CG-3’ 
Forward NcoI -b 
Nbox-R 
5’-CG ATA AGC TTA GCT GGT GCC CGC ATC GCC GCC AAT TTT 
CGC CGC AAT CTG GCG CGC GCG CTG CAG CGC ATC TTT AAA CGC 
ATC GTT CAC ATA GCC CAT GGA TGC-3’ 
Reverse HindIII -b 
a
 corresponding nucleotides in the cDNA sequence: AF165892 for FIR and NM_003902 for FBP 
b
 these primers were not used in PCR, but paired together and cloned into the expression vector 
Restriction sites are underlined and STOP codons are in italic 
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 Table 2 Summary of the FIR and FBP constructs. 
 
Construct name Protein Residues cloneda Forward primer Reverse primer 
FIR RRM1-RRM2b FIR 103-297 F-RRM1-L R-RRM2-L 
FIR RRM1-RRM2 (103-287) FIR 103-287 F-RRM1-L R-RRM2-S 
FIR RRM1-RRM2 (110-297) FIR 110-297 F-RRM1-S R-RRM2-L 
FIR RRM1-RRM2 (110-287) FIR 110-287 F-RRM1-S R-RRM2-S 
FIR RRM1 (103-207) FIR 103-207 F-RRM1-L R-RRM1-L 
FIR RRM1 (103-188) FIR 103-188 F-RRM1-L R-RRM1-S 
FIR RRM1 (110-207) FIR 110-207 F-RRM1-S R-RRM1-L 
FIR RRM1 (110-188) FIR 110-188 F-RRM1-S R-RRM1-S 
FIR RRM2 (189-297) FIR 189-297 F-RRM2-L R-RRM2-L 
FIR RRM2 (189-287) FIR 189-287 F-RRM2-L R-RRM2-S 
FIR RRM2 (208-297) FIR 208-297 F-RRM2-S R-RRM2-L 
FIR RRM2 (208-287) FIR 208-287 F-RRM2-S R-RRM2-S 
FBP Nbox-KH1-KH4 FBP 27-455 FBP-F-Nbox FBP-R-KH4 
FBP KH1-KH4 FBP 85-455 FBP-F-KH1 FBP-R-KH4 
FBP Nbox FBP 27-52 Nbox-F Nbox-R 
a
 numbering according to NP_055096 for FIR and NP_003893 for FBP 
b
 main construct of FIR used 
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the primers that introduced 5’ NcoI and 3’ HindIII restriction sites (Tables 1 and 2).  
The PCR products were further processed as described above for FIR. 
The FBP Nbox (amino acids 27-52, NP_003893) expression plasmid was 
generated by pairing two complementary oligonucleotides (Tables 1 and 2) and their 
subsequent cloning into pETM-30 vector as described above. The sequence of 
oligonucleotides was optimised for expression in E. coli cells and introduced N-terminal 
Y residue to facilitate quantification of the recombinant peptide. 
The nucleotide sequence of the expression plasmids was confirmed by DNA 
sequencing (Lark Technologies). 
 
 
 
2.4.2 Protein expression 
 
Expression of the FBP Nbox-KH1-KH4 and FBP KH1-KH4 proteins has been 
performed by David Hollingworth at the National Institute for Medical Research, 
London, UK. 
Unlabelled recombinant FBP and FIR proteins were expressed in E. coli BL21 
(DE3) cells (Invitrogen) growing in Luria-Bertani broth (LB medium) with kanamycin 
(50 µg/ml) (Sigma). 25 µl of the cells were transformed using a standard heat shock 
protocol with 0.5 µl of the expression plasmid (~ 20 ng/ml). 100-300 µl of transformed 
cells were used to inoculate 100 ml starting cultures in LB media. The cells were grown 
at 37 °C until the optical density at 600 nm (OD600) reached a value of 1. 50 ml of      
the starting cultures were used to inoculate 1.25 l of LB media and the cells were grown 
at 37 °C until the OD600 = 0.6. Protein expression was induced with isopropyl               
β-D-1-thiogalactopyranoside (IPTG) (0.5 mM final concentration) (Sigma). The cells 
were cultured for further four hours, harvested by centrifugation (Beckman J2-21 
centrifuge, rotor JA-10, 7000 rpm, 10 min., 4 °C) and stored at -80 °C. Labelled (15N or 
15N13C) FIR RRM1-RRM2, (15N) FIR RRM2 and (15N or 15N13C) FBP Nbox were 
obtained by expressing the constructs in cells growing in M9 minimal media containing 
13C6-D-glucose (Cambridge Isotope Laboratories) as the only source of carbon and/or 
15NH4Cl or (15NH4)2SO4 (Cambridge Isotope Laboratories) as the only source of 
61 
nitrogen. 15N13C2H-labelled FIR RRM1-RRM2 was obtained by growing the cells in     
a 2H2O (GOSS Scientific Instruments Ltd.) solution of the media above. 
 
 
 
2.4.3 Protein purification 
 
Purification of FBP Nbox peptide on a Zorbax 300 SB-C18 column and 
purification of FBP protein constructs have been performed by David Hollingworth at 
the National Institute for Medical Research, London, UK. 
Frozen cells were resuspended in Equilibration buffer (10 mM Tris-HCl pH 8.0, 
10 mM imidazole, 200 mM NaCl, 2 mM β-mercaptoethanol) (10 ml per 1 l of cell 
culture) with 0.5% (v/v) Triton X-100, DNase I (Roche) and lysozyme (Sigma), 
sonicated on ice (Branson Sonifier 250, power output 90 W, 90% duty cycle, 3 x 40 s) 
and centrifuged (Beckman J2-21 centrifuge, rotor JA-20, 18000 rpm, 40 min., 4 °C). 
The overexpressed recombinant HisTag-GST-FIR RRM1-RRM2 and HisTag-
GST-FIR RRM2 proteins were purified from the soluble fraction using immobilised 
metal ion affinity chromatography (IMAC) columns (Qiagen) according to                  
the manufacturer’s instructions. Briefly, the soluble fraction was applied onto the IMAC 
column (5 ml volume, gravity flow) equilibrated with 50 ml of Equilibration buffer. 
Next, the column was washed (50 ml of Washing buffer – 10 mM Tris-HCl pH 8.0,    
10 mM imidazole, 1 M NaCl, 2 mM β-mercaptoethanol) and the protein was eluted with 
25 ml steps of 30, 100 and 300 mM imidazole in 10 mM Tris-HCl pH 8.0, 1 M NaCl,   
2 mM β-mercaptoethanol (Elution buffers 30, 100 and 300). The majority of the fusion 
proteins was found in 100 mM imidazole fractions. The HisTag-GST fusion was 
removed by overnight TEV protease digestion (2.5 µM enzyme) at 4 °C during dialysis 
against Equilibration buffer, followed by a second IMAC step. Briefly, the digested 
protein was applied onto the equilibrated (50 ml of Equilibration buffer) IMAC column. 
Once the solution passed through, additional 5 ml of Equilibration buffer was added to 
wash out the recombinant protein not bound to the column and then the flow-through 
fraction was further purified passing it through the second IMAC column. The FIR 
RRM1-RRM2 and FIR RRM2 solutions were concentrated (final volume < 5 ml) in    
an Amicon stirred cell (10 kDa cut-off membrane, Millipore) and purified by size-
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exclusion chromatography (SEC) (HiLoad Superdex 75 16/60 column, Pharmacia) in  
10 mM Tris-HCl pH 8.0, 200 mM NaCl, 2 mM β-mercaptoethanol. The SEC step was 
omitted in one of the preparations (see Results). The pure proteins (> 95 % as assessed 
by SDS-PAGE and Coomassie staining) were dialysed against 10 mM Tris-HCl pH 8.0 
(or pH 7.4), 50 mM NaCl, 100 µM TCEP, concentrated in an Amicon stirred cell       
(10 kDa cut-off membrane, Millipore) to 0.4-0.8 mM and stored in 10 mM Tris-HCl  
pH 8.0 (or pH 7.4), 50 mM NaCl, 2 mM TCEP, 0.05% (w/v) NaN3 in the presence of 
protease inhibitors (Roche) at -80 °C. 
Unlabelled FBPs Nbox peptides (Table 3), with and without an N-terminal        
Y residue, were chemically synthesised (Peptide Synthesis Facility, University of 
Bristol and in-house, respectively). The peptides were resuspended in 10 mM Tris-HCl 
pH 7.4 at concentration ~ 2 mM and the pH was adjusted to 7.4 with NaOH.              
The addition of Y residue does not affect Kds of FBPs Nbox – FIR RRM1-RRM2 
complexes as assessed by NMR titrations (14 ± 8 µM vs. 8 ± 5 µM for FBP Nbox and   
6 ± 6 µM vs. 13 ± 6 µM for FBP2 Nbox). Thus, for simplicity in the following results 
the peptides are referred as FBP Nbox and FBP2 Nbox for both the peptides with and 
without Y residue. 
Labelled (15N or 15N13C) FBP Nbox peptide (with N-terminal Y) was purified by 
IMAC as described above (the peptide was found in 100 and 300 mM elution fractions), 
dialysed against 10 mM Tris-HCl pH 8.0, 10 mM NaCl and applied to a Zorbax 300 
SB-C18 column (250 x 9.4 mm I.D.; 5-µm particle size, 300-Å pore size; Agilent 
Technologies) at a flow rate of 2 ml/min. and temperature of 40 °C. Initial run 
conditions were 2% eluent B, followed by a step to 20%. The desired peptide was then 
eluted with a linear A-B gradient from 20% B to 55% B over 45 minutes (0.35% 
acetonitrile/min.), where eluent A was 0.1% aqueous trifluoroacetic acid (TFA) in water 
and B was 0.1% TFA in 90% acetonitrile. Desired peak was collected, lyophilised, 
resuspended in water and re-lyophilised. The peptide was stored in 10 mM Tris-HCl  
pH 5.0 (or 8.0), 0.05% (w/v) NaN3 in the presence of protease inhibitors (Roche) at       
-80 °C. 
FBP Nbox-KH1-KH4 and FBP KH1-KH4 were purified by IMAC as described 
above. The IMAC-purified proteins, still containing a high nucleic acid content, were 
concentrated, buffer exchanged into 10 mM Tris-HCl pH 7.4, 50 mM NaCl, 2 mM      
β-mercaptoethanol, and applied to a MonoQ 5/50GL anion exchange column 
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Table 3 Chemically synthesised peptides recapitulating the Nbox peptides of FBP 
proteins. 
 
Peptide Amino acid sequencea Residue number         
in the protein 
FBP Nbox (Y)VNDAFKDALQRARQIAAKIGGDAGTS 27-52 
FBP2 Nbox (Y)RKDAFADAVQRARQIAAKIGGDAATT 70-95 
FBP3 Nbox    KAEGFVDALHRVRQIAAKIDSIPHLN 15-40 
a
 the N-terminal Y residue added to the FBP and FBP2 Nboxes does not affect their 
affinity for FIR RRM1-RRM2 as assessed by NMR titrations 
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(GE Healthcare) equilibrated in the same buffer. The flow-through, which contained 
protein only, was collected, concentrated and buffer exchanged into 10 mM Tris-HCl 
pH 7.4, 20 mM NaCl, 2 mM β-mercaptoethanol. This protein was applied to a 1 ml 
HiTrap Heparin column (GE Healthcare). The protein product was eluted using a linear 
gradient of 20 mM NaCl to 100 mM NaCl in the same buffer, over 30 minutes at a flow 
rate of 1 ml/min. The proteins were stored in 10 mM Tris-HCl pH 7.4, 50 mM NaCl,    
2 mM TCEP, 0.05% (w/v) NaN3 in the presence of protease inhibitors (Roche) at           
-80 °C. 
Proteins and peptides concentrations were determined from the absorbance at 
280 nm and their molecular weights and purity were confirmed by electrospray mass 
spectrometry (in-house). Concentrations of peptides without Y were determined from 
the absorbance at 258 nm. 
 
 
 
2.4.4 ssDNA oligonucleotides 
 
All ssDNA oligonucleotides (Table 4) and Scaffold-Independent Analysis (SIA) 
oligonucleotides pools were chemically synthesised (Sigma and Integrated DNA 
Technologies). 
 
 
 
2.4.5 Circular dichroism 
 
All CD experiments were performed on a Jasco J-715 spectropolarimeter (Jasco) 
equipped with a PTC-348 Peltier temperature-control system. The samples of FIR 
RRM1-RRM2 were prepared in 10 mM Tris-HCl pH 7.4, 50 mM NaCl and 2 mM 
TCEP at 0.14 mg/ml (a far-UV spectrum) or 0.27 mg/ml (thermal unfolding) 
concentrations. A far-UV spectrum of FIR RRM1-RRM2 was recorded at 25 °C.       
For thermal unfolding, a solution of RRM1-RRM2 was gradually heated (from 2 °C to 
65 °C, 2 °C/min., step = 0.1 °C) and the unfolding was monitored at 220 nm. Far-UV 
CD spectra of 50 µM FBPs Nbox peptides in 10 mM Tris-HCl pH 7.4, 20 mM NaCl 
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Table 4 Chemically synthesised ssDNA oligonucleotides used in the binding studies. 
 
Oligonucleotide 
name 
Sequence 
ssFUSE87a 5’-TGCT CCCTG AAATG ATCTA TATTT AATAT ATAAT GTATA TTCCC TCGGG ATTTT TTATT 
TTGTG TTATT CCACG GCATG AAAAA CAA-3’ 
ssFUSE40 5’-ATAAT GTATA TTCCC TCGGG ATTTT TTATT TTGTG TTATT-3’ 
ssFUSE6-40       5’-GTATA TTCCC TCGGG ATTTT TTATT TTGTG TTATT-3’ 
ssFUSE11-40             5’-TTCCC TCGGG ATTTT TTATT TTGTG TTATT-3’ 
ssFUSE16-40                   5’-TCGGG ATTTT TTATT TTGTG TTATT-3’ 
ssFUSE1-35 5’-ATAAT GTATA TTCCC TCGGG ATTTT TTATT TTGTG-3’ 
ssFUSE1-30 5’-ATAAT GTATA TTCCC TCGGG ATTTT TTATT-3’ 
ssFUSE1-25 5’-ATAAT GTATA TTCCC TCGGG ATTTT-3’ 
ssFUSE29       5'-GTATA TTCCC TCGGG ATTTT TTATT TTGT-3’ 
TGTGT 5’-TGTGT-3’ 
TTTTT 5’-TTTTT-3’ 
TATAT 5’-TATAT-3’ 
AAAAA 5’-AAAAA-3’ 
a
 ssFUSE87 corresponds to nucleotides 751-837 of non-coding strand of the c-myc gene (X00364); nucleotides in italic recapitulate      
the ssFUSE40 within ssFUSE87 
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were recorded at 5 °C. The CD signal is reported as the mean residue CD extinction 
coefficient (∆εMRW). The secondary structure content of the different peptides was 
calculated using the SELCON, CDSSTR and CONTIN/LL programs, that are available 
online (http://lamar.colostate.edu/~sreeram/CDPro/). 
 
 
 
2.4.6 NMR spectroscopy 
 
Labelled (15N, 15N13C or 15N13C2H) samples of FIR RRM1-RRM2 were prepared 
in 90% H2O/10% 2H2O solutions of 10 mM Tris-HCl pH 8.0, 50 mM NaCl, 2 mM 
TCEP at concentrations in the range 0.25-0.35 mM. Samples of 15N13C-labelled FBP 
Nbox were prepared in 90% H2O/10% 2H2O solutions of 10 mM Tris-HCl pH 5.0 at 
concentrations in the range 0.35-0.4 mM. Samples of FIR RRM1-RRM2 – FBP Nbox 
complex (labelled : unlabelled ratio = 1 : 2 – 1 : 3 where one of the complex component 
is 15N- or 15N13C-labelled) were prepared in 90% H2O/10% 2H2O or 100% 2H2O 
solutions of 10 mM Tris-HCl pH 8.0, 50 mM NaCl, 2 mM TCEP. The concentration of 
the labelled component was in the range 0.2-0.6 mM. Sample of 15N-labelled FIR 
RRM1-RRM2 – unlabelled ssFUSE29 at 0.4 mM : 0.2 mM ratio was prepared in 90% 
H2O/10% 2H2O solution of 10 mM Tris-HCl pH 7.4, 50 mM NaCl, 2 mM TCEP. 
NMR spectra were recorded on 15N-, 15N13C- or 15N13C2H-labelled samples at  
37 °C or 45 °C on Varian Inova and Bruker Avance spectrometers equipped with 
cryoprobes and operating at 600, 700 and 800 MHz 1H frequencies. The spectra were 
processed with the NMRPipe package (Delaglio et al., 1995) and analysed with Sparky 
(Goddard and Kneller, 2004). 
1HN, 15N, 13Cα, 13Cβ and 13C’ assignments were obtained from standard 
HNCACB, CBCA(CO)NH, HN(CO)CACB, HNCA, HN(CO)CA and HNCO backbone 
experiments (Bax and Grzesiek, 1993; Yamazaki et al., 1994). Side-chain resonance 
assignment was achieved from HCCH TOCSY (mixing time = 12 ms) (Kay et al., 
1993), 15N TOCSY (mixing time = 60 ms) (Marion et al., 1989) and 15N and 13C 
NOESY HSQC experiments (mixing time = 100 ms) (Fesik and Zuiderweg, 1988) 
optimised to observe aliphatic or aromatic resonances. The distance restraints for 
structure calculations were obtained from above mentioned NOESY HSQC experiments 
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and 13C-filtered 13C-edited NOESY HSQC (mixing time = 100 ms) (Zwahlen et al., 
1997). 
1HN exchange protection data were obtained from sofast 15N HMQC (Schanda et 
al., 2005) recorded immediately after resuspension of 15N-labelled FIR RRM1-RRM2 
or 15N-labelled FIR RRM1-RRM2 – unlabelled FBP Nbox complex in 100% 2H2O 
solution of 10 mM Tris-HCl pH 8.0, 50 mM NaCl, 2 mM TCEP. 
T1, T2 and hetNOE parameters were obtained from standard experiments (Kay 
et al., 1989) recorded on 15N-labelled samples at 37 °C and 600 MHz 1H frequency and 
analysed by using NMRPipe routines (Delaglio et al., 1995). T1/T2 ratio of residues in 
well-defined secondary structure elements were used to estimate the rotational 
correlation times of proteins and complexes with the program ModelFree 
(http://biochemistry.hs.columbia.edu/labs/palmer/software/modelfree.html). 
Samples, temperature, solvent and 1H frequency of spectrometers used for 
individual 3D and relaxation experiments can be found in Appendix II. 
 
 
 
2.4.7 Structure calculations 
 
Distance and angle restraints were used to perform structure calculations with 
ARIA 1.2 (Linge et al., 2001). Experimental distance restraints were achieved by 
integrating Sparky assigned NOE peaks with XEASY (Bartels et al., 1995). Dihedral 
restraints (φ and ψ) were obtained from the chemical-shift-based TALOS database 
(Cornilescu et al., 1999). For the protein, H-bond restraints were added in subsequent 
calculations if an exchange-protected 1HN was H-bonded in at least 50% of                 
the preliminary structures generated in a given run. For the peptide, H-bond restraints 
were added for the α-helical region of the peptide (A30-K44). 
In iterations 0-7 of ARIA calculations fifty randomised conformers were subject 
to simulated annealing with a standard CNS protocol (Brunger et al., 1998). The ten 
lowest-global-energy structures were used for assignment at the next iteration.              
In iteration 8 the number of generated structures was increased to 200. Finally,           
the 20 lowest-energy obtained structures were water refined (Linge et al., 2003).        
For the structure calculations of the complex, the automatic distance calibration was 
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turned off and the inter-molecular distances were calibrated semi-quantitatively (short = 
2.8 Å, medium = 3.5 Å, long = 5.0 Å and very long = 6.0 Å), while the upper bounds 
for all intra-molecular restraints were set up to 6 Å. The quality of each generated 
family was evaluated with PROCHECK_NMR (Laskowski et al., 1996). The structures 
were displayed and analysed with MOLMOL (Koradi et al., 1996), PYMOL 
(www.pymol.org) and InsightII (Accelrys). Families of FIR RRM1-RRM2 and FIR 
RRM1-RRM2 – FBP Nbox complex were deposited in the PDB with the accession 
codes 2KXF and 2KXH, respectively. 
 
 
 
2.4.8 Binding assays 
 
2.4.8.1 NMR 
 
25-75 µM 15N-labelled samples of FIR RRM1-RRM2 in 10 mM Tris-HCl       
pH 7.4, 50 mM NaCl, 2 mM TCEP were titrated with unlabelled FBP Nbox or ssDNA 
oligonucleotides (29mer or 5mers). Titrations of 15N- and 15N13C-labelled FBP Nbox 
with unlabelled FIR RRM1-RRM2 were performed in 10 mM Tris-HCl pH 5.0, 6.5 or 
8.0, 50 mM NaCl, 2 mM TCEP at 50-70 µM peptide concentrations.                           
For the tri-molecular titrations, saturated complexes of 25-75 µM 15N-labelled FIR 
RRM1-RRM2 with ssFUSE29 (1 : 1.5 ratio), 5’-TGTGT-3’ oligonucleotide (1 : 8 ratio) 
or FBP Nbox (1 : 6 ratio) in 10 mM Tris-HCl pH 7.4, 50 mM NaCl, 2 mM TCEP were 
titrated with FBP Nbox or 5’-TGTGT-3’ oligonucleotide. 15N sofast HMQC (Schanda 
et al., 2005), or 13C HSQC (Palmer et al., 1991) spectra were recorded at each titration 
point at 37 °C or 45 °C on Varian Inova and Bruker Avance spectrometers equipped 
with cryoprobes and operating at 600, 700 and 800 MHz 1H frequencies. The set-ups for 
individual titration experiments can be found in Appendix III. To obtain Kd values, first 
the average chemical shift perturbations (∆<=>?) at each titration point for 7-10 non-
overlapped peaks were calculated: 
 
∆<=>?  @A∆<B10 E
4 5 
∆<F4 
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where: 
∆<B chemical shift change in 15N dimension ∆<F chemical shift change in 1H dimension 
 
Then, ∆<=>? were plotted as a function of titrant : analyte (depending on the set-up 
either ligand : protein or protein : peptide) ratio and a two-parameter nonlinear least-
squares fit of the data was performed for each peak in the program Origin (OriginLab), 
using a one-site binding model which corrects for dilution effect (Kannt et al., 1996): 
 
∆<=>?  12 ∆<H=I JK  LK4  4NO 
K  1 5 N 5 PN 5 QPQR=  
where: 
∆<=>? average chemical shift perturbation of a given resonance at a given titration point 
∆<H=I chemical shift perturbation of a given resonance for N ST N titrant : analyte ratio 
P analyte concentration at the start of the titration 
Q stock concentration of the titrant 
R= association constant 
 
Kd values are reported as an average ± 2 standard deviations. 
It is import to notice that the appearance of NMR spectra of the complexes is 
affected by the rate of exchange process between the free and bound states of the 
interacting molecules. Three different exchange regimes can be distinguished: 
 
Slow exchange   2π|νW  νX| Y J Z[ 5 Z\O 
Intermediate exchange  2π|νW  νX|~ J Z[ 5 Z\O 
Fast exchange    2π|νW  νX| ] J Z[ 5 Z\O 
where: 
νF  resonance frequency of the nucleus in the free state 
νB  resonance frequency of the nucleus in the bound state 
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τF  lifetime in the free state 
τB  lifetime in the bound state 
 
In case of slow exchange two separate resonances are observed for a given nucleus at 
frequencies of free and bound species. In case of fast exchange a single averaged 
resonance is observed at frequency corresponding to the weighted average of 
frequencies of free and bound species. Thus, in case of fast exchange, the position of the 
resonance reports on the fraction of the bound molecules and this relationship is used to 
derive Kd values of the complex using the methodology described above. In case of 
intermediate exchange, the lineshape of the resonances is not longer Lorentzian and 
despite a single maximum can still be observed it does not longer report accurately on 
the fraction of bound molecules. Thus, inclusion of resonances in the intermediate 
exchange into analysis used to derive Kd values can introduce significant systematic 
errors (Feeney et al., 1979). In the case of titrations of FIR RRM1-RRM2 with FBP and 
FBP2 Nboxes the resonances with the highest ∆δavg were in the intermediate exchange 
as revealed by resonance broadening for partially (~20-80%) saturated protein. One 
solution to this situation is to exclude such the resonances from the analysis and to 
perform the analysis for resonances with small difference in the resonance frequencies 
between the free and bound states. However, in this case analysis relies on measuring 
small shifts in the peak positions that can be compromised by the resolution of the NMR 
spectra. Indeed in case of FIR RRM1-RRM2 titrations with FBP/FBP2 Nboxes the 
values of chemical shift difference were too small to allow a reliable measurement of 
the dissociation constants. Therefore, we simulated peak shifts and lineshape changes 
using a macro written by Dr Thomas A. Frenkiel (National Institute for Medical 
Research, London, UK) based on numerical solution of the Bloch-McConnell equation 
for the propagation of errors (Figure 9). The simulation was performed using a 15 Hz 
linewidth for the protein, a Kd of 10 µM, a kon of 1 x 108 M-1s-1 and a constant protein 
concentration of 50 µM on three resonances that shift respectively by 20 Hz, 50 Hz and 
200 Hz. These conditions recapitulate the ones of our titrations and place the resonance 
with the larger shift in a fast-to-intermediate regime of exchange. The differences 
between the Kds determined (Figure 9B) for the three resonances provide a realistic 
error for our experimental conditions and indicate that the error we use is larger (see 
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Figure 9 Simulated lineshape changes (A) and peak shifts (B) of three resonances that 
shift respectively by 20 Hz, 50 Hz and 200 Hz during a titration. The simulations were 
performed for protein linewidth of 15 Hz, protein concentration of 50 µM,                     
a Kd of 10 µM and a kon of 1 x 108 M-1s-1. 
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Figure 33) than the theoretical error due to inclusion of resonances with the highest 
shifts into the analysis. 
 
 
 
2.4.8.2 Scaffold-Independent Analysis 
 
Scaffold-Independent Analysis (SIA) was performed by Dr. Irene Diaz-Moreno 
(National Institute for Medical Research, London, UK) as described in Beuth et al. 
(Beuth et al., 2007) with 16 pools of 5mer DNA oligonucleotides (nANNN, nGNNN, 
nCNNN etc., where N is any nucleotide). In brief, solutions of 25 µM 15N-labelled FIR 
RRM1-RRM2 in 10 mM Tris-HCl pH 7.4, 50 mM NaCl, 2 mM TCEP were titrated 
with individual DNA pools (ratios 1 : 0, 1 : 1 and 1 : 4). 15N sofast HMQC spectra 
(Schanda et al., 2005) were recorded at each titration point at 37 °C on a Varian Inova 
spectrometer equipped with cryoprobe and operating at 800 MHz 1H frequency. 
Average chemical shift perturbations ∆<=>? (calculated as above) of 15 peaks were 
analysed to obtain SIA scores (Beuth et al., 2007). First, for each peak, the values of 
∆<=>? at the final titration point with individual DNA pools were calculated. Then, the 
values of ∆<=>? obtained from titrations with four DNA pools with a fixed nucleotide in 
one position (e.g. for nucleotide fixed in position 1 DNA pools used were nANNN, 
nGNNN, nCNNN and nTNNN) were normalised to the highest of the four. Finally, for 
each DNA pool, the normalised shift values were averaged over all 15 peaks to yield a 
final SIA score for a given nucleotide at a given position. For an example of the 
oligonucleotide composition of DNA pool and calculation of SIA scores for FIR 
RRM1-RRM2 protein see Appendix IV. The final results were visualized with 
WebLogo (http://weblogo.berkeley.edu/logo.cgi) and validated by performing the 
titration experiments with four ad hoc 5mer ssDNA, which were chosen based on the 
SIA scores. 
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2.4.8.3 Bio-Layer Interferometry 
 
All BLI experiments were performed in 10 mM Tris-HCl pH 7.4, 150 mM NaCl, 
2 mM TCEP, 0.5 mg/ml BSA on an Octet Red instrument (ForteBio, Inc., Menlo Park, 
CA) operating at 25 °C. Streptavidin-coated biosensors with immobilised biotinylated 
ssFUSE DNA (Sigma) were exposed to different concentrations of FIR RRM1-RRM2, 
FBP Nbox-KH1-KH4 and FBP KH1-KH4 or combinations of them as described in    
the results section. 
The simplest model for the interaction of immobilized DNA (D) with a mobile 
protein (P) involves the reversible formation of a 1 : 1 complex (DP), with association 
rate constant kon (units: M-1s-1) and dissociation rate constant koff (units: s-1). The 
equilibrium dissociation constant for the interaction is given by Kd = koff/kon (units: M). 
Under pseudo first-order conditions ([PTot] >> [DTot]) the differential rate equation 
describing the change in concentration of DP with time is: 
 
d_DPadt  kde_Pfdga
_Dfdga  _DPa  kdhh_DPa 
 
Because the instrument’s response, R, is directly proportional to the amount of complex 
formed this equation can be rearranged to give: 
 dRdt  kdeRjkl_Pfdga  R
kde_Pfdga 5 kdhh 
where: 
Rmax the response observed at complete saturation of the immobilised DNA 
 
The time course for the association phase is then described by the exponential function: 
 
R
t  Rmn21  epqrsg3 
where: 
Req the plateau response observed at a particular value of [PTot] 
kobs observed rate constant 
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The observed rate constant kobs (units: s-1) can be determined using standard non-linear 
least-squares methods and depends on protein concentration according to: 
 
kdt,  kde_Pfdga 5 kdhh 
 
The association and dissociation rate constants can be determined by plotting kobs 
against [PTot]. The ratio of the kinetic constants (koff/kon) is equal to the equilibrium 
dissociation constant (Kd). 
When the sensors are moved to wells without protein (at time t0) the complex 
dissociates exponentially with time according to the following equation: 
 
R
t  R
tuepqvv
ggw 
 
Analysis of the dissociation phase therefore provides an independent measure of koff. 
An independent value for the equilibrium dissociation constant can also be 
determined from the values of the plateau signal (Req) observed at different protein 
concentrations using the following equation: 
 
Rmn  _PfdgaRjklKy 5 _Pfdga 
where: 
Rmax the response observed at complete saturation of the immobilised DNA 
 
This approach can also be applied for reactions that are too fast for a kinetic analysis. 
It is important to notice that the values of kon, koff and Kd reported are derived 
from single experiments because the multiple repetitions were not feasible due to the 
lack of the material. Therefore the errors reported are the fitting errors and they do not 
account on the possible variations in the values obtained from independently repeated 
experiments. 
The BLI analysis must also consider that, in principle, the DNA oligonucleotides 
used are long enough to accommodate an additional protein molecule(s) bound on non 
optimal site. Indeed at high protein concentration it was necessary to use a double 
exponential fits to account for a minor component probably associated with some 
residual non-specific binding to the DNA. Furthermore, in case of FIR protein at least 
75 
two optimal DNA sequences are present in the ssFUSE40 DNA used. Due to the lack of 
additional information, the analysis was performed with the assumption that the 
multiple binding sites for FIR are equivalent and non-interacting. This is based on the 
similar affinity that RRM1-RRM2 shows for the two high affinity T and TG-rich sites 
present on ssFUSE40. The consistency of the results obtained from the analysis of 
association phase, dissociation phase and the amplitude of BLI signal suggests that the 
non-specific binding does not significantly affect the results. 
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Chapter 3 
 
Results – Structure            
of the first two RNA 
recognition motifs (RRM) 
of FIR (FIR RRM1-RRM2) 
3.  
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3.1 Expression and purification of the FIR RRM1-RRM2 
protein 
 
The FUSE-mediated regulation of c-myc proto-oncogene relies on the interplay 
between ssFUSE, FBP and FIR. The first two RRMs of FIR (FIR RRM1-RRM2) are 
necessary and sufficient to interact with ssFUSE and FBP and FBP2, but not FBP3, 
proteins (Chung et al., 2006). Thus, I undertook further studies to structurally and 
biophysically characterise this part of FIR protein. 
The first challenge towards in vitro studies of isolated domains is obtaining 
stable and soluble protein. Nowadays, many computational methods are available to 
predict the boundaries of the domains within protein (Card and Gardner, 2005). 
However, small variations in the positions of N- and C-termini of the expressed 
constructs may greatly affect the behaviour of the domains in the solution (Card and 
Gardner, 2005). Therefore, parallel cloning and expression of slightly different 
constructs are frequently performed to screen for the solubility and stability of            
the domains (Card and Gardner, 2005). Two forward and two reverse primers were 
designed upstream and downstream of FIR cDNA sequences coding for RRM1 and 
RRM2 domains (Table 1, Figure 10). Combinations of these primers were used to clone 
four variants of each of FIR RRM1, FIR RRM2 and FIR RRM1-RRM2 (Figure 10). 
The soluble proteins were obtained for FIR RRM1-RRM2 and FIR RRM2 constructs, 
but not for FIR RRM1 (data not shown). 
The 15N-labelled samples of the longest variants of the FIR RRM2 (residues 
189-297) and FIR RRM1-RRM2 (residues 103-297) were prepared for further 
characterisation. The proteins were purified from the soluble fractions of the bacterial 
cells lysates on IMAC columns. SDS-PAGE analysis revealed bands with the masses 
corresponding to the HisTag-GST fusion proteins of FIR RRM1-RRM2 (~ 50 kDa) and 
FIR RRM2 (~ 40 kDa) (Figure 11, Elution 100 lanes). The second intense band            
(~ 30 kDa) in the FIR RRM2 sample likely represents the fusion itself suggesting that 
the construct is not well tolerated by E. coli cells. The fusions were removed from      
the recombinant proteins by TEV protease digestion and second IMAC step, yielding 
the bands with expected molecular masses (~ 22 kDa for FIR RRM1-RRM2 and           
~ 10 kDa for FIR RRM2) (Figure 11, Flow-through 1 and 2 lanes). Finally, these 
samples were cleaned using SEC and stored at -80 °C until use. 
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Figure 10 Cloning of the first two RRM domains of FIR. Eight primers (bottom) were 
used to clone four variants of each of FIR RRM1-RRM2, FIR RRM1 and FIR RRM2 
(arrows). 
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Figure 11 SDS-PAGE analysis of the recombinant FIR RRM1-RRM2 and FIR RRM2 
proteins. The recombinant fusion proteins were purified on the IMAC columns from  
the soluble fractions of the bacterial cell lysates (Elution 100). The eluted proteins were 
treated overnight with TEV protease (After TEV) and the fusions (HisTag-GST) were 
removed by a two-step purification on the IMAC columns. The recombinant FIR 
RRM1-RRM2 and FIR RRM2 were found in the flow-through fractions (1 and 2), while 
the tags were retained on the columns (Elution 1 and 2). 
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3.2 Initial characterisation of the FIR RRM2 and FIR 
RRM1-RRM2 proteins 
 
3.2.1 NMR spectroscopy 
 
The fold and stability of the recombinant FIR RRM2 and FIR RRM1-RRM2 
proteins were assessed using 1H-15N correlation NMR experiments, where each peak 
reports on a pair of covalently bonded 1H and 15N nuclei. The resonance frequencies of 
the observed nuclei and therefore the position of the corresponding peaks in                
the spectrum are dependent on the local chemical environments. These resonance 
frequencies are also dependent on the magnetic field strength at which the NMR 
measurements are performed and to remove this variable and facilitate the comparison 
of different experiments at various field strengths the frequencies are reported on           
a chemical shift parts per million (ppm) scale according to the equation: 
 
<_zz{a  10 · }  }}  
where: 
δ chemical shift in ppm 
ν Larmor frequency of a given nucleus 
νref Larmor frequency of the line from the agreed reference compound 
 
The influence of chemical environment on the resonance frequencies allows one to 
evaluate the fold of a protein from the dispersion of the signals in the NMR spectra. In 
an 1H-15N correlation spectrum, the chemical shifts of the backbone amide groups of 
proteins in a random-coil conformation are clustered around 125 ppm (except glycines – 
110 ppm) in the 15N dimension and 8.3 ppm in the 1H dimension, whereas structured 
proteins resonances normally show larger signal dispersion (Rehm et al., 2002).          
2D sofast 15N HMQC spectra of FIR RRM2 and FIR RRM1-RRM2 recorded at 27 °C 
show well dispersed signals (~ 106 ppm to ~ 132 ppm in a 15N dimension and ~ 6.5 ppm 
to ~ 11 ppm in a 1H dimension) (Figure 12) and confirm the folded state of                  
the recombinant proteins. Interestingly, the peaks of FIR RRM2 do not overlap with 
FIR RRM1-RRM2 signals, showing that amide groups of the same residues in the two 
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Figure 12 NMR studies of FIR RRM2 (red) and FIR RRM1-RRM2 (blue) fold and 
stability. 2D sofast 15N HMQC were recorded on 0.1 mM samples in 10 mM Tris-HCl 
pH 7.4, 50 mM NaCl, 2 mM TCEP at 27 ºC (top) and 37 ºC (bottom). FIR RRM2 
interacts with RRM1 and is not stable at higher temperature. 
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constructs are not in equivalent chemical environments and confirming that FIR RRM1 
and RRM2 interact with each other. Furthermore, at 37 °C FIR RRM1-RRM2 is still 
properly folded, while FIR RRM2 equilibrium is shifted towards unfolded species, 
demonstrating that its stability depends on the interaction with RRM1 (Figure 12). 
 
 
 
3.2.2 Circular dichroism 
 
The far-UV CD spectrum of a protein reflects the secondary structure content 
(Figure 13A, inset) and the spectra of proteins that contain different secondary elements 
are assumed to be a linear combination of the spectra of the individual elements (Martin 
and Schilstra, 2008). Importantly, the contributions are not equivalent because of 
differences in the CD extinction coefficients of chromophores within different 
secondary structure elements, for example in case of αβ proteins (e.g. RRM domains) 
the spectrum is dominated by the α-helical component (Martin & Schilstra, 2008).    
The far-UV spectrum of the FIR RRM1-RRM2 protein shows the presence of α-helices 
(negative bands at ~ 208 nm and ~ 222 nm) and confirms the folded state of the protein 
(Figure 13A). 
The CD signal changes in response to conformational rearrangements and 
therefore it can be used to study the thermal stability of the protein. A sample of FIR 
RRM1-RRM2 was gradually heated and CD signal was monitored at 220 nm. The data 
showed that thermal unfolding of RRM1-RRM2 protein is irreversible and therefore      
a full thermodynamic analysis is not possible. However, the transition midpoint of      
the protein, defined as the temperature at which a CD signal is halfway between         
the values for the two states (that I assume to be folded and unfolded protein), is 57.2 °C 
(Figure 13B). Interestingly, a single-step transition is observed, indicating that RRM1 
and RRM2 unfold at similar or the same temperature, which is in agreement with       
the inter-domain interaction. 
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Figure 13 CD studies of the FIR RRM1-RRM2 protein fold and stability. A) Far-UV 
spectrum of the RRM1-RRM2 recorded at 25 °C and pH 7.4. The minima at 208 nm 
and 222 nm indicate a significant α-helical content. Inset – the far-UV spectra of:         
a) – an all-α-helical protein (myoglobin, 4mbn); b) – an all-β-strand protein 
(prealbumin, 2pab) and c) – an unordered protein (acid denaturated staphylococcal 
nuclease). All spectra are available on the internet at: http://lamar.colostate.edu/ 
~sreeram/CDPro/. B) CD-monitored thermal unfolding curve of the FIR RRM1-RRM2 
protein. The dashed line indicates the midpoint of the transition. 
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3.3 Optimisation of the experimental parameters for NMR 
studies 
 
The S/N ratio of NMR signal is dependent on the concentration of the protein 
and its molecular weight/aggregation state that affect the resonance linewidth.           
The resonance linewidth, defined as the width at half-height of the peak (Figure 14), is 
proportional to the transverse relaxation rate constant R2. The values of the R2 rate 
constant, in turn, are proportional to the overall rotational correlation time (τc) that 
reports on the molecular weight and shape of the studied species. For a globular       
non-aggregated protein, a theoretical values of τc can be obtained from Stoke’s equation 
(Cavanagh, 2007): 
 
τ  4πηr3kXT  
where: 
ηw viscosity of the solvent 
kB Boltzmann constant 
T temperature 
rH effective hydrodynamic radius of the protein, that can be estimated from          
the molecular weight of the protein from the equation: 
r  @3VM4πN
 5 r 
where: 
V specific volume of the protein 
Mr molecular weight of the protein 
NA Avogadro’s number 
rw thickness of the hydration layer 
 
In general, for the bigger proteins (larger Mr), the R2 values are higher and 
consequently, the resonance linewidths are broader. In case of aggregation, the Mr of   
the species in the sample increases, causing broadening of the resonances and 
decreasing S/N (Figure 14). 
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Figure 14 Schematic representation of the relationship between resonance linewidth 
(W) and molecular weight (M). Resonance linewidth (W) is defined as a full-width at 
half-height (0.5 h) of the resonance lineshape. Increase in the molecular weight (M) of 
the species, also due to aggregation (7 x M4), results in the broadening of resonance 
linewidth (W). Because the integral of the resonance (V) is constant for the same 
amount of atoms, the S/N decreases for heavier species. 
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Initially, it was noticed that the purity of recombinant FIR RRM1-RRM2 is 
satisfactory prior to SEC (see Figure 11). Therefore, this purification step was omitted 
to shorten the preparation procedure and to increase the yield of the protein. However,  
a comparison of the 1D (Figure 15A) and 2D (data not shown) NMR spectra of FIR 
RRM1-RRM2 (with and without SEC purification) revealed that incorporation of       
the SEC step improved S/N in the NMR spectra and resulted in narrower linewidths.    
In the chromatogram from SEC, FIR RRM1-RRM2 protein is eluted at the expected 
retention volume of ~ 80 ml (Figure 15B). Faster-migrating peaks (at ~ 50 ml, ~ 67 ml 
and ~ 75 ml) with A260/A280 ratio ≈ 2 likely represent trace amounts of nucleic acids   
co-purified with the protein. We concluded that the presence of nucleic acid broadens 
FIR RRM1-RRM2 resonances. 
The interaction between two macromolecules changes the chemical environment 
of amide groups at the contact interfaces and therefore 1H-15N correlation experiments 
could be employed to monitor the interactions in the FUSE–FBP–FIR system.              
As a preliminary step to the binding assays I optimised quality of the 2D 15N HSQC 
spectra by screening temperature and salt concentration. The best conditions (37 °C and 
50 mM NaCl) were used in subsequent binding experiments where 15N-labelled FIR 
RRM1-RRM2 protein was titrated with either the FBP Nbox peptide or the 29mer 
ssFUSE (ssFUSE29) (Figure 16). The selective chemical shift perturbations (CSP) 
indicate that both the peptide and the ssFUSE bind to the FIR RRM1-RRM2 protein. 
Based on these results further NMR studies were planned to determine the high 
resolution structure of the FIR RRM1-RRM2 alone and in the complex with FBP Nbox 
peptide. 
3D backbone NMR experiments used for structural studies of proteins are 
intrinsically insensitive due to the rapid relaxation rates (high R2) of the nuclei involved 
in the magnetisation transfer (Gardner and Kay, 1998). The concentration of protein 
used must therefore be higher than the one used in 1H-15N correlation experiments 
(Markley et al., 2003). Unfortunately, preliminary NMR experiments performed on       
1 mM sample of 15N13C-labelled FIR RRM1-RRM2 protein showed that the conditions 
used for the binding studies, where the protein was at a lower (50-150 µM) 
concentration, are not suitable to obtain good quality data, probably because of transient 
aggregation. Therefore, a new set of optimisation experiments was carried out testing    
a range of protein concentrations, buffers, pH, salt concentrations, anti-aggregation 
agents and reducing agent concentrations. In most cases no significant change was  
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Figure 15 SEC purification step significantly improves S/N. A) Amide proton (left) and 
methyl (right) regions of 1D 1H NMR spectra recorded on 0.35 mM samples of the FIR 
RRM1-RRM2 that was not (green) or was (red) subject to SEC. Improved S/N and 
resolution are obtained after SEC purification as a result of narrower resonance 
linewidths. B) Chromatogram from SEC of the FIR RRM1-RRM2 sample. Faster-
migrating peaks with relatively high absorbance at 260 nm are separated from the main 
protein peak (~ 80 ml). 
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Figure 16 Titrations of the 15N-labelled FIR RRM1-RRM2 with the FBP Nbox peptide 
and with the ssFUSE29. A) Superimposed 2D 15N HSQC spectra recorded during       
the titration of the RRM1-RRM2 with the FBP Nbox peptide. The different titration 
points (protein : peptide ratios) are colour-coded as follow: 1 : 0 – red; 1 : 0.4 – blue;    
1 : 1 – green and 1 : 3 – orange. B) Superimposed 2D 15N HSQC spectra recorded 
during the titration of the RRM1-RRM2 with the ssFUSE. Different titration points 
(protein : DNA ratios) are colour-coded as follow: 1 : 0 – red; 1 : 0.5 – blue; 1 : 1 green 
and 1 : 3 orange. In both panels the arrows indicate examples of perturbed cross-peaks 
(from the free to the bound position). 
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observed, but ~ 2 fold improvement in S/N was achieved in the 2D (1H-13C) version of 
the HNCACB spectrum when the protein concentration was reduced from 1 mM to    
0.4 mM and the pH was changed from 7.4 to 8.0 (data not shown). 
 
 
 
3.4 Backbone and side-chain assignment of the FIR RRM1-
RRM2 
 
A ~ 60-70% completeness of backbone assignment was obtained from spectra 
recorded on 15N13C-labelled FIR RRM1-RRM2 samples, with the missing resonances 
mainly from residues in RRM1. To obtain a more complete backbone assignment it was 
necessary to deuterate FIR RRM1-RRM2. Because backbone experiments correlate 
exchangeable protons with 15N and 13C nuclei, it is possible to substitute                      
the non-exchangeable (13C-attached) protons with deuterons without any loss of 
information. This substitution removes the dipolar interaction between the 13C nuclei 
and the attached protons, which represents the largest component of 13C relaxation 
(Venters et al., 1996). Thus, deuteration leads to the decrease in the rate of transverse 
relaxation of 13C and 1HN nuclei and to the increase in the sensitivity of multi-
dimensional NMR experiments (Gardner and Kay, 1998; Venters et al., 1996).              
A 60-70% deuteration of the FIR RRM1-RRM2 (as assessed from 1D NMR 
experiments) provided ~ 2 fold gain in S/N in NMR experiments compared to     
15N13C-labelled RRM1-RRM2 at pH 8.0 (data not shown). In summary,                      
the optimisation of the experimental conditions and the deuteration of the sample 
increased significantly the number of correlations visible in 3D NMR experiments   
(e.g. HNCACB, Figure 17). 
 By integrating the information from the different backbone experiments I could 
assign 160 out of 185 backbone amides of the FIR RRM1-RRM2 (Figure 18, see 
Appendix V). Interestingly, if the domains are analysed separately the assignment of 
RRM1 is less complete than the one of RRM2 (59 amino acids out of 72 assigned – 
82% completeness for RRM1 vs. 72 amino acids out of 76 – 95% completeness for 
RRM2) (Figure 18). The process of backbone assignment was validated by comparing 
the secondary structure elements identified based on the chemical shifts of 13Cα and 13Cβ 
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Figure 17 An improvement in sensitivity of through-bond experiments is obtained upon 
optimisation of the experimental parameters and partial deuteration of the protein. 
Comparison of the 2D versions of the 3D HNCACB experiment recorded on 1 mM 
15N13C-labelled FIR RRM1-RRM2 at pH 7.4 (left panel) and 0.4 mM 15N13C2H-labelled 
FIR RRM1-RRM2 at pH 8.0 (right panel). Only signals of the amino acids in                 
a random-coil region are visible in the 2D HNCACB spectrum recorded on                    
a non-deuterated sample with non-optimised conditions (left panel). Conversely, signals 
of the amino acids in structured regions, that have significantly higher rotational 
correlation time, are visible in an equivalent spectrum recorded on the deuterated 
sample with optimised conditions (right panel). 
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Figure 18 Overview of the backbone assignment of FIR RRM1-RRM2. The residues 
with assigned and unassigned backbone amide resonances are in blue and black, 
respectively. Prolines, which are not detectable in 1H-15N correlation spectra, are in red. 
The N-terminal four residues, that are a by-product of cloning, are not displayed.         
α-helices (boxes) and β-strands (arrows), identified based on 13Cα and 13Cβ chemical 
shifts, are indicated above the protein sequence in grey (RRM1), green (RRM2) and 
black (linkers). 
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resonances (Metzler et al., 1993) and the characteristic patterns of the NOE cross-peaks 
(Neuhaus and Williamson, 2000) with the expected arrangement of secondary structure 
elements within RRM (Maris et al., 2005) (Figure 18). Interestingly, two additional     
α-helical regions were identified, which are located in the N-terminus of the construct 
(αN) and in the linker between the RRMs (αL). 
 Side-chain assignment resulted in the identification of most of the 1H, 13C and 
some 15N resonances (Appendix V). Here, the missing chemical shift assignments are 
mainly of the residues with long side-chains (e.g. lysines, glutamates, glutamines) 
located on the protein surface and of the residues in flexible loops that are very 
overlapped, have often chemical shifts with random-coil values and show broadened 
methylene resonances most likely due to the high mobility of these regions.                  
A challenging task was also assignment of 1H and 13C in aromatic rings, especially 
those of phenylalanines (nine in FIR RRM1-RRM2) and tyrosines (eight in FIR RRM1-
RRM2). The standard 13C NOESY and HCCH TOCSY experiments used for aliphatic 
side-chain assignment are not efficient in magnetisation transfer in the aromatic ring. 
Unfortunately, the large number of aromatic residues made it impossible to assign 
unambiguously the resonances of 1H from the aromatic ring without further information 
on the connected 13C resonances. The latter was obtained from a 3D 13C NOESY 
experiment optimised for aromatic residues recorded on a doubly labelled sample. 
Furthermore, the increased sensitivity of this experiment for correlations involving 1H 
and 13C resonances from the aromatic ring was particularly useful in the determination 
of the structure, because the additional correlations to ring protons fix the position of 
bulky and rigid aromatic ring in the hydrophobic core of the protein and impose strong 
restraints on the calculated structures. 
 
 
 
3.5 Structure calculations of the FIR RRM1-RRM2 
 
The restraints for structure calculations were derived from 1) NOESY spectra 
(NOE distance restraints), 2) 2H exchange experiment (H-bond distance restraints) and 
3) analysis of chemical shifts with TALOS software (torsion angle restraints). During 
first run of ARIA most of the intra-residual, some of the sequential and medium-range, 
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and approximately ~ 300 long-range NOE distance restraints were used as 
unambiguously assigned, while the rest of NOE cross-peaks were left for automatic 
assignment by ARIA. These distance restraints were supported with TALOS-derived 
torsion angle restraints that were available for most of the secondary structure elements. 
H-bond restraints were not introduced in the first run, because the acceptor group of   
the H-bond can be identified only indirectly from the examination of preliminary 
structures. 
In the following ARIA runs, I gradually increased the number of restraints and 
constantly evaluated them to identify and remove/correct any erroneous data. Briefly:  
1) I verified the NOE restraints that were unambiguously and automatically assigned by 
ARIA and, if correct, I used them as manually assigned in the following runs.               
2) I inserted an H-bond distance restraint only when an exchange-protected 1HN formed 
an H-bond in at least 50% of the calculated conformers in the preceding ARIA run and 
this H-bond is consistent with other available restraints. 3) I removed torsion angle 
restraints from the following runs if the restraint was violated or a large number of NOE 
distance restraints violations was observed nearby. In the final run of ARIA 4368 NOE 
distance restraints (2780 inter-residual), 63 H-bond restraints and 236 φ and ψ torsion 
angle restraints were used (Table 5). 
 
 
 
3.6 Solution structure of the FIR RRM1-RRM2 
 
The obtained solution structure of the FIR RRM1-RRM2 is well defined with 
the root mean square deviation (RMSD) from the mean structure of 0.91 Å for 
backbone atoms and 1.36 Å for all heavy atoms (Table 5 and Figures 19, 20A and 20B). 
The exceptions are the loop regions where some flexibility is observed. The domains 
(RRM1 – residues R113-R187 and RRM2 – residues R210-P288) have                       
the β1α1β2β3α2β4 topology typical of RRM domains with two α-helices packed against 
four-strand anti-parallel β-sheet (Maris et al., 2005). The β-sheet is arranged in β4β1β3β2 
order when looking from the front and with N-terminus of β1 facing north. Also α2/β4 
loops of the domains form additional small two-stranded anti-parallel β-sheets as often 
found in RRMs (Maris et al., 2005). 
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Table 5 NMR statistics for FIR RRM1-RRM2. 
 
 FIR RRM1–RRM2 (103-297) 
NMR distance and dihedral restraints  
Distance restraints 4368 
Intra-residue 1588 
Inter-residue 2780 
Sequential (|i – j| = 1) 906 
Medium-range (1 < |i – j| ≤ 4) 487 
Long-range (|i – j| > 4) 1387 
TALOS φ and ψ restraints 236 
Hydrogen bond restraints 63 
  
Structure statistics  
Mean total energy (kcal/mol) -6489 ± 115 
Dihedral angles violations > 5º 0 
NOE violations > 0.5Å 0 
NOE violations > 0.3Å 0.9 ± 0.9 
Mean NOE energy (kcal/mol) 62 ± 5 
  
RMSD from idealised covalent geometry  
Bond lengths (Å) 0.0036 ± 0.0001 
Bond angles (º) 0.480 ± 0.011 
  
RMSD from the mean structure (Å) res. 105-288 
Backbone atoms 0.91 ± 0.10 
Heavy atoms 1.36 ± 0.09 
  
RMSD from the mean structure (Å) secondary structure elements only* 
Backbone atoms 0.59 ± 0.09 
Heavy atoms 1.03 ± 0.09 
  
Ramachandran plot analysis  
Most favoured regions (%) 83.9 
Additional allowed regions (%) 14.3 
Generously allowed regions (%) 0.9 
Disallowed regions (%) 0.9 
* residues: 105-111, 113-117, 125-132, 138-143, 155-160, 164-172, 184-185, 194-208, 
210-214, 222-229, 235-243, 248-257, 260-269 and 281-284 
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Figure 19 Local RMSD vs. FIR RRM1-RRM2 sequence. The 20 calculated conformers 
were superimposed in Molmol (Koradi et al., 1996) using residues 105-111, 113-117, 
125-132, 138-143, 155-160, 164-172, 184-185, 194-208, 210-214, 222-229, 235-243, 
248-257, 260-269 and 281-284 and the local RMSD were calculated for backbone and 
heavy atoms. The highest RMSD are observed at the N- and C-termini and in the loop 
regions. 
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Figure 20 Structure of the FIR RRM1-RRM2. A) Ribbon representation with RRM1 in 
light blue and RRM2 in dark blue. The amino terminal 
 
and linker alpha helices (αN and 
αL) are coloured in white-to-light blue and a light blue-to-dark blue colour gradients, 
respectively. B) Backbone traces of the 20 lowest-energy FIR RRM1-RRM2 
conformers. The structure is well defined, except for a few flexible loops.                    
C) Superimposition of the ribbon representations of the structures of FIR RRM1-RRM2 
free (blue, this study), in complex with the FBP Nbox (green, this study) and in 
complex with ssFUSE (brown, Crichlow et al., 2008). The lowest-energy NMR 
structures (free and FBP Nbox complex) are shown. There are no major structural 
changes in the FIR RRM1-RRM2 upon FBP or ssDNA binding. 
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FIR RRM1 and RRM2 interact with each other through a hydrophobic core 
formed by α2 helix and α1/β2 loop of RRM1 and the β-sheet of RRM2 (1100 Å2 of 
buried surface) (Figures 20A and 21). The central part of the interface is occupied by 
conserved aromatic residues of RRM2: Y212, Y252 and F254 that interact with E164, 
P137 and V162 in RRM1 (Figure 21A). The inter-domain orientation is fixed by           
a network of mainly hydrophobic contacts between RRM1, RRM2 and the two 
additional α-helical elements, e.g. L108 (αN) – P163 (RRM1), A107 (αN) – I197 (αL), 
L108 (αN) – T287 (RRM2), P134 (RRM1) – R281 (RRM2) and L201 (αL) – P288 
(RRM2) (Figure 21B). 
The recorded relaxation data confirmed that RRM1 and RRM2 do not tumble 
independently giving a rotational correlation time τc of 10.6 ns, as expected for              
a ~ 22 kDa single-unit protein (Maciejewski et al., 2000). Furthermore, the steady-state 
heteronuclear NOE (hetNOE) values clearly indicate that flexibility is limited only to 
the loop regions, particularly β2/β3 loops (Figure 22). Overall FIR RRM1-RRM2 
structure is very similar in the free form and in the complex with FBP Nbox (discussed 
later) or 25mer ssFUSE (Crichlow et al., 2008) (Figure 20C). The calculated RMSD 
between an averaged NMR structure in the free form and the X-ray structure is 1.9 Å 
for backbone atoms and 2.4 Å for all heavy atoms. Furthermore, the relaxation data 
show that there is no major variations in the internal dynamics upon binding of FIR 
RRM1-RRM2 to FBP Nbox or ssDNA, except expected increase in the rotational 
correlation time and decreased T2 values at the protein – peptide interface that will be 
discussed later (Figure 22). 
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Figure 21 The inter-domain interaction between RRM1 and RRM2 has a hydrophobic 
character. A) Detailed view of a core hydrophobic inter-domain interaction. RRM1 is in 
light blue and RRM2 in dark blue. The key residues are displayed in a stick 
representation in light green (RRM1) and dark green (RRM2). B) A schematic 
representation of interactions that stabilise the orientation of the RRM1, RRM2 and two 
additional α-helical elements (αN and αL). 
Figure 22 Relaxation data. A) Amide resonances' 
hetNOE (bottom) values for FIR RRM1
FBP Nbox (red circles) and FIR RRM1
vs. RRM1-RRM2 sequence.
15N T1 (top), 
-RRM2 (black squares), FIR RRM1
-RRM2 – ssFUSE29 (2 : 1 ratio 
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15N T2 (middle) and 
-RRM2 – 
– blue triangles) 
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4.1 FBP Nbox peptide expression and purification 
 
 The most cost- and time-efficient method of the production of isotopically 
enriched proteins relies on overexpression of the desired constructs in E. coli cells.    
The bacterial cells are cultured in minimal media, where the only sources of nitrogen 
and carbon contain 15N (e.g. (15NH4)2SO4) and 13C (e.g. 13C6-D-glucose) isotopes.     
The recombinant proteins produced in E. coli cells are exposed to non-native folding 
conditions and/or proteases present in the bacterial cells. This is a great concern when 
separate domains, large unfolded regions or short peptides are to be produced. 
The identified region of FBP involved in the interaction with FIR RRM1-RRM2 
(FBP Nbox) is only 26 amino acids long (Chung et al., 2006). To increase the yield of 
the FBP Nbox peptide in E. coli cells it was produced as a HisTag-GST fusion.         
The overexpressed recombinant protein was present in a soluble fraction of lysed 
bacterial cells (Figure 23). The standard lysis, IMAC purification and TEV digestion 
protocol, used in our laboratory, allowed me to obtain an expected product of              
the molecular weight of ~ 3 kDa, without any signs of lower molecular weight 
degradation products (Figure 23: Flow-through 2 lanes). The recombinant peptide was 
further purified by high performance liquid chromatography (HPLC) to eliminate any 
traces of proteolytic activity. The final yield of the 15N13C-labelled FBP Nbox peptide 
was ~ 0.5 mg per litre of culture. 
 
 
 
4.2 Biophysical characterisation and assignment of the FBP 
Nbox peptide 
 
 Preliminary experiments on the 15N13C-labelled FBP Nbox peptide at pH 8.0 
showed that resonances in 1H-15N (but not in 1H-13C) correlation spectra are very broad 
and mostly undetectable (data not shown). This broadening is temperature- and         
pH-dependent (Figure 24A), indicating that it is caused by the chemical exchange of 
protons between amide groups of the peptide backbone and water molecules (Dempsey, 
2001; Hernandez and LeMaster, 2009). Decrease in both temperature and pH lead to   
an increased number of detectable amide resonances and at pH 5.0 nearly all of 
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Figure 23 SDS-PAGE analysis of the FBP Nbox peptide purification. The HisTag-
GST-FBP Nbox fusion protein was purified on the IMAC column from the soluble 
fraction of the bacterial cell lysate (Elution 100 and 300). The eluted protein was treated 
overnight with TEV protease (After TEV) and the fusion (HisTag-GST) was removed 
by a two-step purification on the IMAC column (flow-through and elution fractions      
1 and 2). The recombinant FBP Nbox peptide was found in the flow-through fractions 
(1 and 2), while the tags retained on the columns (Elution 1 and 2). 
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Figure 24 15N sofast HMQC spectra of the FBP Nbox. A) Experiments recorded under 
different conditions. The exchange of amide protons with water molecules can be 
reduced by decreasing either the temperature (5 °C) or pH (pH = 5.0). B) The assigned 
spectrum of the FBP Nbox peptide. 
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them (29 out of 31) appeared in the 15N HMQC spectrum of the FBP Nbox peptide 
(Figure 24B). As expected, there were also three pairs of side-chain amide resonances 
of glutamines (Q36 and Q40) and asparagine (N28). pH titration (from 5.0 to 8.0) did 
not reveal significant CSP in 13C HSQC spectra, except a few peaks that turned out to 
correspond to the C-terminus of the peptide (data not shown). Therefore, the assignment 
of the peptide was achieved at pH 5.0 where standard 3D backbone experiments 
(correlating HN protons to other backbone atoms) could be recorded with sufficient 
sensitivity. The side-chain assignment was obtained from 15N TOCSY and HCCH 
TOCSY through-bond experiments. The chemical shifts of side-chain resonances     
(e.g. Cγ, Cδ, Hγ, Hδ) of the FBP Nbox peptide have nearly random-coil values (Wishart 
et al., 1995), as expected for the isolated peptide. However, the chemical shifts of Cα, 
Cβ and Hα significantly deviate from the random-coil values, suggesting that the peptide 
possesses some secondary structure (Figure 25A). Indeed, TALOS-derived φ and ψ 
torsion angles of the residues D29-I41 have values characteristic of α-helix. 
Furthermore, the far-UV CD spectrum shows a significant content (~ 40%) of α-helix in 
the solution of FBP Nbox peptide (Figure 25B). 
 
 
 
4.3 The interaction between FIR RRM1-RRM2 and FBP 
Nbox peptide 
 
Titration of the 15N-labelled FIR RRM1-RRM2 with an unlabelled FBP Nbox 
peptide mapped the interaction surface to the solvent-exposed face of the RRM2 (area 
of ~ 15 x 25 Å), including the β1/α1, α2/β4 loops and α1, α2 helices (Figure 26A). 
Furthermore, CSPs limited to this well defined region indicate that the protein does not 
undergo global rearrangements upon peptide binding. In the reverse titrations at pH 6.5 
and pH 5.0 (15N13C-labelled FBP Nbox peptide titrated with an unlabelled FIR RRM1-
RRM2), 19 backbone amide resonances of the peptide were perturbed (Figure 26B).     
A 19-residue linear peptide is too long to be accommodated on the mapped interaction 
surface of FIR RRM2. However, the large number of affected resonances could be 
explained if the peptide interacts with the FIR RRM1-RRM2 in an α-helical 
conformation, and the observed CSPs are the result of not only binding, but also  
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Figure 25 FBP Nbox peptide is α-helical in solution. A) Chemical shift index for       
the FBP Nbox peptide. The positive and negative (∆13Cα - ∆13Cβ)smoothed values indicate 
α-helices and β-strands, respectively (Metzler et al., 1993; Wishart et al., 1995).          
B) Far-UV CD spectrum of the free FBP Nbox peptide. 
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Figure 26 α-helical FBP Nbox peptide binds with low micromolar affinity to             
the RRM2 domain of FIR. A) Weighted chemical shift changes of the FIR RRM1-
RRM2 upon addition of the FBP Nbox vs. protein sequence. The secondary structure 
elements and the boundaries of the domains are indicated above. B) Weighted chemical 
shift changes of the FBP Nbox upon addition of FIR RRM1-RRM2 vs. peptide 
sequence. 1H-15N cross-peaks, that disappear during the titration, are assigned a ∆δavg 
value of 0.28. C) A section of superimposed 13C HSQC spectra recorded during          
the titration of FBP Nbox peptide with FIR RRM1-RRM2. The spectra are colour-coded 
according to peptide : protein ratio: 1 : 0 – red, 1 : 0.5 – blue, 1 : 1 – cyan, 1 : 2 – yellow 
and 1 : 3 – green. The start and end positions of CαHα cross-peaks are connected with 
dashed lines. The consistent downfield shifts in a 13C dimension and upfield shifts in     
a 1H dimension indicate stabilisation of the FBP Nbox peptide in an α-helical 
conformation upon binding to the FIR RRM1-RRM2. D) Isotherm of the FBP Nbox 
binding to FIR RRM1-RRM2 (NMR). 
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stabilisation of the secondary structure. Interestingly, CαHα cross-peaks in 13C HSQC 
spectra were consistently shifted downfield in a 13C dimension and upfield in               
1H dimension during the titration of the 15N13C-labelled FBP Nbox peptide with           
an unlabelled FIR RRM1-RRM2, so that the 13Cα and 1Hα chemical shift values moved 
towards the ones of an α-helix (Figure 26C). TALOS analysis of the chemical shifts of 
the peptide resonances showed that FIR binding extends the α-helical region from 
residues D29-I41 to V27-I45. 
The perturbed resonances are in the fast-to-intermediate exchange regime during 
the course of the titrations and hence the shifts in the peaks position report on a fraction 
of the bound labelled (i.e. observed) component and can be used to obtain the Kd of    
the complex. The weighted CSP were plotted vs. the ratio between the binding partners 
concentrations and then fitted to a one-site binding model. The obtained Kd values are 
15 ± 8 µM (15N13C-labelled FBP Nbox) and 14 ± 8 µM (15N-labelled FIR RRM1-
RRM2) (Figure 26D). 
 
 
 
4.4 Structure determination of the FIR RRM1-RRM2 – FBP 
Nbox peptide complex 
 
Structure determination of the FIR RRM1-RRM2 – FBP Nbox complex was 
achieved with the standard procedure and automatic structure calculations, however    
an optimisation of the experimental conditions and careful analysis were required.    
This is because high concentrations of FIR RRM1-RRM2 were unachievable and       
the complex formed a 25 kDa single unit with a dynamic interface, that lead to           
the broadening of the resonances. The relaxation data recorded on the complex indicate 
that T2 values of the FIR RRM1-RRM2 backbone 15N resonances at the contact 
interface are shorter than expected when compared with the rest of residues (Figure 27). 
(The overall reduction in the T2 values in the complex is anticipated due to the higher 
molecular weight of the complex). To reduce the exchange broadening, and therefore 
improve the quality of the spectra, the subsequent experiments were recorded at 
different protein : peptide ratio, so the labelled component was always saturated in        
> 95%. 
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Figure 27 Amide resonances' 15N T2 values of RRM2 in FIR RRM1-RRM2 (black 
squares) and FIR RRM1-RRM2 – FBP Nbox complex (red circles) vs. protein 
sequence. The residues contacting with the peptide (yellow shading) display lower-than-
average 15N T2 in the complex, but not in the free form, consistently with a dynamic 
interface. 
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4.4.1 Backbone and side-chain assignment of the complex 
 
The 3D 13C NOESY experiment recorded on 15N13C-labelled FIR RRM1-RRM2 
– FBP Nbox peptide complex showed that the pattern of NOE cross-peaks is very 
similar to that obtained for the FIR RRM1-RRM2 alone (data not shown). This means 
that there is no global rearrangement in the protein structure upon binding to FBP Nbox 
peptide, in agreement with titration experiments where the CSP is limited to one side of 
the protein. Because of lack of global changes and the fast-to-intermediate exchange 
regime the assignment of FIR RRM1-RRM2 could be transferred from the free form to 
the bound one in a two-step procedure. First, the assignment of backbone amide 
resonances was achieved following the evolution of the 1H-15N cross-peaks during     
the titration of the protein with the peptide. Then, combination of 3D 15N and 13C 
NOESY spectra of the complex allowed me to complete the assignment of the 13C and 
13C-attached proton resonances (see Appendix V). The whole process was validated 
with 3D HNCA backbone experiment recorded on the complex to resolve any 
discrepancies due to the overlap of 15N HMQC spectra from the titration. 
The procedure applied for the assignment of FIR RRM1-RRM2 in the complex 
could have not been used for the assignment of FBP Nbox due to the exchange 
broadening of peptide backbone amide resonances at pH 8.0, that was still significant 
after complex formation. We could not reduce this exchange process by decreasing pH 
or temperature (as done for the free peptide), because of instability of the protein. 
However, there was no significant overlap in 13C HSQC spectra recorded during         
the titration of 15N13C-labelled peptide with FIR RRM1-RRM2, which allowed me to 
follow the evolution of 1H-13C cross-peaks and to transfer the assignment of 13C and 1H 
from the free form of the peptide to the bound one (see Appendix V). This assignment 
was cross-checked using 3D 13C NOESY and 3D HCCH TOCSY experiments recorded 
on the complex (15N13C-labelled FBP Nbox). 
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4.4.2 Obtaining structural restraints 
 
The intra-molecular distance (NOE-derived and H-bond) and angle restraints for 
the peptide and the protein were achieved as described for the FIR RRM1-RRM2, with 
one exception. Despite strong evidence of α-helical conformation of the peptide in     
the complex (pattern of the NOE and TALOS-derived dihedral angles) the backbone 
amide resonances were still in fast exchange with the water molecules, making 
exchange-protection experiment unfeasible. Therefore, H-bond restraints were assumed 
for the α-helical region of the peptide (A30-K44), identified with chemical shift values 
of the backbone and Cβ resonances and with NOE patterns. 
 The inter-molecular restraints are crucial for the structure determination of      
the complex. To identify sparse inter-molecular cross-peaks among many                
intra-molecular ones in the 13C NOESY spectra two different experiments were 
recorded: 13C-filtered 13C NOESY (15N13C-labelled FIR RRM1-RRM2) and               
13C NOESY without 13C decoupling during the proton indirectly acquired dimension 
(15N13C-labelled FIR RRM1-RRM2 or 15N13C-labelled FBP Nbox). In the former 
experiment, the initial magnetisation of 13C- (protein) but not 12C-attached (peptide) 
protons is dephased by additional pulses prior to the standard 13C NOESY pulse 
sequence (Nietlispach et al., 2004). Consequently, NOE cross-peaks are observed only 
when the NOE effect occurs between 12C- (peptide) and 13C-attached (protein) protons. 
Unfortunately, the longer pulse sequence worsens the S/N in the spectra. In the latter 
experiment, a standard 13C NOESY pulse sequence is applied, but without                  
13C decoupling during labelling with the indirect 1H frequencies. Therefore in             
the recorded spectra correlations between two 13C-attached protons (intra-molecular) 
appear as a doublet, while correlations between 13C- and 12C-attached protons (inter-
molecular) give rise to a singlet signals. Unfortunately, most of the cross-peaks in      
the spectrum are intra-molecular that significantly increases the spectra overlap and 
hampers identification of the inter-molecular correlations. 
 A combination of the information from the two experiments allowed me to 
identify 72 inter-molecular cross-peaks (Appendix VI). The assignment of 13C and 13C-
attached protons for these cross-peaks was already known (from intra-molecular 
assignment). However, the assignment of the indirect 1H was more complex because  
the unlabelled component was only ~ 35-50% bound in the sample. Therefore,            
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the chemical shift of a given resonance was a linear combination of the chemical shifts 
observed in the free and bound forms. An initial set of 14 unambiguously assigned 
inter-molecular cross-peaks (Table 6) from groups spanning the length of the peptide 
was obtained by analysis of the 13C NOESY spectra (for examples see Figures 28 and 
29) and used, together with intra-molecular restraints, to generate a preliminary 
structure of the complex. Further assignment of the inter-molecular cross-peaks was 
obtained iteratively, based on the already available structure. 
 
 
 
4.4.3 Structure calculations 
 
 Structure calculations of the complex with the standard protocol used for FIR 
RRM1-RRM2 alone were plagued by a poor convergence, despite having identified      
a set of 72 inter-molecular restraints. A possible explanation for this result is               
the overestimation of the inter-molecular distances by the automatic calibration 
procedure of ARIA, that does not take into account the general broadening of 
resonances at the interface. To compensate the different relaxation properties of          
the resonances at the interface a conservative approach was taken, where all inter-
molecular distances were calibrated semi-quantitatively and the upper bounds for all 
intra-molecular distance restraints were set up to 6 Å. This procedure relies on a high 
redundancy of the set of FIR RRM1-RRM2 intra-molecular restraints, that 
counterweight the loss of precision in the defined distances. The obtained family of 
structures is converged and well-defined with RMSD from the mean structure of 1.00 Å 
for backbone atoms and 1.45 Å for all heavy atoms (Table 7 and Figure 30). 
 
 
 
4.5 Description of the structure of FIR RRM1-RRM2 – FBP 
Nbox complex 
 
The structure of FIR RRM1-RRM2 in the complex with FBP Nbox is very 
similar to the structure of the protein alone (Figure 31A and see Figure 20C) with  
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Table 6 A set of 14 inter-molecular restraints used at the initial stage of structure 
calculations of FIR RRM1-RRM2 – FBP Nbox complex. 
 
No. FIR RRM1-RRM2 
atom(s) 
FBP Nbox peptide 
atom(s) 
Upper bound [Å] 
1 F232 HA A30 QB 3.5 
2 V228 QG1 L35 QQD 3.5 
3 A231 QB A30 QB 5.0 
4 A231 QB D33 HB2 3.5 
5 A231 QB D33 HB3 3.5 
6 D224 HB2 I41 QG2/I41 QD1 5.0 
7 D224 HB3 I41 QG2/I41 QD1 5.0 
8 V228 QG1 I41 QG2/I41 QD1 2.8 
9 V228 QG2 I41 QG2/I41 QD1 5.0 
10 L220 QD1 I41 QG2/I41 QD1 3.5 
11 L220 QD2 I41 QG2/I41 QD1 3.5 
12 L275 QD1 I41 QG2/I41 QD1 2.8 
13 S269 HB2 V27 QQG 5.0 
14 S269 HB3 V27 QQG 5.0 
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Figure 28 Identification and 
assignment of inter-molecular 
restraints. Left, the sections of      
the spectra from three different     
3D NOESY experiments recorded 
on the 15N13C FIR RRM1-      
RRM2 – FBP Nbox complex.      
The comparison of the spectra 
allowed me to identify correlations 
to 12C-attached protons (inter-
molecular restraints). Right, sections 
of different NMR spectra showing 
the chemical shift of A30 Qβ in     
the free, partially bound and fully 
bound form of the FBP Nbox 
peptide. 
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Figure 29 Identification and assignment 
of inter-molecular restraints. Left,          
the sections of the spectra from two 
different 3D NOESY experiments 
recorded on the 15N13C FBP Nbox – FIR 
RRM1-RRM2 complex. The comparison 
of the spectra allowed me to identify 
correlations to 12C-attached protons (inter-
molecular restraints). Right, sections of 
different NMR spectra showing             
the chemical shift of F232 Hα in the free, 
partially bound and fully bound form of 
the FIR RRM1-RRM2. 
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Table 7 NMR statistics for FIR RRM1-RRM2 – FBP Nbox complex. 
 
FIR RRM1–RRM2 (103-297) – FBP 
Nbox (27-52) complex 
NMR distance and dihedral restraints  
Distance restraints 4611 
Intra-residue 1632 
Inter-residue 2979 
Sequential (|i – j| = 1) 878 
Medium-range (1 < |i – j| ≤ 4) 546 
Long-range (|i – j| > 4) 1483 
Inter-molecular 72 
TALOS φ and ψ restraints 280 
Hydrogen bond restraints 36 
  
Structure statistics  
Mean total energy (kcal/mol) -7598 ± 180 
Dihedral angles violations > 5º 2.2 ± 0.9 
NOE violations > 0.5Å 0 
NOE violations > 0.3Å 2.6 ± 1.2 
Mean NOE energy (kcal/mol) 67 ± 6 
  
RMSD from idealised covalent geometry  
Bond lengths (Å) 0.0036 ± 0.0001 
Bond angles (º) 0.507 ± 0.008 
  
RMSD from the mean structure (Å) (res. 105-288, 27-45) 
Backbone atoms 1.00 ± 0.09 
Heavy atoms 1.45 ± 0.08 
  
RMSD from the mean structure (Å) secondary structure element only* 
Backbone atoms 0.71 ± 0.08 
Heavy atoms 1.18 ± 0.08 
  
Ramachandran plot analysis  
Most favoured regions (%) 82.2 
Additional allowed regions (%) 15.3 
Generously allowed regions (%) 1.0 
Disallowed regions (%) 1.5 
* residues 105-111, 113-117, 125-132, 138-143, 155-160, 164-172, 184-185, 194-208, 
210-214, 222-229, 235-243, 248-257, 260-269 and 281-284 of FIR RRM1-RRM2 and 
residues 30-44 of FBP Nbox 
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Figure 30 Local RMSD in the complex vs. FIR RRM1-RRM2 (top) and FBP Nbox 
(bottom) sequence. The 20 calculated conformers were superimposed in Molmol 
(Koradi et al., 1996) using residues 105-111, 113-117, 125-132, 138-143, 155-160, 164-
172, 184-185, 194-208, 210-214, 222-229, 235-243, 248-257, 260-269 and 281-284 of 
FIR RRM1-RRM2 and residues 30-44 of FBP Nbox and the local RMSD were 
calculated for backbone and heavy atoms. The highest RMSD are observed at the N- 
and C-termini and in the loop regions. 
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Figure 31 Hydrophobic contacts mediate the interaction between FIR RRM1-RRM2 
and FBP Nbox peptide. A) Backbone trace of the 20 lowest-energy conformers of      
the FIR RRM1-RRM2 (blue) – FBP Nbox (brown) complex. B) FBP Nbox peptide 
(ribbon representation – blue) bound to FIR RRM1-RRM2 (surface representation – 
only RRM2 is visible). FIR RRM1-RRM2 residues showing substantial CSP upon 
binding to the peptide are coloured in red. The hydrophobic residues of FBP Nbox 
involved in the interaction (left) and the four alanine residues of FBP Nbox in             
the central part of interface (right) are labelled. The FIR RRM1-RRM2 secondary 
structure elements involved in the peptide binding are indicated. C) Surface 
representation of FIR RRM1-RRM2 (only RRM2 visible – left), of the solvent exposed 
surface of FBP Nbox (middle), and of the FIR-interacting surface of FBP Nbox (right). 
Hydrophobic residues are shown in yellow, residues with positive and negative charges 
are displayed in blue and red respectively. 
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RMSD of 2.0 Å for backbone atoms and 2.4 Å for all heavy atoms between averaged 
free and bound structures. The relaxation measurement did not reveal any large changes 
in the protein dynamics, with the exception of the changes observed in the inter-
molecular interface, that reflects the dynamic nature of the interaction (see Figure 22). 
In general we observe larger T1 and smaller T2 values for the FIR RRM1-RRM2 in   
the complex, with a corresponding increase in the rotational correlation time                
(τc = 12.3 ns vs. τc = 10.6 ns for FIR RRM1-RRM2 alone). These changes are consistent 
with the larger molecular weight of the complex (24.6 kDa vs. 21.9 kDa for the protein 
alone). 
The bound FBP Nbox peptide adopts α-helical conformation and is located in    
a shallow groove between α1 helix and β1/α1 loop on one side and α2 helix and α2/β4 
loop on the other (Figures 31 and 32). The contact interface matches very well CSP data 
obtained from the titration experiments (Figure 31B). The N-terminus of the FBP Nbox 
is located where α1 and α2 helices of FIR RRM2 meet and the C-terminus is docked 
between β1/α1 and α2/β4 loops, so the peptide covers essentially the entire length of 
RRM2 domain. The interaction is hydrophobic (Figure 31C) and involves a narrow 
stretch of residues on RRM2 (F232, A231, V228, M270, F273, L275 and L220), that 
provide binding platform for the hydrophobic face of FBP Nbox peptide (Figure 31C 
and 32). Residues L220, L275 and F273 of FIR form a hydrophobic pocket that 
accommodates the side-chain of I41 of the FBP Nbox peptide; F273 and V228 make 
hydrophobic interactions with A38 and finally, A34 of the peptide is sandwiched 
between A231, V228, F232 (RRM2) and F31 (FBP Nbox peptide). Interestingly, four 
alanines are found among nine residues that form hydrophobic side of the peptide 
(Figure 31C). The central area of the interface is occupied by two of those alanines 
(A34 and A38), while the bulky hydrophobic residues are loosely packed against        
the protein. Such an arrangement results in a weak inter-digitation between the side-
chains of the peptide and protein and ensures that the interaction is specific, but 
transient, as required for the biological function of FIR. 
119 
 
Figure 32 Detailed view of the FIR RRM2 – FBP Nbox interface. A) The peptide 
(yellow) and protein (orange) residues show no significant inter-digitation between 
side-chains. B) A schematic representation of the protein–peptide interaction in           
the complex. 
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Results – Protein–protein 
and protein–DNA 
interactions                        
in the FUSE–FBP–FIR 
system 
5.  
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5.1 Comparison of the binding of three FBPs Nbox peptides 
to FIR RRM1-RRM2 
 
The FBP family consists of three members: FBP (FBP1), FBP2 and FPB3. 
Interestingly, in a yeast two-hybrid assay FIR RRM1-RRM2 interacts with FBP and 
FBP2, but not FBP3, Nbox sequences (Chung et al., 2006). I show for the first time that 
all three peptides directly interact with FIR RRM1-RRM2 (Figure 33). NMR titration 
experiments indicate that the surface of interaction is conserved across the FBP family 
(Figure 33B). However, the exchange regime of the affected resonances show that 
individual complexes have different binding kinetics. The protein resonances are in    
the fast-to-intermediate exchange regime on the chemical shift timescale during          
the titrations with FBP and FBP2 Nboxes and in the fast exchange regime during        
the titration with FBP3 Nbox. The difference in the exchange regime may reflect        
the differences in the dissociation constants of the complexes. Indeed, fitting of          
the binding curves to one-site binding model shows that FIR RRM1-RRM2 binds 
Nboxes of FBP and FBP2 with similar affinities (Kd = 14 ± 8 µM and Kd = 6 ± 6 µM 
respectively), while the affinity for FBP3 Nbox is ~ 30-fold weaker (Kd = 280 ± 36 µM) 
(Figure 33C). 
The origin of differences observed in the affinity of FIR RRM1-RRM2 for 
Nboxes has not been addressed experimentally, but it is possible to make some 
hypotheses based on the available structure of the complex, peptides sequence 
alignment and the α-helicity of the peptides. Sequence alignment revealed that Nboxes 
of FBP and FBP2 proteins share 77% identity, while FBP3 Nbox is more divergent 
(46% and 42% identity with Nboxes of FBP and FBP2, respectively) (Figure 33A). 
Interestingly, the Nboxes of FBP and FBP3 differ only in three residues (V27, A30 and 
A38 of FBP) at the protein–peptide interface. At the first position, all three peptides 
have different residues and FBP3 (lysine) is more similar to FBP2 (arginine) than to 
FBP (valine). However, 1) this position is at the edge of the contact interface and         
2) FBP3 binds weaker to FIR RRM1-RRM2 than the other two peptides and thus, this 
position is unlikely to define the affinity of the complexes. At the second and third 
different positions, Nboxes of FBP and FBP2 are identical (two alanines), while in 
FBP3 there are glycine and valine, respectively. Replacement of A30 (in FBP) by 
glycine (in FBP3) leads to the decrease in the hydrophobic contact interface and thus, 
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Figure 33 Comparison of the binding of three different FBPs Nbox peptides to FIR 
RRM1-RRM2. A) Sequence alignment of Nbox sequences from FBP, FBP2 and FBP3 
proteins. The dots represent identical residues to FBP Nbox sequence. The positions of 
the amino acids in the protein sequence is indicated. The residues of FBP Nbox that 
form an α-helix upon interaction with the FIR RRM1-RRM2 are highlighted in yellow. 
B) Sections of superimposed 1H-15N correlation spectra recorded during titrations of 
FIR RRM1-RRM2 with FBP Nbox (left), FBP2 Nbox (middle) and FBP3 Nbox (right). 
The resonances are in fast-to-intermediate exchange regime during the titration with 
FBP and FBP2 Nboxes and in fast exchange regime during the titration with FBP3 
Nbox. C) Isotherms of the binding of different Nboxes to FIR RRM1-RRM2.            
The affinity of the protein for FBP3 Nbox is ~ 30-fold weaker than for Nboxes of FBP 
and FBP2. D) Far-UV CD spectra of the FBP, FBP2 and FBP3 Nbox peptides. FBP and 
FBP2 Nboxes have a significant content of α-helix. 
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may cause the decrease in the affinity. Replacement of A38 (in FBP) by valine            
(in FBP3) places a large hydrophobic side-chain in the centre of the interface causing    
a steric hindrance. Indeed, the available mutational analysis of the FBP Nbox peptide 
confirms these observations (Chung et al., 2006). Apart from different amino acid 
sequence, FBP3 Nbox peptide has lower propensity to form an α-helix than the Nboxes 
of FBP and FBP2 have – 0% vs. ~ 40% of α-helix content as assessed by CD       
(Figure 33D). This may have important consequences for the affinity of the protein for 
the peptide, because this interaction can be described by a two-step model, where       
the peptide adopts α-helical conformation and then interacts with the protein: 
 
Peptidekeydjd % Peptideml % Peptide  Protein complex 
 
Therefore, the weaker affinity of FIR RRM1-RRM2 for FBP3 Nbox may arise from 
both the substitutions at the contact interface and the α-helix propensity of the peptide. 
 
 
 
5.2 DNA sequence preference of FIR RRM1 
 
The scaffold-independent analysis (SIA) of FIR RRM1 described in this section 
has been performed with the help of Dr. Irene-Diaz Moreno at the National Institute for 
Medical Research, London, UK. 
It has been reported that FIR RRM1-RRM2 interacts with ssFUSE DNA only 
via its first domain (Crichlow et al., 2008). CSP data obtained by titrating FIR RRM1-
RRM2 with a ssFUSE29 DNA (Chung et al., 2006) confirmed that the DNA binds     
the nucleic acid recognition surface of RRM1 but not the one of RRM2, that is indeed 
engaged in the interaction with RRM1 (Figure 34). The DNA binding surface mapped 
by CSP encompasses most of the residues of the β-sheet as well as those of β2/β3 and 
α2/β4 loops of RRM1, including the residues that make direct contacts with the only 
nucleotide visible in the published X-ray structure (Crichlow et al., 2008). 
Despite FIR protein being linked to transcription regulation (Liu et al., 2000) 
and splicing (Page-McCaw et al., 1999) little is known about its nucleic acid sequence 
preference. Missing-base interference footprinting revealed that FIR can bind to 
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Figure 34 FIR interacts preferentially with T and G-rich sequences via its first RRM 
domain. A) DNA binding surface of FIR RRM1. Residues showing significant CSP 
upon titration with the ssFUSE29 are in blue and residues whose amide resonance are 
not assigned are in black. The position of the single nucleotide visible in the X-ray 
structure (orange) is reported on the FIR RRM1-RRM2 structure. The side-chains of  
the aromatic residues located in the conserved RNP2 and RNP1 nucleic acid binding 
motifs (Y115, F155, F157) are displayed. The DNA molecule binds the canonical 
nucleic acid binding surface of the RRM1 domain. B) Ribbon representation of FIR 
RRM1-RRM2. The β-sheet of RRM2 (dark blue), that is a putative DNA binding 
surface, is engaged in the inter-domain contacts with RRM1 (light blue). C) Graphic 
representation of FIR RRM1-RRM2 DNA sequence preference. The picture was 
generated by plotting the SIA data with the Weblogo server (http://weblogo. 
berkeley.edu/logo.cgi). D) NMR binding isotherms of four ssDNA pentamers 
interacting with FIR RRM1-RRM2 and the measured dissociation constants (n/d – not 
determined). 
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multiple T-rich sites on ssFUSE DNA (Benjamin et al., 2008). However, the only 
visible nucleotides in the X-ray structure of FIR RRM1-RRM2 dimer bound to ssFUSE 
DNA are adenine and cytosine (Crichlow et al., 2008). Typically, RRM domains 
recognise four nucleotides (Maris et al., 2005) and we used SIA (Beuth et al., 2007) to 
characterise ssDNA sequence preference of FIR RRM1 in four nucleotide positions. 
The results showed that the protein prefers Ts and Gs and selects against As in all 
measured positions, returning a consensus sequence of (T/G)(T/G)TT (Figure 34C and 
Table 8). 
The findings were validated by testing the binding of four ad hoc 5mer ssDNAs 
(TTTTT, TGTGT, TATAT, AAAAA) to FIR RRM1-RRM2. The T and TG-rich 
oligonucleotides, which are in fact present in the FUSE sequence, bind the protein with 
the same affinity (Kd = 39 ± 14 µM and Kd = 25 ± 12 µM respectively). Inclusion of 
two adenines into the sequence (TATAT) leads to a five-fold drop in affinity              
(Kd = 170 ± 80 µM), while a polyA sequence does not show significant binding   
(Figure 34D). 
 
 
 
5.3 Interaction between FIR RRM1-RRM2 and ssFUSE 
 
The BLI experiments on the FIR RRM1-RRM2 – ssFUSE40 DNA interaction 
described in this section have been performed with the help of Dr. Stephen R. Martin at 
the National Institute for Medical Research, London, UK. 
The moderate sequence preference of FIR RRM1 suggests that the protein will 
bind to multiple sites within the longer T-rich FUSE sequence. Indeed, NMR titration of 
FIR RRM1-RRM2 with the ssFUSE29 showed that the protein is saturated at ~ 0.4-0.6 
DNA : protein ratio suggesting at least 2 : 1 stoichiometry of the binding. The 
resonances perturbed during the titration are in a fast-to-intermediate exchange regime, 
indicating that the Kd is in low micromolar range. However, the conditions of the 
experiment and the quality of data did not allow me to obtain accurate Kd. The FIR – 
DNA interaction was further explored with BLI using a FUSE-derived 40mer ssDNA – 
a sequence that encompasses ssFUSE29 (see Table 4). The longer DNA includes all the 
nucleotides that are protected by FBP and FIR binding in missing-base interference 
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Table 8 SIA scores for FIR RRM1-RRM2. 15 peaks were analysed for each DNA pool. 
 
FIR NXNNN NNXNN NNNXN NNNNX 
A 0.49 0.42 0.34 0.61 
C 0.62 0.65 0.61 0.60 
G 0.81 0.84 0.49 0.74 
T 0.86 0.89 0.93 0.97 
                                15 peaks             15 peaks             15 peaks            15 peaks 
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experiments (Benjamin et al., 2008). This sequence was used because our primary aim 
was to characterise tri-molecular interactions in the system. Biotinylated ssFUSE40 was 
immobilised on streptavidin-coated biosensors. The association kinetics was studied by 
exposing sensors to different concentration of FIR (0.31 to 10 µM). After completion of 
binding the dissociation kinetics was monitored by moving FIR-loaded sensors to wells 
containing buffer (Figure 35A, left). For simplicity, the analysis was performed with  
the assumption that the multiple binding sites for FIR are equivalent and non-
interacting. Kinetic curves were analysed using a double exponential fit to account for   
a minor component probably associated with some residual non-specific binding.      
The observed rate constant for the major part of the association phase (kobs) was linearly 
dependent on FIR concentration and analysis yielded association and dissociation rate 
constants of 9.1 ± 0.6 x 104 M-1s-1 and 0.68 ± 0.03 s-1 respectively (Kd = 7 ± 1 µM) 
(Figure 35A, right). Examination of the dissociation phase yielded an independent 
measure of the dissociation rate constant (0.74 ± 0.05 s-1) and analysis of                     
the dependence of the amplitude of the BLI signal on FIR concentration yielded          
an independent estimate of the dissociation constant (7 ± 2 µM). 
The crystal structure of FIR RRM1-RRM2 in the complex with ssFUSE shows 
that the protein forms a dimer in the asymmetric unit (Crichlow et al., 2008). Based on 
this and on a 2 : 1 stoichiometry for the complex obtained from SEC-LS/RI/UV (size 
exclusion chromatography coupled with light scattering, refractive index and ultraviolet 
absorbance) data it has been proposed that FIR RRM1-RRM2 dimerises on the ssFUSE 
DNA (Crichlow et al., 2008). We explored this possibility by performing NMR titration 
experiments. As already mentioned, the DNA interacts with FIR RRM1-RRM2 with     
at least 2 : 1 stoichiometry, consistently with the results of Crichlow et al. (Crichlow et 
al., 2008) (Figure 35B). The observed CSP were analysed with respect to any shift at 
the potential dimer interface (Figure 35C). There are 11 amide protons within 10 Å of 
the interface in the FIR RRM2, for seven of them the resonances are assigned and    
non-overlapping. Interestingly, none of these resonances is affected upon the binding of 
ssFUSE29, suggesting that the dimer is not formed. In RRM1, the proposed dimer 
interface is in the proximity to the DNA binding surface and therefore it is likely to 
observe CSP for residues in the putative dimer interface. To decouple dimerisation from 
DNA binding, I compared the CSP obtained during titration with the ssFUSE29 and      
a DNA 5mer that binds with a 1 : 1 stoichiometry (Figure 35D). The patterns of CSP are 
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Figure 35 DNA binding and protein dimerisation by FIR RRM1-RRM2. A) Binding of 
increasing concentrations of FIR RRM1-RRM2 (0.31 µM, 0.63 µM, 1.25 µM, 2.5 µM, 
5 µM and 10 µM) to ssFUSE 40 (left) and the corresponding plot of dependence of    
the observed association rate (kobs) on protein concentration, as recorded by BLI.         
B) Isotherms for the binding of the ssFUSE29 to FIR RRM1-RRM2 (NMR). S268 and 
S269 are two residues of RRM2 ~ 5 Å away from the proposed dimer interface which 
do not experience CSP in response to DNA binding. C) An X-ray structure of FIR 
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RRM1-RRM2 bound to the ssFUSE DNA (2QFJ). The FIR RRM1-RRM2 dimer is 
represented with a grey ribbon and residues whose HN protons are less than 10 Å from 
the dimer interface are displayed in blue. The nucleotides visible in the X-ray structure 
are shown in orange. D) CSP of FIR RRM1-RRM2 resonances upon addition of 
ssFUSE29 or TGTGT pentamer. CSP by the ssFUSE29 (blue) largely overlap with CSP 
by the TGTGT pentamer (yellow) defining a common binding surface (green). Small 
differences are observed in the protein N-terminal helix, that is opposite                      
the dimerisation area. These differences can be attributed to the transient contacts with 
additional nucleotides in the longer DNA. FIR RRM1-RRM2 does not dimerise on     
the ssFUSE29 DNA. 
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very similar, supporting the lack of dimerisation. The only (small) additional 
perturbations upon the binding of the longer DNA emerge in the N-terminal helix of 
RRM1. This helix is located on the protein side that is opposite the dimerisation 
interface, and the perturbations are most likely caused by transient and non-specific 
interactions of the DNA phosphates with the side-chains of two arginine residues. 
Furthermore, the rotational correlation time of the FIR RRM1-RRM2 – ssFUSE29 
complex (τc = 18.8 ns) is too small for a ~ 50 kDa quasi-globular FIR RRM1-RRM2 
dimer – ssFUSE29 complex (Figure 22). Interestingly, binding to the 29mer is only 
slightly stronger than binding to the 5mer. This difference can be easily accounted for 
by the presence of adjacent binding sites and is not consistent with a significant 
cooperativity expected for the binding of FIR dimer to the DNA. 
In summary, the lack of CSP in RRM2 upon DNA binding, the analogous 
pattern of CSP in RRM1 upon titration with the 29mer and 5mer DNAs, the low 
rotational correlation time of the FIR RRM1-RRM2 – ssFUSE29 complex and            
the absence of a substantial cooperativity in the FIR binding to the longer DNA all 
argue against a significant DNA-mediated FIR RRM1-RRM2 dimerisation. 
 
 
 
5.4 Simultaneous and independent recognition of ssFUSE 
and FBP Nbox peptide by FIR RRM1-RRM2 
 
FIR RRM1-RRM2 binding interfaces for ssFUSE and FBP Nbox are located on 
the different domains and on the opposite sides of the protein (Figure 36A). In order to 
check if these two interactions are independent or if an allosteric mechanism exists     
the spectra of di-molecular complexes (protein – peptide and protein – DNA) were 
compared with a spectrum recorded upon addition of ssFUSE29 to the complex of FIR 
RRM1-RRM2 and FBP Nbox (Figure 36B). The CSPs observed in the tri-molecular 
titration combine the CSPs observed in separate titrations with ssDNA and the peptide 
indicating that FIR RRM1-RRM2 forms a tri-molecular complex with its binding 
partners. The possibility of allosteric cooperativity of peptide and DNA binding was 
excluded by comparing the affinity of specific interactions in tri- and di-molecular 
complexes. The affinity of FIR RRM1-RRM2 for the FBP Nbox peptide is not affected 
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Figure 36 FIR RRM1-RRM2 simultaneously and independently interacts with ssDNA 
and FBP Nbox. A) Surface representation of FIR RRM1-RRM2. Residues showing 
significant CSP upon addition of ssFUSE29 and the FBP Nbox peptide are coloured in 
blue and red respectively. B) Superimposed 1H-15N correlation spectra show that FIR 
RRM1-RRM2 interacts independently with a ssFUSE29 and the FBP Nbox peptide. 
The spectra of FIR RRM1-RRM2+ssFUSE29, FIR RRM1-RRM2+FBP Nbox and FIR 
RRM1-RRM2+ssFUSE29+FBP Nbox are in blue, red and green respectively.               
A representative region containing one RRM1 resonance (V114) perturbed by DNA 
binding and one RRM2 resonance (D222) perturbed by peptide binding is displayed. 
The chemical shift changes of FIR RRM1-RRM2 peaks in the protein – DNA and 
protein – peptide complexes are additive in the tri-molecular complex, indicating 
independent binding. C) FBP and DNA bind independently to FIR RRM1-RRM2.    
Left – Superimposition of the isotherms for binding of TGTGT ssDNA to FIR RRM1-
RRM2 (black) and to FIR RRM1-RRM2 – FBP Nbox complex (red). DNA binding to 
FIR RRM1-RRM2 is not affected by the presence of bound FBP Nbox peptide.      
Right – Superimposition of the isotherms for binding of the FBP Nbox peptide to FIR 
RRM1-RRM2 (black) and to FIR RRM1-RRM2 – TGTGT ssDNA (red). FBP Nbox 
peptide binding to FIR RRM1-RRM2 is not affected by the presence of bound DNA. 
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by the presence of bound TGTGT pentamer (Kd = 22 ± 8 µM in the presence of TGTGT 
pentamer vs. Kd = 14 ± 8 µM in the absence of DNA) nor does the presence of            
the bound peptide affect the affinity of FIR RRM1-RRM2 for the TGTGT pentamer  
(Kd = 32 ± 18 µM in the presence of the peptide vs. Kd = 25 ± 12 µM in the absence of 
the peptide) (Figure 36C). 
 
 
 
5.5 FBP binding to ssFUSE 
 
 The analysis of BLI experiments described in this section has been performed 
with the help of Dr. Stephen R. Martin at the National Institute for Medical Research, 
London, UK. The two proteins (FBP Nbox-KH1-KH4 and FBP KH1-KH4) used in    
the experiments have been produced by David Hollingworth at the National Institute for 
Medical Research, London, UK. 
The published data indicate that FBP protein binds to T-rich sequences 
(Benjamin et al., 2008; Braddock et al., 2002) as does FIR. The minimal size of FUSE-
derived ssDNA necessary for FBP binding was determined with BLI. A number of 
biotinylated DNAs were immobilised on streptavidin-coated sensors, that were 
subsequently exposed to a range of FBP concentrations (0.5 to 8 nM) to study             
the association kinetics. The dissociation kinetics was followed by moving sensors with 
bound protein to the wells containing buffer. Kinetic analysis at high FBP concentration 
required double exponential fits to account for a minor component associated with   
non-specific binding. Initially, the experiments were performed with two different 
FUSE-derived ssDNAs (87mer – ssFUSE87 and 40mer – ssFUSE40) and two different 
FBP protein constructs (FBP Nbox-KH1-KH4 and FBP KH1-KH4) (Figure 37).        
The observed rate constants for the major part of the association phases (kobs) were 
linearly dependent on FBP concentration. The analysis showed that the dissociation 
constants are identical for the binding to ssFUSE87 and ssFUSE40 (Kd ~ 1.7 nM) and 
revealed only a small (two-fold) difference in association and dissociation rate constants 
for the binding to ssFUSE87 and ssFUSE40 (kon ~ 5.0 x 105 M-1s-1, koff ~ 8.0 x 10-4 s-1 
vs. kon ~ 2.6 x 105 M-1s-1, koff = 4.3 x 10-4 s-1) (Table 9). This observed difference in the 
rate constants may reflect the accessibility and/or flexibility of the immobilised 
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Figure 37 FBP binding to ssFUSE studied with BLI. Binding of increasing 
concentrations of FBP Nbox-KH1-KH4 (left) and FBP KH1-KH4 (right) to ssFUSE87 
(top) and ssFUSE40 (bottom). Each panel shows kinetics curves and the dependence of 
the observed association rate (kobs) on protein concentration together with obtained kon, 
koff and Kd values. The protein concentrations were 0.5 nM, 1 nM, 2 nM, 4 nM and       
8 nM. The FBP Nbox does not contribute to the DNA binding and ssFUSE87 does not 
contain additional sequences compared to ssFUSE40 that are recognised by FBP. 
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Table 9 Kinetics parameters of two different FBP constructs binding to ssFUSE87 and 
ssFUSE40. 
 
Oligonucleotide Protein kon [M-1s-1] koff [s-1] Kd [nM] 
ssFUSE87 
FBP Nbox-KH1-KH4 (4.5 ± 0.8) x 105 (7.3 ± 1.2) x 10-4 1.6 ± 0.4 
FBP KH1-KH4 (5.2 ± 1.2) x 105 (8.6 ± 1.9) x 10-4 1.7 ± 0.6 
ssFUSE40 
FBP Nbox-KH1-KH4 (2.5 ± 0.1) x 105 (4.6 ± 0.4) x 10-4 1.8 ± 0.2 
FBP KH1-KH4 (2.7 ± 0.2) x 105 (4.0 ± 0.5) x 10-4 1.5 ± 0.3 
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DNA on the surface. Furthermore, the presence of Nbox in the FBP construct did not 
affect the binding to either of the two DNA (Table 9). We concluded that FBP Nbox 
does not participate in the DNA binding and that ssFUSE87 does not contain any 
additional FBP target sequences compared to ssFUSE40. Importantly, the defined DNA 
sequence is consistent with the FBP-binding sequence defined by Benjamin et al. 
(Benjamin et al., 2008). 
Additional experiments with different length oligonucleotides derived from 
ssFUSE40 (Figure 38) and FBP KH1-KH4 protein were carried out to further confine 
the DNA sequence recognised by FBP. The truncations of ssFUSE40 from the 5’ end 
(ssFUSE6-40, ssFUSE11-40 and ssFUSE16-40) did not significantly affect FBP 
binding (Kd = 1.9 ± 0.4 nM, Kd = 2.1 ± 0.6 nM and Kd = 2.6 ± 0.8 nM respectively), 
while 10-nucleotide (ssFUSE1-30) and 15-nucleotide (ssFUSE1-25) truncations from 
the 3’ end diminished the binding ~ 15-fold (Kd = 27 ± 6 nM) and ~ 100-fold             
(Kd = ~ 100 nM) respectively (Figure 38 and Table 10). Thus, a ssFUSE that is           
25-nucleotide long and that contains T-rich sequences is sufficient to bind FBP protein 
with high affinity. 
 
 
 
5.6 FBP-mediated tethering of the FIR to the ssFUSE 
 
The analysis of BLI experiments described in this section has been performed 
with the help of Dr. Stephen R. Martin at the National Institute for Medical Research, 
London, UK. The two proteins (FBP Nbox-KH1-KH4 and FBP KH1-KH4) used in    
the experiments have been produced by David Hollingworth at the National Institute for 
Medical Research, London, UK. 
The effect of FBP Nbox on FIR binding to ssFUSE was studied using BLI. 
Sensors with immobilised ssFUSE40 were exposed first to FBP Nbox-KH1-KH4 and 
FBP KH1-KH4 at 100 nM, then to FBP solutions at the same concentration containing 
150 nM FIR RRM1-RRM2, and finally to FBP solutions, again at the same 
concentration but without FIR (Figure 39). Significant binding of FIR was detected with 
FBP Nbox-KH1-KH4 (red curve) but no binding was detected with FBP KH1-KH4 
(blue curve). The 10-fold increase in the FBP KH1-KH4 (up to 1 µM) did not lead to 
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Figure 38 FBP binds to T-rich sequences. Top – a sequence alignment of 
oligonucleotides used to study FBP binding to ssDNA with BLI. Bottom – binding of 
increasing concentrations of FBP KH1-KH4 (0.5 nM, 1 nM, 2 nM, 4 nM and 8 nM) to 
different ssFUSE oligonucleotides. Deletions of the T-rich sequence at the 3’ end of 
ssFUSE40 significantly decrease FBP binding. 
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Table 10 Kinetics parameters of FBP KH1-KH4 binding to different ssFUSE-derived 
oligonucleotides. 
 
Oligonucleotide kon [M-1s-1] koff [s-1] Kd [nM] 
ssFUSE87 (5.2 ± 1.2) x 105 (8.6 ± 1.9) x 10-4 1.7 ± 0.6 
ssFUSE40 (2.7 ± 0.2) x 105 (4.0 ± 0.5) x 10-4 1.5 ± 0.3 
ssFUSE6-40 (2.1 ± 0.2) x 105 (4.0 ± 0.5) x 10-4 1.9 ± 0.4 
ssFUSE11-40 (1.6 ± 0.3) x 105 (3.3 ± 0.7) x 10-4 2.1 ± 0.6 
ssFUSE16-40 (1.3 ± 0.3) x 105 (3.4 ± 0.5) x 10-4 2.6 ± 0.8 
ssFUSE1-35 (2.1 ± 0.3) x 105 (6.7 ± 0.8) x 10-4 3.2 ± 0.6 
ssFUSE1-30 (2.6 ± 0.5) x 105 (7.1 ± 0.1) x 10-3 27 ± 6 
ssFUSE1-25 2.2 x 105   a (2.2 ± 0.3) x 10-2 ~ 100 
a
 kon assumed to be similar to all other oligonucleotides 
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Figure 39 FBP Nbox recruits FIR to ssFUSE DNA. BLI binding assays show that      
the presence of the Nbox in FBP construct increases the affinity of FIR for the DNA. 
The BLI biosensors were derivatised with ssFUSE40 and exposed to different 
combinations of protein constructs (indicated on right), as reported in the figure. 
Response unit changes in three parallel experiments are displayed. 
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FIR binding (data not shown) and as expected, the binding of 150 nM FIR to ssFUSE40 
could not be detected at this concentration (green curve). Unfortunately, a detailed 
kinetic analysis of FIR RRM1-RRM2 binding to the bound FBP Nbox-KH1-KH4 was 
impossible because of interference at high FIR concentrations from FIR binding to     
the DNA. Nevertheless, it is clear from inspection of the kinetic curves that the effect of 
FBP Nbox-KH1-KH4 is to decrease the dissociation rate constant for FIR from 0.68 s-1 
to ~ 0.3 s-1 and to increase the association rate constant by a factor of 5-10. This would 
correspond to an increase in the affinity from Kd = 7 µM to Kd = ~ 0.3 – 0.7 µM. 
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6.1 Summary of the key findings 
 
The recruitment of the FIR repressor to the ssFUSE – FBP complex is of central 
importance in the cell cycle dependent regulation of c-myc. The first two RRM domains 
of FIR function as a structural scaffold for the interactions between the three 
components of the FUSE–FBP–FIR system. In this thesis, I describe the structural and 
biophysical characterisation of the interactions between FIR and both FBP and ssFUSE, 
as well as exploring the FBP–ssFUSE interaction. This work has allowed me to propose 
a molecular model that captures important aspects of the regulation. 
 
 
 
6.1.1 Structure of the first two RRM domains of FIR 
 
 The individual domains of FIR RRM1-RRM2 have a classical RRM fold, where 
two α-helices pack onto a four-stranded anti-parallel β-sheet. The two domains interact 
with each other, burying 1100 Å2 of solvent accessible surface. The inter-domain 
interface encompasses the α-helices of RRM1 and the β-sheet of RRM2, and occludes 
the canonical RNA/DNA binding surface of RRM2. Two additional α-helical elements 
(in the N-terminus of the construct and in the linker between the two domains) further 
stabilise the relative orientation between RRM1 and RRM2. 
The CD-monitored thermal denaturation of FIR RRM1-RRM2 shows a single 
transition point. This, together with the increase in stability of the domains when in    
the RRM1-RRM2 construct, emphasises that the two domains are joined in a single 
structural unit. Backbone relaxation data from NMR experiments confirm that            
the rotational correlation time (10.6 ns) is that expected for a compact ~ 20 kDa 
macromolecule (Maciejewski et al., 2000), consistent with FIR RRM1-RRM2 forming  
a single rigid unit. Furthermore, the T2 and hetNOE values show that significant     
intra-molecular motions are limited to the flexible loops and to the very ends of the FIR 
RRM1-RRM2 construct. 
An inter-domain interaction between RRM domains has been reported for three 
other proteins in the absence of nucleic acid: hnRNPA1 (Shamoo et al., 1997; Xu et al., 
1997), PTB (Vitali et al., 2006) and PRP24 (Bae et al., 2007) (Figure 40). In hnRNPA1, 
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Figure 40 Comparison of known RRM–RRM interactions in the absence of nucleic 
acid. Ribbon representation of A) the first two RRM domains of hnRNPA1 (1HA1),   
B) RRM3 and RRM4 of PTB (2EVZ), C) the first three RRM domains of PRP24 
(2GHP) and D) the first two RRM domains of FIR (this study). 
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the two RRM domains creates an extended β-sheet surface (composed of eight strands), 
that increases the affinity for RNA (Shamoo et al., 1997; Xu et al., 1997). In PTB,      
the two C-terminal RRM domains (RRM3 and RRM4) interact and this places the two 
nucleic acid binding sites far away from each other, implying either a bend in the RNA 
or binding of two separated sequences (Vitali et al., 2006). In PRP24, the first three 
RRMs are involved in inter-domain interactions (Bae et al., 2007). RRM2 of PRP24 
interacts via its β-sheet surface with the β-sheet surface of RRM1 and with the α-helical 
surface of RRM3 (Bae et al., 2007). There are, however, no contacts between the RRM1 
and RRM3 domains (Bae et al., 2007). Furthermore, NMR experiments show that all 
three domains of PRP24 contribute to the RNA binding, and therefore that the structural 
organisation of the domains probably changes upon binding to RNA (Bae et al., 2007). 
In FIR, as in PRP24, the inter-domain interaction between RRM1 and RRM2 occludes 
the nucleic acid binding surface of RRM2 (β-sheet surface). However, our NMR 
titration experiments and the X-ray structure of the FIR RRM1-RRM2 – ssFUSE 
complex (Crichlow et al., 2008) prove that RRM2 is not involved in the RNA/DNA 
binding. Therefore, a role of the pre-blocked organisation of FIR may be to 
appropriately position the protein within the FUSE regulatory complex. Analysis of our 
backbone relaxation data and comparison of FIR RRM1-RRM2 structures alone and 
Nbox-bound with the published ssDNA-bound structure (Crichlow et al., 2008) 
demonstrate that the protein fold and inter-domain arrangement are not modified by   
the interactions and further support a possible architectural function for the RRM1-
RRM2 inter-domain interaction. 
 
 
 
6.1.2 Structure of the FIR RRM1-RRM2 – FBP Nbox complex 
 
 The characterisation of the FBP Nbox by far-UV CD and NMR revealed that  
the peptide assumes an α-helical conformation in solution. The analysis of 15N, 1Hα, 
13Cα and 13Cβ chemical shifts defined the α-helix boundaries (D29 – I41), which are 
consistent with the ~ 40% α-helix content estimated by far-UV CD. Interestingly, it has 
been suggested that the Nbox forms an amphipathic helix, which binds to FIR via its 
hydrophobic face (Chung et al., 2006; Duncan et al., 1994). CSP analysis of the peptide 
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failed to confirm this hypothesis, because the perturbations were observed on both 
hydrophobic and hydrophilic faces of the putative helix during the titration with FIR 
RRM1-RRM2. However, this large effect can be attributed to the stabilisation of        
the Nbox in the helical conformation, that is confirmed by the observed chemical shift 
changes of the backbone (particularly for CαHα) resonances. Furthermore, φ and ψ 
dihedral angles derived from chemical shifts indicate that the helix extends to residues 
V27-I45 once the Nbox is in the complex. These 19 residues correspond to five turns of 
the helix with a length of ~ 27 Å, which is consistent with the interaction surface 
mapped on the FIR RRM2 (~ 15 x 25 Å). The interaction between the Nbox and 
RRM1-RRM2 is relatively weak (Kd ~ 15 µM) and the interface of the complex is 
dynamic, as reflected in the shorter-than-average T2 values of the resonances at          
the interface. 
 In the structure, the FBP Nbox peptide binds to FIR RRM1-RRM2 as               
an amphipathic α-helix with its hydrophobic face making contacts with a shallow 
hydrophobic groove on the α-helical side of the FIR RRM2 domain – consistent with 
CSP data on FIR RRM1-RRM2. Interestingly, there is no extensive inter-digitation of 
amino acid side-chains: the centre of the interface is occupied by alanines on the peptide 
side, while the longer hydrophobic side-chains of the peptide are loosely packed against 
the RRM2 surface. The structure of the complex explains the results of the published 
mutational analysis of the FBP–FIR interaction (Chung et al., 2006). In this work,          
a strong impairment of binding was observed for A34V and A38V mutants of             
the peptide that place a large hydrophobic chain in the centre of the inter-molecular 
interface and cause steric hindrance. Mutations of large hydrophobic residues (F31A or 
L35A), that are partially packed against the FIR RRM2, also attenuate the binding, but 
the effect is weaker than for the mutations of alanines, and can be attributed to the loss 
of specific hydrophobic interactions. In contrast, mutation of the loosely packed A42 
(A42V) does not lead to a significant decrease in binding affinity. Recapitulating,       
the peptide–protein interface is designed to provide a low affinity (Kd ~ 15 µM), but 
highly specific recognition – a hallmark of the transient FIR–FBP interaction that is 
crucial for recruitment of FIR to the FUSE, but also has to be disrupted without 
impairing FUSE–FIR binding in order to allow FBP ejection from the DNA. 
The change in the conformation of the Nbox upon complexation suggests that its 
propensity to form an α-helix could influence the interaction. Indeed, the peptide–
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protein interaction is disrupted upon substitution of two solvent-exposed residues (K32 
and D33) with prolines (a known helix-breaker), but not with alanines (Chung et al., 
2006). Also mutation of A38 to another helix-breaking residue – glycine – impairs     
the binding (Chung et al., 2006). Finally, we found that FBP3 Nbox peptide,               
the weakest binder of the FBPs Nbox peptides, has also the lowest content of α-helix in 
solution. Therefore the sequence of the peptide defines the binding affinity both by 
creating specific inter-molecular side-chain – side-chain contacts and by determining 
the propensity of Nbox to assume the correct secondary structure. 
 The binding of FBP Nbox peptide in a shallow groove on the α-helical face of 
FIR RRM2 represents a novel mode of protein–protein interaction in the RRM family 
(Figure 41). In principle, both the α and β sides of RRM domains can be involved in  
the inter-protein interactions. In the Y14 – Mago – PYM tri-molecular complex,         
the RRM domain of Y14 interacts via its β-sheet surface with Mago, and via its β2/β3 
loop with PYM (Bono et al., 2004). Similarly, UPF3b and p14 use the β-sheet face of 
RRM to bind respectively UPF2 and SF3b155 (Kadlec et al., 2004; Schellenberg et al., 
2006). The Raver1 – vinculin interaction is directed by the binding of vinculin to        
the β1/α1, β2/β3 and α2/β4 loops in RRM1 of Raver1 (Lee et al., 2009). In the other 
known protein–protein complexes, RRM domains recognise their binding partner via 
the α-helical face. A short peptide of Raver1 (SLLGEPP) is placed across the α1 and α2 
helices of PTB RRM2 (Rideau et al., 2006). In the U2B’’ – U2A’ complex, the α1 helix 
of RRM in U2B’’ packs against a β-sheet surface of the leucine-rich region in U2A’ 
(Price et al., 1998). Finally, a separate distinct mode of recognition is represented by  
the UHM subfamily of RRM domains (Kielkopf et al., 2004). Here, the RXF motif     
(X being any residue) and acidic residues on the helical side of the UHM domain bind   
a conserved W and positive residues in the UHM ligand motif (ULM), as in U2AF35 – 
U2AF65 (Kielkopf et al., 2001), U2AF65 – SF1 (Selenko et al., 2003) and SPF45 – 
SF3b155 (Corsini et al., 2007) complexes. The recognition of FBP Nbox by the helical 
face of FIR RRM2 presents a novel mode of interaction because 1) the Nbox assumes 
an α-helical conformation and 2) the peptide binds in a quasi-parallel orientation to    
the α1 helix of RRM2 rather than across both α1 and α2 helices. 
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Figure 41 FIR–FBP interaction represents a novel recognition mode in the RRM 
family. Ribbon representations of the structures of protein–protein complexes between 
RRM domains (grey) and their binding partners (blue and green): Y14 – Mago – PYM 
(1RK8), UPF3b – UPF2 (1UW4), p14 – SF3b155 (2F9D), Raver1 – Vinculin (3H2U), 
U2AF35 – U2AF65 (1JMT), U2AF65 – SF1 (1O0P), SPF45 – SF3b155 (2PEH),  
U2B’’ – U2A’ (1A9N) and FIR – FBP (this study). In the PTB – Raver1 complex      
the Raver1 peptide position is reported (blue) on the structure of PTB RRM2 in          
the complex with RNA (2ADB), according to the published model (Rideau et al., 2006). 
U2AF35, U2AF65 and SPF45 RRM domains belong to the UHM subfamily, which 
binds a conserved W and positive residues in the ligand peptides. 
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6.1.3 Binding of FIR RRM1-RRM2 and FBP KH1-KH4 to ssFUSE 
 
 Both FIR and FBP interact with ssFUSE. The current model of FIR–ssFUSE 
recognition is based on the X-ray structure of FIR RRM1-RRM2 bound to a 25mer 
ssFUSE-derived sequence and SEC-LS/RI/UV (size exclusion chromatography coupled 
with light scattering, refractive index and ultraviolet absorbance) data on protein–DNA 
interaction (Crichlow et al., 2008). In the crystals, FIR dimerises via a large interface 
that involves both RRM domains (Crichlow et al., 2008). Both FIR molecules are bound 
to DNA, but poor electron density allowed full determination of only one bound 
nucleotide per protein molecule (Crichlow et al., 2008). Based on the asymmetry of 
DNA binding (CG for one FIR molecule and AT for the other) and solvent fraction 
analysis, it was concluded that the two FIR molecules, as a dimer, interact with one 
molecule of DNA (Crichlow et al., 2008). SEC-LS/RI/UV measurements revealed that 
FIR RRM1-RRM2 binds to ssDNA with a 2 : 1 stoichiometry and that it is monomeric 
in the absence of nucleic acid (Crichlow et al., 2008). However, these experiments did 
not show if the two binding proteins are actually interacting. Furthermore, the authors 
reported that analysis of the binding by fluorescence allowed them to measure two 
distinct Kds (2 µM and 74 µM) for the two binding events (Crichlow et al., 2008). This 
is not consistent either with the SEC-LS/RI/UV data, where a fully bound complex is 
obtained at a concentration of ~ 60 µM of FIR RRM1-RRM2 or with a strong 
cooperativity that should be observed for the homodimerising molecules (Crichlow et 
al., 2008). 
My results argue that no FIR RRM1-RRM2 dimerisation occurs upon binding of 
FIR RRM1-RRM2 to ssFUSE. We tested this by titrating FIR RRM1-RRM2 with         
a 29mer ssFUSE. CSP analysis maps the recognition surface to β-sheet and β2/β3 and 
α2/β4 loops of the RRM1 domain, including the residues interacting with the two 
modelled nucleotides in the X-ray structure of the FIR RRM1-RRM2 – ssFUSE 
complex (Crichlow et al., 2008). The stoichiometry of the binding is 2 : 1, consistent 
with the SEC-LS/RI/UV data (Crichlow et al., 2008) and reflecting the sequence 
preference of the FIR RRM1 – that we show here binds better to Ts and Gs. Indeed, two 
T-rich stretches are present in the tested ssFUSE29 (see Table 4). The quality of         
the NMR data and the relatively tight binding did not allow me to define the Kds for   
the two binding events: nonetheless, a fast-to-intermediate exchange regime of           
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the resonances indicates that the dissociation constant is in the low micromolar range, 
consistent with Kd = 7 µM for the FIR RRM1-RRM2 – ssFUSE40 complex determined 
using BLI. Interestingly, CSP analysis with both the 29mer and a 5mer, whose sequence 
is included within the 29mer and has been indicated as high affinity by SIA, did not 
show any perturbations for residues at the putative dimer interface. Consistent with this,             
the rotational correlation time of the complex is shorter than what would be expected 
for a dimer–ssDNA complex. Finally, no substantial cooperativity exists for the binding 
of FIR to ssDNA – as the affinity for the 29mer is only marginally tighter than that for 
the 5mer. The observed difference in the affinity for different ssDNAs can be easily 
explained by the presence of quasi-equivalent binding sites within the longer DNA 
molecules. Taken together our data indicate that FIR does not dimerise on the DNA. 
 FBP has four nucleic acid-binding modules – KH1 to KH4 – and at least two of 
them are necessary for efficient binding of ssDNA (Duncan et al., 1994; Michelotti et 
al., 1996). Here, for the first time the interaction between FBP and ssFUSE has been 
studied quantitatively. The BLI experiments with two different constructs – FBP   
Nbox-KH1-KH4 and FBP KH1-KH4 – showed that the Nbox peptide does not 
contribute significantly to ssDNA binding and that the dissociation constants of          
the complexes are ~ 1.5 nM. Interestingly, 3’ truncations of ssFUSE, that eliminate    
the T-rich sequence, result in decreased affinity for the FBP protein and show that this 
T-rich stretch is crucial for the high affinity protein–nucleic acid interaction. The three 
orders of magnitude difference between FIR and FBP affinities for ssDNA (7 µM vs. 
1.5 nM) indicates that the faster recruitment of FBP to ssFUSE is driven by its higher 
affinity rather than by differences in protein concentration as proposed in a recent paper 
(Chung et al., 2006). 
 
 
 
6.1.4 The role of the FBP Nbox peptide in FIR recruitment 
 
 It has been suggested, based on electrophoretic mobility shift assay (EMSA), 
that the FBP and FIR proteins form a tri-molecular complex on an 87mer ssFUSE 
(Benjamin et al., 2008). Here, we confirm that despite their similar sequence preference, 
the FBP and FIR proteins can bind simultaneously to a 40mer ssFUSE DNA. We also 
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show that FIR uses opposite surfaces in RRM1 and RRM2 to interact with both ssFUSE 
and FBP. Furthermore, the affinity of the FIR RRM1-RRM2 for ssDNA is increased  
10- to 20-fold in the presence of the FBP construct containing Nbox and KH1 to KH4 
domains (FBP Nbox-KH1-KH4), but not in the presence of the FBP construct without 
the Nbox (KH1-KH4). Therefore, we prove that the amphipathic peptide of the activator 
(FBP) acts as a recruitment element for the repressor (FIR). 
 The enhanced binding of FIR is not due to an allosteric effect linking FIR–
ssFUSE and FIR–FBP interactions. In three-component NMR titrations the presence of 
bound ssDNA does not affect the affinity of FIR for the peptide and vice versa.         
The absence of an allosteric effect is important because ejection of FBP precedes 
ejection of FIR (Liu et al., 2006) and thus disruption of FIR–FBP interaction should not 
affect FIR interaction with ssFUSE DNA. Instead, the interaction between FIR and 
Nbox provides a physical tether that couples FIR–ssFUSE binding to the much stronger 
FBP–ssFUSE binding. Theoretically, if FIR–ssFUSE and FIR–FBP interactions were 
fully coupled the observed Kd of FIR binding should approach the product of              
the Kds for the two complexes, i.e. 7 x 10-6 x 15 x 10-6 = 1.05 x 10-10 M. However,      
the Nbox is separated from the first KH domain of FBP by a 50 amino acid flexible 
linker, that acts as a decoupling element and reduces the effect by 3000-fold to         
6500-fold (estimated Kd = 0.3 – 0.7 µM). This value is in agreement with                    
the theoretically predicted 5500-fold decrease for systems with 50-residue unstructured 
linkers separating the two binding sites with Kds of 7 µM and 15 µM (Shamoo et al., 
1995). 
 
 
 
6.2 A model of FUSE–FBP–FIR regulation 
 
The existing model of FUSE-mediated regulation of c-myc (see Fig. 3) (Liu et 
al., 2006) explains the biological data, but does not provide the details of the mechanism 
at the molecular and structural level. My work explains how the architectural 
arrangement of the RRM domains of the FIR protein, together with the specific 
interactions between FUSE, FBP and FIR, contributes to the management of the c-myc 
transcription. My data clarify: 1) what is the driving force for the recruitment of          
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the activator (FBP) to the FUSE regulatory element; 2) how the repressor (FIR) is 
recruited to the same element and 3) how FUSE–FBP–FIR interactions may contribute 
to the switch between activation and repression of the c-myc transcription. 
The transcription of c-myc is started in response to multiple inputs at                
the promoter, which increase the rate of the escape of the paused polymerase (Liu et al., 
2006; Wierstra and Alves, 2008). The torsional stress generated leads to the melting of 
the FUSE element (Liu et al., 2006). Subsequently, FBP is recruited to boost               
the transcription. It was proposed that FBP binding precedes FIR binding, because FBP 
is five times more abundant in the cell than FIR (Liu et al., 2006). However, our data 
suggest that the primary determinant of the recruitment order is the difference in affinity 
of FBP and FIR for ssDNA with FBP binding three orders of magnitude more tightly 
than FIR to ssFUSE (Kd ~ 1.5 nM vs. Kd ~ 7 µM). The bound FBP establishes 
interactions with the basic transcriptional machinery at the c-myc promoter and further 
increases the rate of the polymerase escape (Liu et al., 2006). 
Following the FBP-driven boost in the transcription, a repressor (FIR) is bound 
to the FBP–ssFUSE complex. This specific recruitment of FIR is central to                  
the FUSE-mediated regulation because it defines the length of the FBP promoted 
unhindered activation of c-myc. We show that binding of FIR to the regulatory complex 
is dependent on the FIR interaction with the FBP Nbox peptide. We also demonstrate 
that this effect is purely due to physical tethering of FIR and not due to an allosteric 
effect. Lack of allostery is functionally important for the FUSE–FBP–FIR regulatory 
mechanism – it means that the FBP–FIR interaction can be disrupted without affecting 
FIR–ssFUSE affinity, and therefore, that the activator can leave the regulatory element 
before the repressor. Furthermore, the physical tethering of FIR is precisely tuned to 
allow enough c-myc expression to occur. A coupling that was too weak would slow 
down FIR binding and would cause detrimental overexpression of c-myc. Conversely, 
coupling that was too strong would lead to a rapid recruitment of FIR and immediate 
shut off of the expression (Figure 42). The actual coupling leads to 10- to 20-fold 
increase in the affinity of FIR for ssFUSE. This is achieved by an amphipathic helix of 
FBP that binds to the RRM2 surface of FIR with a moderate affinity (Kd ~ 15 µM) and 
by a ~ 50 amino acid flexible linker that links this helix to the first KH domain – that 
acts as a decoupling element reducing the coupling effect ~ 5000-fold. 
FIR acts as a repressor and it has been shown that it remains associated with    
the ssFUSE, after the ejection of FBP protein (Liu et al., 2006). However, the molecular 
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Figure 42 Three different modes of FBP–FIR coupling and their effects on FIR binding 
and c-myc transcription. Left – In the absence of any coupling between FBP and FIR  
the affinity of FIR for the ssFUSE (Kd ~ 7 µM) would be too low for FIR to bind         
the ssFUSE. FBP activation of c-myc transcription (bottom) would therefore continue 
unperturbed. Middle – Boxed, the physiological scenario. The weak binding of           
the Nbox to FIR RRM2 and the 50-amino acid linker between the Nbox and KH1 are 
responsible for the physiologically weak coupling between FBP and FIR. This coupling 
is necessary to create the required peak in c-myc expression (bottom) and regulate      
the cell cycle. Right – A stronger coupling between FBP and FIR created by,               
for example, a small molecular weight compound binding at the interface between      
the two molecules would increase ~ 100-fold the apparent affinity of FIR for the FBP–
ssFUSE complex and would speed FIR recruitment and lead to a shorter expression of 
c-myc (bottom). 
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mechanism of the switch between activation and repression is poorly understood. 
Recently, a model was proposed where FIR dimerisation is linked to the ejection of FBP 
from the FUSE regulatory element (Crichlow et al., 2008). In this model, two molecules 
of FIR bind to the ssFUSE and dimerise. This leads to the looping of the DNA and 
structural rearrangements within the whole regulatory complex, which ultimately cause 
ejection of the FBP protein (Figure 43) (Crichlow et al., 2008). The model was based on 
the observed dimerisation of FIR on the ssFUSE in the X-ray structure. However,       
we show here that dimerisation does not take place in solution and therefore cannot be 
the driving force for the switch. Furthermore, the model is not consistent with our 
proposed mechanism of the recruitment, because FBP is able to bind and recruit only 
one molecule of FIR. Our data show that the FIR–FBP interaction does not 
allosterically affect the FIR–ssFUSE binding. Also, even though FIR binds to ssFUSE 
three orders of magnitude more weakly than FBP does, it is FIR that remains associated 
with the DNA for longer in the cell (Liu et al., 2006). Therefore, the FIR–ssFUSE 
interaction in the absence of FBP has to be stabilised by other components of              
the regulatory complex. A possible candidate is the XPB subunit of TFIIH transcription 
factor, that is involved in the initiation of c-myc transcription, and that interacts with  
the N-terminal part of FIR. Interestingly, FBP also interacts with XPB and it is tempting 
to speculate that FIR binding to ssFUSE and its subsequent interaction with XPB leads 
to a rearrangement of the TFIIH complex and thereby to the disruption of FBP–TFIIH 
interaction and ejection of FBP. Such a scenario seems more likely than a direct 
competition of FIR and FBP for the same binding site, as FBP and FIR interact with the 
XPB subunit of TFIIH using very different protein sequences (Liu et al., 2001; Liu et 
al., 2000). It is important to notice that FIR uses two RRM domains to interact with FBP 
and ssFUSE. This is unlikely to be imposed by the requirement for the lack of an 
allosteric effect as it was reported that a single RRM domain (RRM2 of PTB) can 
mediate protein–protein and protein–nucleic acid interaction without any allostery 
(Rideau et al., 2006). Therefore, the pre-formed single-unit organisation of two RRM 
domains within FIR protein may provide a special scaffold for the interactions, leading 
to the large rearrangements within the complex and causing FBP ejection. 
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Figure 43 Model of the on/off switch in the transcriptional regulation of c-myc 
proposed by Crichlow et al. (adapted from Crichlow et al., 2008). A) FBP binds first to 
the FUSE and activates c-myc transcription. B) Subsequently two molecules of FIR bind 
to the FUSE and C) by dimerisation, looping out the DNA and conformational 
rearrangements of the complex eject FBP protein and lead to the repression of c-myc 
expression. 
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6.3 Perspectives 
 
6.3.1 FUSE–FBP–FIR system as a drug target 
 
 In most cancer pathologies where c-myc function is disrupted the effect is caused 
by deregulation of the gene expression (and not by mutations in the c-MYC protein) 
(Oster et al., 2002; Vita and Henriksson, 2006). Because of the huge complexity of     
the transcriptional regulation of c-myc many of these pathologies very likely arise from 
the mutations, that directly or indirectly affect c-myc promoter regulation (Wierstra and 
Alves, 2008). The identification of such mutations and subsequent treatment would 
require a very personalised therapy approach, which would be both expensive and long. 
Importantly, FUSE–FBP–FIR acts independently from the single inputs converging to 
the c-myc promoter and therefore represents an attractive target for drugs. One possible 
intervention is the blockage of FBP binding to ssFUSE, for example with 
benzoylanthranilic acid inhibitors (Huth et al., 2004). However, this blockage may have 
some serious side-effects because the interactions of FBP with other DNA and/or RNA 
sequences will also be affected, thereby disrupting the multiple functions of FBP. 
Indeed, siRNA experiments confirmed that FBP proteins regulate expression of a broad 
range of genes (Chung et al., 2006). 
My results suggest an alternative approach that would speed up the recruitment 
of FIR to the activated c-myc promoter and prolong FIR-mediated repression.            
The structure of the FIR RRM1-RRM2 – FBP Nbox complex and the studies on their 
interaction suggest that a low molecular weight ligand could be selected that would 
stabilise the interaction between the two partners (Figure 42). Therefore the recruitment 
of FIR should occur earlier and should significantly decrease FBP-mediated activation 
of the c-myc proto-oncogene. Interestingly, a similar enhancement of protein–protein 
interaction has been recently described for 14-3-3 protein and its target peptides 
(Ottmann et al., 2009). Here the complex is stabilised by cotylenin A – a fungal 
diterpene glycoside, that has pro-differentiative activity and therefore is a potential anti-
cancer agent (Ottmann et al., 2009). 
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6.3.2 FUSE–FBP–FIR system as a research tool 
 
 A highly controlled gene expression is desired both as a research and therapeutic 
tool (Guo et al., 2008; Yamamoto et al., 2001). Many different approaches have been 
employed to drive expression of a target gene at the right level, right place and right 
time (Guo et al., 2008). Broad applications of these systems had been preceded by years 
of studies to define necessary elements, determine a mode of action and evaluate 
usefulness and safety (Guo et al., 2008; Yamamoto et al., 2001). Furthermore, in spite 
of the fact that all the systems are derived from natural counterparts they were often 
modified and joined in different combinations to broaden a spectrum of reachable 
profiles of expression (Guo et al., 2008; Yamamoto et al., 2001). For example, usage of 
heterologous promoters allows the expression of a desired gene ubiquitously             
(e.g. CMV, EF1α promoters) or limits it to a particular tissue, developmental stage or 
cell cycle stage (e.g. the albumin promoter limits expression to hepatocytes) (Guo et al., 
2008). The promoters may be also responsive to environmental conditions such as heat 
shock, hypoxia, radiation, chemotherapy and viral infection (Guo et al., 2008). 
Particular attention is given to small-molecule-inducible expression systems that allow  
a regulated gene to be switched on/off at strictly controlled times, and thus, provide       
a possibility to tightly control level of expression, and above all, increase the safety as 
the gene can be switched off when necessary (Guo et al., 2008). 
 FUSE–FBP–FIR represents an attractive heterologous system that can be 
employed to create a characteristic peak of expression. The principal advantage of this 
regulation is the ability to tightly control the level and period of expression via self-
inhibition. The mechanism can be used in combination with a highly regulated promoter 
(as in c-myc promoter) to create a chimeric regulatory unit that combines a strict control 
and an efficient up-regulation. However, virtually any promoter can be coupled with  
the FUSE–FBP–FIR system, because it responds to ongoing transcription (Liu et al., 
2006). In fact, the mechanism has been already used to reprogram a response of          
the metallothionein IIA promoter, which initiates transcription upon addition of Zn2+ 
(Liu et al., 2006). Furthermore, the system can be tuned to obtain a desired shape of   
the peak, for example by varying a distance between the promoter and the FUSE 
sequence (Liu et al., 2006). Additional studies are necessary to fully evaluate              
the regulatory capabilities of the FUSE–FBP–FIR system. 
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Appendix I Amino acid sequences of FIR and FBP (NP_003893) proteins. Sequences 
of human (NP_055096) and rat (AF165892) FIR proteins are aligned. The region cloned 
in the longest FIR RRM1-RRM2 construct is highlighted in yellow and it is 100% 
identical between the two proteins. For both FIR and FBP proteins the boundaries of 
domains are indicated above. 
 
FIR     1   MATATIALQV NGQQGGGSEP -----AAAAA VVAAGDKWKP  
rFIR   19   MATATIALQV NGQQGGGSEP AAAAAAAAAA VVAAGDKWKP  
            ********** **********      ***** ********** 
 
 
FIR    36   PQGTDSIKME NGQSTAAKLG LPPLTPEQQE ALQKAKKYAM  
rFIR   59   PQGTESIKME NGQSTGTKLG LPPLTPEQQE ALQKAKKYAM  
            ****:***** *****.:*** ********** ********** 
 
                                                   RRM1 
FIR    76   EQSIKSVLVK QTIAHQQQQL TNLQMAAQRQ RALAIMCRVY  
rFIR   99   EQSIKSVLVK QTIAHQQQQL TNLQMAAQRQ RALAIMCRVY  
            ********** ********** ********** ********** 
 
                               RRM1                    . 
FIR   116   VGSIYYELGE DTIRQAFAPF GPIKSIDMSW DSVTMKHKGF  
rFIR  139   VGSIYYELGE DTIRQAFAPF GPIKSIDMSW DSVTMKHKGF  
            ********** ********** ********** ********** 
 
                            RRM1               . 
FIR   156   AFVEYEVPEA AQLALEQMNS VMLGGRNIKV GRPSNIGQAQ  
rFIR  179   AFVEYEVPEA AQLALEQMNS VMLGGRNIKV GRPSNIGQAQ  
            ********** ********** ********** ********** 
 
                                       RRM2            . 
FIR   196   PIIDQLAEEA RAFNRIYVAS VHQDLSDDDI KSVFEAFGKI  
rFIR  219   PIIDQLAEEA RAFNRIYVAS VHQDLSDDDI KSVFEAFGKI  
            ********** ********** ********** ********** 
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                               RRM2                    . 
FIR   236   KSCTLARDPT TGKHKGYGFI EYEKAQSSQD AVSSMNLFDL  
rFIR  259   KSCTLARDPT TGKHKGYGFI EYEKAQSSQD AVSSMNLFDL  
            ********** ********** ********** ********** 
 
                RRM2     . 
FIR   276   GGQYLRVGKA VTPPMPLLTP ATPGGLPPAA AVAAAAATAK  
rFIR  299   GGQYLRVGKA VTPPMPLLTP ATPGGLPPAA AVAAAAATAK  
            ********** ********** ********** ********** 
 
 
FIR   316   ITAQEAVAGA AVLGTLGTPG LVSPALTLAQ PLGTLPQAVM  
rFIR  339   ITAQEAVAGA AVLGTLATPG LVSPALTLAQ PLGALPQAVM  
            ********** ******.*** ********** ***:****** 
 
 
FIR   356   AAQAPGVITG VTPARPPIPV TIPSVGVVNP ILASPPTLGL  
rFIR  379   AAQAPGVITG VTPARPPIPV TIPSVGVVNP ILASPPTLGL  
            ********** ********** ********** ********** 
 
 
FIR   396   LEPKKEKEEE ELFPESERPE MLSEQEHMSI SGSSARHMVM  
rFIR  419   LEPKKEKEEE ELFPESERPE MLSEQEHMSI SGSSARHMVM  
            ********** ********** ********** ********** 
 
                                   RRM3/UHM            . 
FIR   436   QKLLRKQEST VMVLRNMVDP KDIDDDLEGE VTEECGKFGA  
rFIR  459   QKLLRKQEST VMVLRNMVDP KDIDDDLEGE VTEECGKFGA  
            ********** ********** ********** ********** 
 
                             RRM3/UHM                  . 
FIR   476   VNRVIIYQEK QGEEEDAEII VKIFVEFSIA SETHKAIQAL  
rFIR  499   VNRVIIYQEK QGEEEDAEII VKIFVEFSMA SETHKAIQAL  
            ********** ********** ********:* ********** 
171 
               RRM3/UHM   . 
FIR   516   NGRWFAGRKV VAEVYDQERF DNSDLSA 
rFIR  539   NGRWFGGRKV VAEVYDQERF DNSDLSA 
            *****.**** ********** ******* 
  
172 
                                             Nbox      . 
FBP     1   MADYSTVPPP SSGSAGGGGG GGGGGGVNDA FKDALQRARQ  
 
                Nbox     . 
FBP    41   IAAKIGGDAG TSLNSNDYGY GGQKRPLEDG DQPDAKKVAP  
 
                                         KH1           . 
FBP    81   QNDSFGTQLP PMHQQQSRSV MTEEYKVPDG MVGFIIGRGG  
 
                                KH1                    . 
FBP   121   EQISRIQQES GCKIQIAPDS GGLPERSCML TGTPESVQSA  
 
               KH1   .                       KH2        . 
FBP   161   KRLLDQIVEK GRPAPGFHHG DGPGNAVQEI MIPASKAGLV  
 
                                KH2                    . 
FBP   201   IGKGGETIKQ LQERAGVKMV MIQDGPQNTG ADKPLRITGD  
 
                   KH2       .                     KH3  . 
FBP   241   PYKVQQAKEM VLELIRDQGG FREVRNEYGS RIGGNEGIDV  
 
                                KH3                    . 
FBP   281   PIPRFAVGIV IGRNGEMIKK IQNDAGVRIQ FKPDDGTTPE  
 
                       KH3            . 
FBP   321   RIAQITGPPD RCQHAAEIIT DLLRSVQAGN PGGPGPGGRG  
 
                                       KH4             . 
FBP   361   RGRGQGNWNM GPPGGLQEFN FIVPTGKTGL IIGKGGETIK  
 
                                KH4                    . 
FBP   401   SISQQSGARI ELQRNPPPNA DPNMKLFTIR GTPQQIDYAR  
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              KH4   . 
FBP   441   QLIEEKIGGP VNPLGPPVPH GPHGVPGPHG PPGPPGPGTP  
 
 
FBP   481   MGPYNPAPYN PGPPGPAPHG PPAPYAPQGW GNAYPHWQQQ  
 
 
FBP   521   APPDPAKAGT DPNSAAWAAY YAHYYQQQAQ PPPAAPAGAP  
 
 
FBP   561   TTTQTNGQGD QQNPAPAGQV DYTKAWEEYY KKMGQAVPAP  
 
 
FBP   601   TGAPPGGQPD YSAAWAEYYR QQAAYYAQTS PQGMPQHPPA  
 
 
FBP   641   PQGQ 
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Experiment FIR RRM1-RRM2 conc. [mM] Sample 
1H frequency of spectrometer 
[MHz] 
CBCA(CO)NH 0.30 15N13C 700 
HN(CO)CACB 0.35 15N13C2H 600 
HNCA 0.30 15N13C 800 
HNCA 0.35 15N13C2H 700 
HN(CO)CA 0.30 15N13C 800 
HNCO 0.30 15N13C 800 
HNCACB 0.35 15N13C2H 700 
HNCACB 0.35 15N13C 700 
HCCH TOCSY 0.30 15N13C 600 
15N TOCSY 0.25 15N 600 
13C NOESY HSQC 0.35 15N13C 800 
13C NOESY HSQC optimised for aromatics 0.35 15N13C 800 
15N NOESY HSQC 0.25 15N 600 
T1 relaxation 0.35 15N 600 
T2 relaxation 0.35 15N 600 
hetNOE 0.35 15N 600 
All experiments performed in 90% H2O/10% 2H2O at 37 °C. 
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FIR RRM1-RRM2 – FBP Nbox complex 
Experiment 
FIR RRM1-
RRM2 conc. 
[mM] 
FBP Nbox 
conc. [mM] 
Sample Solvent 
Temperature 
[°C] 
1H frequency of 
spectrometer 
[MHz] 
HNCA 0.30 0.60 15N13C protein 90% H2O/10% 2H2O 37 600 
HCCH TOCSY 0.75 0.25 15N13C peptide 100% 2H2O 37 600 
HCCH TOCSY 0.60 0.20 15N13C peptide 100% 2H2O 45 600 
15N NOESY 0.60 1.25 15N protein 90% H2O/10% 2H2O 37 800 
13C-filtered 13C NOESY 
HSQC 
0.30 0.60 15N13C protein 100% 2H2O 37 600 
13C NOESY HSQC w/o 
13C decoupling during 
the 1H indirectly 
acquired dimension 
0.30 0.60 15N13C protein 100% 2H2O 37 600 
13C NOESY HSQC w/o 
13C decoupling during 
the 1H indirectly 
acquired dimension 
0.75 0.25 15N13C peptide 100% 2H2O 37 800 
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FIR RRM1-RRM2 – FBP Nbox complex 
Experiment 
FIR RRM1-
RRM2 conc. 
[mM] 
FBP Nbox 
conc. [mM] 
Sample Solvent 
Temperature 
[°C] 
1H frequency of 
spectrometer 
[MHz] 
13C NOESY HSQC w/o 
13C decoupling during 
the 1H indirectly 
acquired dimension 
0.60 0.20 15N13C peptide 100% 2H2O 45 700 
13C NOESY HSQC 0.55 1.45 15N13C protein 100% 2H2O 37 700 
13C NOESY HSQC 0.55 1.45 15N13C protein 90% H2O/10% 2H2O 37 800 
13C NOESY HSQC 0.85 0.30 15N13C peptide 100% 2H2O 37 800 
13C NOESY HSQC 0.65 0.35 15N13C peptide 100% 2H2O 45 700 
13C NOESY HSQC 
optimised for aromatics 
0.55 1.45 15N13C protein 100% 2H2O 37 800 
T1 relaxation 0.40 0.80 15N protein 90% H2O/10% 2H2O 37 600 
T2 relaxation 0.40 0.80 15N protein 90% H2O/10% 2H2O 37 600 
hetNOE 0.40 0.80 15N protein 90% H2O/10% 2H2O 37 600 
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FBP Nbox 
Experiment FBP Nbox conc. [mM] 1H frequency of spectrometer [MHz] 
HNCACB 0.40 600 
CBCA(CO)NH 0.35 700 
15N TOCSY 0.35 600 
HCCH TOCSY 0.35 700 
All experiments performed on 15N13C sample in 90% H2O/10% 2H2O at 37 °C. 
 
 
FIR RRM1-RRM2 – ssFUSE29 complex 
Experiment FIR RRM1-RRM2 conc. [mM] ssFUSE29 conc. [mM] 1H frequency of spectrometer [MHz] 
T1 relaxation 0.40 0.20 600 
T2 relaxation 0.40 0.20 600 
hetNOE 0.40 0.20 600 
All experiments performed on 15N sample in 90% H2O/10% 2H2O at 37 °C. 
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Monitored – analyte 
(start conc. [µM]) 
Titrated in – titrant 
(stock conc. [mM]) 
Experiment 
recorded 
Titration steps (equivalents) pH 
A
pp
endix
 III
 S
et
-up
s
 fo
r
 N
M
R
 titratio
n
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ents
 rep
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rted
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 study
.
 
FIR RRM1-RRM2 (41) FBP Nbox (1.0) sofast 15N HMQC 
0, 0.2, 0.4, 0.6, 0.8, 1.2, 1.6, 2, 3, 4, 6.1, 
10.2 
7.4 
FIR RRM1-RRM2 (41) FBP2 Nbox (1.0) sofast 15N HMQC 
0, 0.13, 0.25, 0.4, 0.5, 0.75, 1, 1.25, 1.9, 2.5, 
3.8, 6.3 
7.4 
FIR RRM1-RRM2 (41) FBP3 Nbox (1.1) sofast 15N HMQC 
0, 0.1, 0.3, 0.6, 1.15, 1.7, 2.3, 2.9, 3.5, 4.6, 
5.8, 6.9, 8.6, 11.5, 14.3 
7.4 
FIR RRM1-RRM2 (41) FBP Nbox with Y (2.0) sofast 15N HMQC 
0, 0.1, 0.25, 0.4, 0.5, 0.75, 1, 1.2, 1.8, 2.4, 
3.7, 6.1 
7.4 
FIR RRM1-RRM2 (41) FBP2 Nbox with Y (2.0) sofast 15N HMQC 
0, 0.1, 0.25, 0.4, 0.5, 0.75, 1, 1.2, 1.8, 2.4, 
3.7, 6.1 
7.4 
FIR RRM1-RRM2 (75) ssFUSE29 (1.5) sofast 15N HMQC 0, 0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.5 7.4 
FIR RRM1-RRM2 (25) TTTTT (3.1) sofast 15N HMQC 0, 0.2, 0.5, 1, 2, 3, 5, 8 7.4 
FIR RRM1-RRM2 (25) TGTGT (3.0) sofast 15N HMQC 0, 0.2, 0.5, 1, 2, 3, 5, 8 7.4 
FIR RRM1-RRM2 (25) TATAT (3.0) sofast 15N HMQC 0, 0.2, 1, 3, 6, 9, 14 7.4 
FIR RRM1-RRM2 (25) AAAAA (3.0) sofast 15N HMQC 0, 0.2, 1, 3, 6, 8 7.4 
FIR RRM1-RRM2 (25)a TGTGT (2.5) sofast 15N HMQC 0, 0.2, 0.5, 1, 2, 3, 5, 8 7.4 
FIR RRM1-RRM2 (41)b FBP Nbox with Y (2.0) sofast 15N HMQC 
0, 0.1, 0.25, 0.4, 0.5, 0.73, 1, 1.2, 1.8, 2.4, 
3.7, 6.1 
7.4 
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Monitored – analyte 
(start conc. [µM]) 
Titrated in – titrant 
(stock conc. [mM]) 
Experiment 
recorded 
Titration steps (equivalents) pH 
FIR RRM1-RRM2 (70)c FBP Nbox (2.0) sofast 15N HMQC 0, 6 7.4 
FIR RRM1-RRM2 (25) DNA pool (2.0 – 3.0)d sofast 15N HMQC 0, 1, 4 7.4 
FBP Nbox (50) FIR RRM1-RRM2 (0.70) sofast 15N HMQC 0, 0.2, 0.5, 1, 2, 3 6.5 
FBP Nbox (50) FIR RRM1-RRM2 (0.70) 13C HSQC 0, 0.5, 1, 2, 3 8.0 
FBP Nbox (71) FIR RRM1-RRM2 (0.38) 
sofast 15N HMQC, 
13C HSQC 
0, 0.2, 0.5, 1, 2, 3 5.0 
a
 a three-molecular titration where FIR RRM1-RRM2 – FBP Nbox (with Y) complex at 1 : 6 ratio was titrated with TGTGT 
oligonucleotide 
b
 a three-molecular titration where FIR RRM1-RRM2 – TGTGT complex at 1 : 8 ratio was titrated with FBP Nbox (with Y) 
c
 a three-molecular titration where FIR RRM1-RRM2 – ssFUSE29 complex at 1 : 1.5 ratio was titrated with FBP Nbox (with Y) 
d
 SIA analysis – 16 different DNA pools where used 
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Appendix IV SIA analysis of FIR RRM1-RRM2 protein. 
 
Each of the 16 pools of 5mer DNA oligonucleotides used for SIA analysis has a fixed 
nucleotide at one position while the other positions are equimolarly occupied by A, G, 
C and T nucleotides. As an example, a full composition of nANNN pool is given below 
(N means any nucleotide). A fixed nucleotide is in blue. A lowercase indicates that this 
position was not examined during SIA analysis of FIR RRM1-RRM2 protein. 
 
Oligonucleotide composition of the nANNN DNA pool 
aAAAA aAGAA aACAA aATAA gAAAA gAGAA gACAA gATAA 
aAAAG aAGAG aACAG aATAG gAAAG gAGAG gACAG gATAG 
aAAAC aAGAC aACAC aATAC gAAAC gAGAC gACAC gATAC 
aAAAT aAGAT aACAT aATAT gAAAT gAGAT gACAT gATAT 
aAAGA aAGGA aACGA aATGA gAAGA gAGGA gACGA gATGA 
aAAGG aAGGG aACGG aATGG gAAGG gAGGG gACGG gATGG 
aAAGC aAGGC aACGC aATGC gAAGC gAGGC gACGC gATGC 
aAAGT aAGGT aACGT aATGT gAAGT gAGGT gACGT gATGT 
aAACA aAGCA aACCA aATCA gAACA gAGCA gACCA gATCA 
aAACG aAGCG aACCG aATCG gAACG gAGCG gACCG gATCG 
aAACC aAGCC aACCC aATCC gAACC gAGCC gACCC gATCC 
aAACT aAGCT aACCT aATCT gAACT gAGCT gACCT gATCT 
aAATA aAGTA aACTA aATTA gAATA gAGTA gACTA gATTA 
aAATG aAGTG aACTG aATTG gAATG gAGTG gACTG gATTG 
aAATC aAGTC aACTC aATTC gAATC gAGTC gACTC gATTC 
aAATT aAGTT aACTT aATTT gAATT gAGTT gACTT gATTT 
cAAAA cAGAA cACAA cATAA tAAAA tAGAA tACAA tATAA 
cAAAG cAGAG cACAG cATAG tAAAG tAGAG tACAG tATAG 
cAAAC cAGAC cACAC cATAC tAAAC tAGAC tACAC tATAC 
cAAAT cAGAT cACAT cATAT tAAAT tAGAT tACAT tATAT 
cAAGA cAGGA cACGA cATGA tAAGA tAGGA tACGA tATGA 
cAAGG cAGGG cACGG cATGG tAAGG tAGGG tACGG tATGG 
cAAGC cAGGC cACGC cATGC tAAGC tAGGC tACGC tATGC 
cAAGT cAGGT cACGT cATGT tAAGT tAGGT tACGT tATGT 
cAACA cAGCA cACCA cATCA tAACA tAGCA tACCA tATCA 
cAACG cAGCG cACCG cATCG tAACG tAGCG tACCG tATCG 
cAACC cAGCC cACCC cATCC tAACC tAGCC tACCC tATCC 
cAACT cAGCT cACCT cATCT tAACT tAGCT tACCT tATCT 
cAATA cAGTA cACTA cATTA tAATA tAGTA tACTA tATTA 
cAATG cAGTG cACTG cATTG tAATG tAGTG tACTG tATTG 
cAATC cAGTC cACTC cATTC tAATC tAGTC tACTC tATTC 
cAATT cAGTT cACTT cATTT tAATT tAGTT tACTT tATTT 
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The procedure for calculation of SIA scores and the numerical values obtained during 
analysis of FIR RRM1-RRM2 protein are reported below. 
 
1. For each peak analysed (in total 15 peaks), average chemical shift perturbations ∆<=>? at the protein : DNA ratio of 1 : 4 were calculated using equation: 
 
∆<=>?  @A∆<B10 E
4 5 
∆<F4 
where: 
∆<B chemical shift change in 15N dimension ∆<F chemical shift change in 1H dimension 
 
The values of ∆<=>? obtained are reported below. 
2. For each peak, the values of ∆<=>? were normalised to the highest value of ∆<=>? obtained for titrations with four different DNA pools with a fixed 
nucleotide in one position. 
3. For each DNA pool, the normalised values of ∆<=>? were averaged over all     
15 peaks to yield a final SIA score for a given nucleotide at a given position. 
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Nucleotide preference of FIR RRM1-RRM2 for the first position tested 
 
DNA pool used for the titration 
∆ [ppm] ∆ normalised to the highest 
value 
nANNN nGNNN nCNNN nTNNN nANNN nGNNN nCNNN nTNNN 
Pe
a
k 
a
n
a
ly
se
d 
R113 0.0241 0.0343 0.0313 0.0371 0.65 0.92 0.84 1.00 
V114 0.0137 0.0388 0.0190 0.0286 0.35 1.00 0.49 0.74 
Y115 0.0523 0.1130 0.1080 0.1510 0.35 0.75 0.72 1.00 
G117 0.0326 0.0308 0.0371 0.0958 0.34 0.32 0.39 1.00 
G124 0.0111 0.0237 0.0371 0.0601 0.18 0.39 0.62 1.00 
I128 0.0138 0.0352 0.0231 0.0431 0.32 0.82 0.54 1.00 
A133 0.0232 0.0240 0.0134 0.0049 0.97 1.00 0.56 0.20 
D142 0.0254 0.0406 0.0250 0.0407 0.62 1.00 0.61 1.00 
W145 0.0447 0.0696 0.0570 0.0696 0.64 1.00 0.82 1.00 
D146 0.0229 0.0546 0.0396 0.0532 0.42 1.00 0.73 0.97 
V158 0.0123 0.0396 0.0192 0.0216 0.31 1.00 0.48 0.55 
N174 0.0360 0.0320 0.0190 0.0140 1.00 0.89 0.53 0.39 
N182 0.0198 0.0382 0.0396 0.0583 0.34 0.66 0.68 1.00 
I183 0.0160 0.0274 0.0198 0.0283 0.57 0.97 0.70 1.00 
V185 0.0295 0.0556 0.0740 0.1216 0.24 0.46 0.61 1.00 
Final SIA score for a given nucleotide                 
in the first position tested 
0.49 0.81 0.62 0.86 
 
 
 
 
 
 
 
 
 
 
 
183 
Nucleotide preference of FIR RRM1-RRM2 for the second position tested 
 
DNA pool used for the titration 
∆ [ppm] ∆ normalised to the highest 
value 
nNANN nNGNN nNCNN nNTNN nNANN nNGNN nNCNN nNTNN 
Pe
a
k 
a
n
a
ly
se
d 
R113 0.0101 0.0400 0.0239 0.0410 0.25 0.98 0.58 1.00 
V114 0.0185 0.0342 0.0219 0.0229 0.54 1.00 0.64 0.67 
Y115 0.0750 0.1279 0.0040 0.1476 0.51 0.87 0.03 1.00 
G117 0.0237 0.0330 0.0450 0.0529 0.45 0.62 0.85 1.00 
G124 0.0053 0.0336 0.0311 0.0388 0.14 0.87 0.80 1.00 
I128 0.0180 0.0220 0.0231 0.0360 0.50 0.61 0.64 1.00 
D142 0.0087 0.0351 0.0332 0.0423 0.21 0.83 0.78 1.00 
W145 0.0585 0.0838 0.0787 0.0867 0.67 0.97 0.91 1.00 
D146 0.0134 0.0498 0.0454 0.0411 0.27 1.00 0.91 0.83 
A156 0.0385 0.0838 0.0943 0.1045 0.37 0.80 0.90 1.00 
F157 0.0659 0.1156 0.0208 0.1205 0.55 0.96 0.17 1.00 
N174 0.0052 0.0361 0.0251 0.0184 0.14 1.00 0.70 0.51 
N182 0.0158 0.0381 0.0430 0.0464 0.34 0.82 0.93 1.00 
I183 0.0094 0.0272 0.0129 0.0247 0.35 1.00 0.47 0.91 
V185 0.2242 0.0447 0.0831 0.1025 1.00 0.20 0.37 0.46 
Final SIA score for a given nucleotide                
in the second position tested 
0.42 0.84 0.65 0.89 
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Nucleotide preference of FIR RRM1-RRM2 for the third position tested 
 
DNA pool used for the titration 
∆ [ppm] ∆ normalised to the highest 
value 
nNNAN nNNGN nNNCN nNNTN nNNAN nNNGN nNNCN nNNTN 
Pe
a
k 
a
n
a
ly
se
d 
R113 0.0158 0.0125 0.0285 0.0464 0.34 0.27 0.61 1.00 
V114 0.0098 0.0177 0.0110 0.0499 0.20 0.35 0.22 1.00 
Y115 0.0383 0.0417 0.0603 0.0088 0.64 0.69 1.00 0.15 
G117 0.0203 0.0235 0.0325 0.0540 0.38 0.44 0.60 1.00 
G124 0.0079 0.0150 0.0205 0.0383 0.21 0.39 0.54 1.00 
I128 0.0102 0.0087 0.0164 0.0277 0.37 0.31 0.59 1.00 
D142 0.0090 0.0427 0.0271 0.0315 0.21 1.00 0.63 0.74 
W145 0.0326 0.0428 0.0788 0.0815 0.40 0.53 0.97 1.00 
D146 0.0132 0.0255 0.0393 0.0591 0.22 0.43 0.66 1.00 
F157 0.0372 0.0720 0.0828 0.1276 0.29 0.56 0.65 1.00 
V158 0.0137 0.0080 0.0109 0.0215 0.64 0.37 0.51 1.00 
N174 0.0074 0.0122 0.0121 0.0196 0.38 0.62 0.62 1.00 
N182 0.0176 0.0407 0.0498 0.0750 0.23 0.54 0.66 1.00 
I183 0.0115 0.0213 0.0190 0.0373 0.31 0.57 0.51 1.00 
V185 0.0375 0.0301 0.0604 0.1383 0.27 0.22 0.44 1.00 
Final SIA score for a given nucleotide                
in the third position tested 
0.34 0.49 0.61 0.93 
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Nucleotide preference of FIR RRM1-RRM2 for the fourth position tested 
 
DNA pool used for the titration 
∆ [ppm] ∆ normalised to the highest 
value 
nNNNA nNNNG nNNNC nNNNT nNNNA nNNNG nNNNC nNNNT 
Pe
a
k 
a
n
a
ly
se
d 
R113 0.0335 0.0350 0.0370 0.0415 0.81 0.84 0.89 1.00 
V114 0.0207 0.0358 0.0246 0.0618 0.33 0.58 0.40 1.00 
G117 0.0225 0.0284 0.0505 0.0450 0.45 0.56 1.00 0.89 
G124 0.0219 0.0263 0.0252 0.0241 0.83 1.00 0.96 0.92 
I128 0.0165 0.0199 0.0134 0.0372 0.44 0.53 0.36 1.00 
D142 0.0276 0.0311 0.0205 0.0278 0.89 1.00 0.74 0.89 
W145 0.0667 0.0935 0.0623 0.1277 0.52 0.73 0.49 1.00 
D146 0.0449 0.0589 0.0435 0.0681 0.66 0.86 0.64 1.00 
A156 0.0663 0.0384 0.0627 0.0948 0.70 0.41 0.66 1.00 
F157 0.1006 0.1152 0.0675 0.1577 0.64 0.73 0.43 1.00 
V158 0.0150 0.0159 0.0101 0.0328 0.46 0.48 0.31 1.00 
N174 0.0128 0.0181 0.0082 0.0259 0.49 0.70 0.32 1.00 
N182 0.0481 0.0695 0.0481 0.0730 0.66 0.95 0.66 1.00 
I183 0.0195 0.0363 0.0189 0.0312 0.54 1.00 0.52 0.86 
V185 0.0725 0.0783 0.0716 0.1041 0.70 0.75 0.69 1.00 
Final SIA score for a given nucleotide                
in the fourth position tested 
0.61 0.74 0.60 0.97 
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Appendix V Backbone and side chain assignment of FIR RRM1-RRM2 and FBP Nbox 
in the free form and in the complex. Ambiguity value of 1 indicates unique assignments 
including isolated methyl protons, geminal atoms, and geminal methyl groups with 
identical chemical shifts (e.g. ILE HD11, HD12, HD13 protons). Ambiguity value of 2 
indicates ambiguity of geminal atoms or geminal methyl proton groups (e.g. ASP HB2 
and HB3 protons, LEU CD1 and CD2 carbons, or LEU HD11, HD12, HD13 and HD21, 
HD22, HD23 methyl protons), which were not stereospecifically assigned. Ambiguity 
value of 3 indicates aromatic atoms on opposite sides of symmetrical rings (e.g. TYR 
HE1 and HE2 protons). 
 
Residue 
name 
Residue 
number Atom name 
Chemical 
shift [ppm] Ambiguity 
Chemical 
shift [ppm] Ambiguity 
FIR RRM1-RRM2 free FIR RRM1-RRM2 bound 
ARG 104 CA 60.09 1 
  
ARG 104 CB 30.30 1 
  
ARG 104 C 177.29 1 
  GLN 105 N 118.16 1 118.00 1 
GLN 105 HN 8.25 1 8.19 1 
GLN 105 CA 59.48 1 59.25 1 
GLN 105 CB 28.45 1 
  GLN 105 C 178.83 1 
  
ARG 106 N 119.39 1 119.33 1 
ARG 106 HN 7.93 1 7.95 1 
ARG 106 CA 59.11 1 58.99 1 
ARG 106 CB 30.05 1 
  
ARG 106 C 178.39 1 
  
ALA 107 N 121.41 1 121.41 1 
ALA 107 HN 7.82 1 7.82 1 
ALA 107 CA 55.25 1 55.12 1 
ALA 107 HA 3.94 1 3.93 1 
ALA 107 CB 18.61 1 18.48 1 
ALA 107 HB 1.47 1 1.46 1 
ALA 107 C 178.67 1 
  
LEU 108 N 117.79 1 117.73 1 
LEU 108 HN 8.16 1 8.14 1 
LEU 108 CA 57.99 1 57.93 1 
LEU 108 HA 4.01 1 3.99 1 
LEU 108 CB 42.01 1 41.95 1 
LEU 108 HB2/HB3 1.81/1.48 2 1.80/1.47 2 
LEU 108 CG 27.43 1 27.43 1 
LEU 108 HG 1.72 1 1.71 1 
LEU 108 CD1/CD2 25.73/24.64 2 25.63/24.52 2 
LEU 108 HD1/HD2 0.84/0.87 2 0.84/0.85 2 
LEU 108 C 178.48 1 
  
ALA 109 N 119.35 1 119.34 1 
ALA 109 HN 7.42 1 7.41 1 
ALA 109 CA 55.44 1 55.21 1 
ALA 109 HA 4.11 1 4.10 1 
ALA 109 CB 18.07 1 18.10 1 
ALA 109 HB 1.45 1 1.44 1 
ALA 109 C 181.10 1 
  
ILE 110 N 118.48 1 118.52 1 
ILE 110 HN 7.59 1 7.59 1 
ILE 110 CA 65.02 1 64.97 1 
ILE 110 HA 3.68 1 3.67 1 
ILE 110 CB 38.39 1 38.25 1 
ILE 110 HB 1.88 1 1.87 1 
ILE 110 CG1 29.57 1 29.48 1 
ILE 110 HG12/HG13 1.71/1.04 2 1.71/1.04 2 
ILE 110 CG2 17.64 1 17.58 1 
ILE 110 HG2 0.85 1 0.84 1 
ILE 110 CD1 13.90 1 13.90 1 
ILE 110 HD1 0.74 1 0.74 1 
ILE 110 C 178.72 1 
  MET 111 N 118.37 1 118.27 1 
MET 111 HN 8.20 1 8.18 1 
MET 111 CA 58.67 1 58.49 1 
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Residue 
name 
Residue 
number Atom name 
Chemical 
shift [ppm] Ambiguity 
Chemical 
shift [ppm] Ambiguity 
FIR RRM1-RRM2 free FIR RRM1-RRM2 bound 
MET 111 HA 3.90 1 3.89 1 
MET 111 CB 34.77 1 34.70 1 
MET 111 HB2/HB3 2.29 2 2.32 2 
MET 111 CG 32.87 1 32.87 1 
MET 111 HG2/HG3 2.61 2 2.60 2 
MET 111 CE 16.74 1 16.75 1 
MET 111 HE 1.97 1 1.97 1 
MET 111 C 176.36 1 
  CYS 112 N 113.70 1 113.68 1 
CYS 112 HN 7.24 1 7.23 1 
CYS 112 CA 62.42 1 62.51 1 
CYS 112 HA 4.16 1 4.15 1 
CYS 112 CB 28.42 1 28.22 1 
CYS 112 HB2/HB3 3.58/3.07 2 3.57/3.06 2 
CYS 112 C 173.38 1 
  ARG 113 N 120.14 1 120.10 1 
ARG 113 HN 7.43 1 7.41 1 
ARG 113 CA 55.81 1 55.62 1 
ARG 113 HA 5.37 1 5.36 1 
ARG 113 CB 33.83 1 33.72 1 
ARG 113 HB2/HB3 1.81/1.74 2 1.80/1.74 2 
ARG 113 CG 28.57 1 28.56 1 
ARG 113 HG2/HG3 1.40/1.74 2 1.40/1.74 2 
ARG 113 CD 43.84 1 43.61 1 
ARG 113 HD2/HD3 2.91/3.08 2 2.91/3.07 2 
ARG 113 C 174.96 1 
  VAL 114 N 117.47 1 117.31 1 
VAL 114 HN 9.09 1 9.08 1 
VAL 114 CA 60.40 1 60.26 1 
VAL 114 HA 4.72 1 4.72 1 
VAL 114 CB 34.99 1 34.97 1 
VAL 114 HB 2.09 1 2.09 1 
VAL 114 CG1/CG2 20.53/22.90 2 20.41/22.87 2 
VAL 114 HG1/HG2 0.90/0.93 2 0.89/0.92 2 
VAL 114 C 174.52 1 
  TYR 115 N 125.38 1 125.28 1 
TYR 115 HN 8.83 1 8.82 1 
TYR 115 CA 56.85 1 56.75 1 
TYR 115 HA 4.49 1 4.48 1 
TYR 115 CB 39.85 1 39.88 1 
TYR 115 HB2/HB3 2.48/2.39 2 2.46/2.38 2 
TYR 115 CD1/CD2 133.01 3 133.01 3 
TYR 115 HD1/HD2 6.39 3 6.39 3 
TYR 115 CE1/CE2 117.68 3 117.62 3 
TYR 115 HE1/HE2 6.23 3 6.23 3 
TYR 115 C 174.52 1 
  VAL 116 N 127.91 1 127.88 1 
VAL 116 HN 8.39 1 8.38 1 
VAL 116 CA 60.38 1 60.27 1 
VAL 116 HA 4.59 1 4.58 1 
VAL 116 CB 33.27 1 33.26 1 
VAL 116 HB 1.57 1 1.56 1 
VAL 116 CG1/CG2 21.46/22.10 2 21.39/21.95 2 
VAL 116 HG1/HG2 0.29/0.72 2 0.29/0.72 2 
VAL 116 C 173.93 1 
  GLY 117 N 111.87 1 111.88 1 
GLY 117 HN 9.10 1 9.11 1 
GLY 117 CA 43.33 1 43.18 1 
GLY 117 HA2/HA3 3.53/4.79 2 3.53/4.78 2 
SER 118 N 
  
111.41 1 
SER 118 HN 
  
8.32 1 
SER 118 CA 58.76 1 58.53 1 
SER 118 HA 
  
3.98 1 
SER 118 CB 63.13 1 62.97 1 
SER 118 HB2/HB3 
  
4.00/4.35 2 
ILE 119 N 117.30 1 117.27 1 
ILE 119 HN 8.12 1 8.13 1 
ILE 119 CA 60.56 1 60.38 1 
ILE 119 HA 3.85 1 3.85 1 
ILE 119 CB 38.77 1 38.68 1 
ILE 119 HB 1.14 1 1.13 1 
ILE 119 CG1 27.63 1 27.55 1 
ILE 119 HG12/HG13 1.21/0.43 2 1.22/0.44 2 
ILE 119 CG2 18.32 1 18.22 1 
ILE 119 HG2 0.70 1 0.69 1 
ILE 119 CD1 14.20 1 14.22 1 
ILE 119 HD1 0.25 1 0.24 1 
TYR 120 CA 
  
58.45 1 
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Residue 
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Residue 
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Chemical 
shift [ppm] Ambiguity 
FIR RRM1-RRM2 free FIR RRM1-RRM2 bound 
TYR 120 HA 4.43 1 4.43 1 
TYR 120 CB 38.69 1 38.64 1 
TYR 120 HB2/HB3 2.76/3.15 2 2.75/3.14 2 
TYR 120 CD1/CD2 132.23 3 132.24 3 
TYR 120 HD1/HD2 7.09 3 7.08 3 
TYR 120 CE1/CE2 119.56 3 119.47 3 
TYR 120 HE1/HE2 6.85 3 6.85 3 
TYR 121 CA 
  
60.57 1 
TYR 121 HA 3.66 1 3.66 1 
TYR 121 CB 37.73 1 37.52 1 
TYR 121 HB2/HB3 2.64/2.81 2 2.64/2.80 2 
TYR 121 CD1/CD2 132.92 3 132.96 3 
TYR 121 HD1/HD2 6.80 3 6.79 3 
TYR 121 CE1/CE2 
  
118.62 3 
TYR 121 HE1/HE2 
  
6.78 3 
TYR 121 C 175.86 1 
  GLU 122 N 128.33 1 128.30 1 
GLU 122 HN 7.66 1 7.70 1 
GLU 122 CA 56.53 1 56.42 1 
GLU 122 HA 4.14 1 4.13 1 
GLU 122 CB 30.39 1 30.34 1 
GLU 122 HB2/HB3 1.57/2.16 2 1.55/2.15 2 
GLU 122 CG 37.01 1 36.85 1 
GLU 122 HG2/HG3 1.84/1.74 2 1.82/1.73 2 
GLU 122 C 176.57 1 
  
LEU 123 N 120.10 1 120.00 1 
LEU 123 HN 7.77 1 7.77 1 
LEU 123 CA 55.02 1 54.80 1 
LEU 123 HA 4.40 1 4.39 1 
LEU 123 CB 42.40 1 42.42 1 
LEU 123 HB2/HB3 1.37/1.93 2 1.37/1.92 2 
LEU 123 CG 27.14 1 27.13 1 
LEU 123 HG 1.83 1 1.82 1 
LEU 123 CD1/CD2 23.06/26.27 2 23.06/26.23 2 
LEU 123 HD1/HD2 0.94/0.94 2 0.93/0.94 2 
LEU 123 C 176.32 1 
  GLY 124 N 107.83 1 107.83 1 
GLY 124 HN 8.27 1 8.26 1 
GLY 124 CA 43.57 1 43.65 1 
GLY 124 HA2/HA3 3.93/4.53 2 3.92/4.51 2 
GLY 124 C 174.30 1 
  GLU 125 N 120.08 1 120.11 1 
GLU 125 HN 8.91 1 8.90 1 
GLU 125 CA 60.58 1 60.43 1 
GLU 125 HA 3.72 1 3.71 1 
GLU 125 CB 30.25 1 30.21 1 
GLU 125 HB2/HB3 2.22/2.16 2 2.21/2.16 2 
GLU 125 CG 36.80 1 36.73 1 
GLU 125 HG2/HG3 2.23 2 2.22 2 
GLU 125 C 177.83 
   
ASP 126 N 116.93 1 116.89 1 
ASP 126 HN 8.83 1 8.85 1 
ASP 126 CA 57.47 1 57.22 1 
ASP 126 HA 
  
4.35 1 
ASP 126 CB 39.81 1 
  
ASP 126 C 178.72 1 
  
THR 127 N 117.49 1 117.51 1 
THR 127 HN 7.64 1 7.63 1 
THR 127 CA 66.69 1 66.53 1 
THR 127 HA 4.01 1 3.99 1 
THR 127 CB 68.52 1 68.42 1 
THR 127 HB 4.18 1 4.16 1 
THR 127 CG2 22.87 1 22.78 1 
THR 127 HG2 1.33 1 1.32 1 
THR 127 C 176.69 1 
  ILE 128 N 121.42 1 121.35 1 
ILE 128 HN 7.44 1 7.43 1 
ILE 128 CA 63.68 1 63.62 1 
ILE 128 HA 3.73 1 3.72 1 
ILE 128 CB 36.25 1 36.24 1 
ILE 128 HB 2.01 1 2.00 1 
ILE 128 CG1 27.68 1 27.62 1 
ILE 128 HG12/HG13 1.21 2 1.20 2 
ILE 128 CG2 17.61 1 17.55 1 
ILE 128 HG2 0.54 1 0.53 1 
ILE 128 CD1 10.80 1 10.69 1 
ILE 128 HD1 0.50 1 0.50 1 
ILE 128 C 177.39 1 
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Chemical 
shift [ppm] Ambiguity 
FIR RRM1-RRM2 free FIR RRM1-RRM2 bound 
ARG 129 N 120.70 1 120.65 1 
ARG 129 HN 8.89 1 8.88 1 
ARG 129 CA 60.93 1 60.94 1 
ARG 129 HA 3.67 1 3.67 1 
ARG 129 CB 30.20 1 30.18 1 
ARG 129 HB2/HB3 1.90/1.96 2 1.89/1.94 2 
ARG 129 CG 28.36 1 28.33 1 
ARG 129 HG2/HG3 1.54 2 1.53 2 
ARG 129 CD 42.95 1 42.79 1 
ARG 129 HD2/HD3 3.16/3.34 2 3.16/3.33 2 
ARG 129 C 177.63 1 
  GLN 130 N 115.04 1 115.03 1 
GLN 130 HN 7.94 1 7.93 1 
GLN 130 CA 58.93 1 58.85 1 
GLN 130 HA 4.04 1 4.04 1 
GLN 130 CB 28.61 1 28.59 1 
GLN 130 HB2/HB3 2.18 2 2.17 2 
GLN 130 CG 34.01 1 33.93 1 
GLN 130 HG2/HG3 2.42/2.55 2 2.41/2.55 2 
GLN 130 C 178.42 1 
  
ALA 131 N 119.03 1 118.99 1 
ALA 131 HN 7.74 1 7.74 1 
ALA 131 CA 53.89 1 53.82 1 
ALA 131 HA 4.20 1 4.20 1 
ALA 131 CB 19.12 1 19.16 1 
ALA 131 HB 1.45 1 1.44 1 
ALA 131 C 177.76 1 
  PHE 132 N 112.01 1 112.04 1 
PHE 132 HN 8.09 1 8.09 1 
PHE 132 CA 60.29 1 60.19 1 
PHE 132 HA 4.74 1 4.74 1 
PHE 132 CB 38.23 1 38.12 1 
PHE 132 HB2/HB3 2.85/3.54 2 2.85/3.53 2 
PHE 132 CD1/CD2 132.30 3 132.34 3 
PHE 132 HD1/HD2 7.96 3 7.96 3 
PHE 132 CE1/CE2 129.69 3 129.65 3 
PHE 132 HE1/HE2 6.88 3 6.88 3 
PHE 132 C 177.63 1 
  
ALA 133 N 130.20 1 130.14 1 
ALA 133 HN 8.65 1 8.64 1 
ALA 133 CA 55.76 1 55.38 1 
ALA 133 HA 4.71 1 4.71 1 
ALA 133 CB 17.39 1 17.39 1 
ALA 133 HB 1.62 1 1.61 1 
PRO 134 CA 65.65 1 65.71 1 
PRO 134 HA 4.04 1 4.03 1 
PRO 134 CB 31.13 1 31.05 1 
PRO 134 HB2/HB3 0.27/2.02 2 0.29/2.04 2 
PRO 134 CG 28.12 1 28.24 1 
PRO 134 HG2/HG3 1.71/1.78 2 1.68/1.77 2 
PRO 134 CD 52.29 1 52.16 1 
PRO 134 HD2/HD3 3.72/3.08 2 3.71/3.09 2 
PRO 134 C 176.45 1 
  PHE 135 N 108.37 1 108.22 1 
PHE 135 HN 6.54 1 6.53 1 
PHE 135 CA 60.00 1 60.00 1 
PHE 135 HA 3.90 1 3.88 1 
PHE 135 CB 38.54 1 38.47 1 
PHE 135 HB2/HB3 3.47/2.62 2 3.46/2.62 2 
PHE 135 CD1/CD2 131.02 3 131.04 3 
PHE 135 HD1/HD2 7.27 3 7.29 3 
PHE 135 CE1/CE2 131.66 3 131.65 3 
PHE 135 HE1/HE2 7.37 3 7.35 3 
PHE 135 CZ 129.29 1 129.53 1 
PHE 135 HZ 7.13 1 7.12 1 
PHE 135 C 174.19 1 
  GLY 136 N 105.86 1 105.91 1 
GLY 136 HN 7.72 1 7.71 1 
GLY 136 CA 44.78 1 44.69 1 
GLY 136 HA2/HA3 3.95/4.11 2 3.93/4.08 2 
PRO 137 CA 62.67 1 62.62 1 
PRO 137 HA 4.66 1 4.65 1 
PRO 137 CB 31.67 1 31.66 1 
PRO 137 HB2/HB3 2.36/2.06 2 2.34/2.05 2 
PRO 137 CG 29.00 1 28.93 1 
PRO 137 HG2/HG3 2.29/2.23 2 2.29/2.21 2 
PRO 137 CD 49.62 1 49.63 1 
PRO 137 HD2/HD3 3.49/3.22 2 3.47/3.18 2 
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FIR RRM1-RRM2 free FIR RRM1-RRM2 bound 
PRO 137 C 177.08 1 
  
ILE 138 N 127.37 1 127.19 1 
ILE 138 HN 8.79 1 8.76 1 
ILE 138 CA 62.41 1 62.15 1 
ILE 138 HA 3.76 1 3.75 1 
ILE 138 CB 39.68 1 39.55 1 
ILE 138 HB 1.65 1 1.64 1 
ILE 138 CG1 29.05 1 29.00 1 
ILE 138 HG12/HG13 0.33/1.92 2 0.32/1.90 2 
ILE 138 CG2 17.65 1 17.60 1 
ILE 138 HG2 0.54 1 0.53 1 
ILE 138 CD1 14.20 1 14.22 1 
ILE 138 HD1 0.77 1 0.76 1 
ILE 138 C 176.34 1 
  
LYS 139 N 131.39 1 131.38 1 
LYS 139 HN 9.53 1 9.51 1 
LYS 139 CA 57.73 1 57.83 1 
LYS 139 HA 4.32 1 4.31 1 
LYS 139 CB 34.28 1 34.26 1 
LYS 139 HB2/HB3 1.41/1.53 2 1.41/1.53 2 
LYS 139 CG 24.70 1 24.64 1 
LYS 139 HG2/HG3 1.30/1.38 2 1.29/1.38 2 
LYS 139 HE2/HE3 2.95 2 2.94 2 
LYS 139 C 176.52 1 
  SER 140 N 111.00 1 110.97 1 
SER 140 HN 7.73 1 7.71 1 
SER 140 CA 57.83 1 57.69 1 
SER 140 HA 4.49 1 4.48 1 
SER 140 CB 65.38 1 65.37 1 
SER 140 HB2/HB3 3.76/3.69 2 3.74/3.69 2 
SER 140 C 178.45 1 
  
ILE 141 N 121.23 1 121.22 1 
ILE 141 HN 8.20 1 8.20 1 
ILE 141 CA 60.69 1 60.39 1 
ILE 141 HA 4.60 1 4.58 1 
ILE 141 CB 40.32 1 40.30 1 
ILE 141 HB 1.64 1 1.63 1 
ILE 141 CG1 28.31 1 28.23 1 
ILE 141 HG12/HG13 0.84/1.50 2 0.83/1.50 2 
ILE 141 CG2 16.96 1 17.03 1 
ILE 141 HG2 0.60 1 0.59 1 
ILE 141 CD1 13.75 1 13.72 1 
ILE 141 HD1 0.76 1 0.74 1 
ILE 141 C 174.15 1 
  
ASP 142 N 128.08 1 128.01 1 
ASP 142 HN 8.92 1 8.91 1 
ASP 142 CA 52.96 1 52.83 1 
ASP 142 HA 5.03 1 5.02 1 
ASP 142 CB 42.96 1 42.90 1 
ASP 142 HB2/HB3 2.83/2.62 2 2.82/2.61 2 
ASP 142 C 175.44 1 
  MET 143 N 123.86 1 123.85 1 
MET 143 HN 8.60 1 8.60 1 
MET 143 CA 54.57 1 54.33 1 
MET 143 HA 4.41 1 4.40 1 
MET 143 CB 34.35 1 34.25 1 
MET 143 HB2/HB3 1.66 2 1.65 2 
MET 143 CG 32.19 1 32.15 1 
MET 143 HG2/HG3 2.33/2.24 2 2.33/2.23 2 
MET 143 CE 15.99 1 15.98 1 
MET 143 HE 1.28 1 1.27 1 
SER 144 CA 57.58 1 57.46 1 
SER 144 HA 4.49 1 4.47 1 
SER 144 CB 63.79 1 63.56 1 
SER 144 HB2/HB3 3.20/3.48 2 3.17/3.46 2 
SER 144 C 173.37 
   
TRP 145 N 122.38 1 122.33 1 
TRP 145 HN 8.26 1 8.25 1 
TRP 145 CA 57.50 1 57.31 1 
TRP 145 HA 4.61 1 4.60 1 
TRP 145 CB 31.57 1 31.52 1 
TRP 145 HB2/HB3 3.07/3.01 2 3.04/3.02 2 
TRP 145 CD1 127.48 1 127.28 1 
TRP 145 HD1 7.13 1 7.12 1 
TRP 145 NE1 129.44 1 129.40 1 
TRP 145 HE1 10.12 1 10.11 1 
TRP 145 CE3 120.50 1 120.54 1 
TRP 145 HE3 7.34 1 7.33 1 
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FIR RRM1-RRM2 free FIR RRM1-RRM2 bound 
TRP 145 CZ2 114.50 1 114.45 1 
TRP 145 HZ2 7.45 1 7.44 1 
TRP 145 CZ3 122.13 1 122.14 1 
TRP 145 HZ3 7.10 1 7.09 1 
TRP 145 CH2 124.64 1 124.64 1 
TRP 145 HH2 7.20 
 
7.19 1 
TRP 145 C 175.26 1 
  
ASP 146 N 125.73 1 125.73 1 
ASP 146 HN 8.28 1 8.26 1 
ASP 146 CA 53.24 1 53.04 1 
ASP 146 HA 4.71 1 4.73 1 
ASP 146 CB 43.04 1 42.97 1 
ASP 146 HB2/HB3 3.10/2.31 2 3.09/2.30 2 
SER 147 CA 60.52 1 60.49 1 
SER 147 CB 63.44 1 
  SER 147 C 174.56 1 
  VAL 148 N 121.37 1 121.40 1 
VAL 148 HN 8.33 1 8.32 1 
VAL 148 CA 65.25 1 65.02 1 
VAL 148 HA 3.90 1 3.88 1 
VAL 148 CB 31.87 1 31.83 1 
VAL 148 HB 2.25 1 2.24 1 
VAL 148 CG1/CG2 22.11/21.02 2 22.05/20.91 2 
VAL 148 HG1/HG2 0.96/0.90 2 0.95/0.88 2 
VAL 148 C 177.75 1 
  
THR 149 N 109.04 1 109.11 1 
THR 149 HN 7.73 1 7.72 1 
THR 149 CA 62.12 1 62.11 1 
THR 149 HA 4.10 1 4.09 1 
THR 149 CB 69.89 1 69.66 1 
THR 149 HB 4.12 1 4.10 1 
THR 149 CG2 21.94 1 21.80 1 
THR 149 HG2 1.11 1 1.10 1 
THR 149 C 175.31 1 
  MET 150 N 116.67 1 116.74 1 
MET 150 HN 8.06 1 8.07 1 
MET 150 CA 56.15 1 55.96 1 
MET 150 HA 3.90 1 3.89 1 
MET 150 CB 28.98 1 
  MET 150 HB2/HB3 2.20/2.38 2 2.21/2.36 2 
MET 150 CE 16.64 1 16.73 1 
MET 150 HE 2.03 1 2.01 1 
MET 150 C 174.57 1 
  
LYS 151 N 117.18 1 117.12 1 
LYS 151 HN 7.30 1 7.32 1 
LYS 151 CA 54.72 1 54.47 1 
LYS 151 HA 4.61 1 4.58 1 
LYS 151 CB 35.76 1 35.64 1 
LYS 151 HB2/HB3 1.40/1.65 2 1.39/1.65 2 
LYS 151 CG 24.76 1 24.63 1 
LYS 151 HG2/HG3 1.22 2 1.22 2 
LYS 151 CD 28.97 1 28.85 1 
LYS 151 HD2/HD3 1.39/1.31 2 1.38/1.30 2 
LYS 151 CE 42.29 1 42.07 1 
LYS 151 HE2/HE3 2.75 2 2.74 2 
LYS 151 C 175.75 1 
  
HIS 152 N 118.08 1 117.98 1 
HIS 152 HN 7.74 1 7.78 1 
HIS 152 CA 54.89 1 54.74 1 
HIS 152 HA 5.01 1 5.00 1 
HIS 152 CB 31.02 1 31.04 1 
HIS 152 HB2/HB3 2.92 2 2.91 2 
HIS 152 CD2 120.34 1 120.09 1 
HIS 152 HD2 6.87 1 6.87 1 
HIS 152 CE1 138.47 1 138.35 1 
HIS 152 HE1 7.28 1 7.28 1 
PHE 155 CA 54.88 1 54.81 1 
PHE 155 HA 5.52 1 5.53 1 
PHE 155 CB 42.31 1 42.11 1 
PHE 155 HB2/HB3 2.96/2.77 2 2.96/2.75 2 
PHE 155 CD1/CD2 132.71 3 132.67 3 
PHE 155 HD1/HD2 6.83 3 6.81 3 
PHE 155 CE1/CE2 131.54 3 131.57 3 
PHE 155 HE1/HE2 7.37 3 7.37 3 
PHE 155 C 173.22 1 
  ALA 156 N 122.20 1 122.21 1 
ALA 156 HN 9.09 1 9.09 1 
ALA 156 CA 50.34 1 50.39 1 
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FIR RRM1-RRM2 free FIR RRM1-RRM2 bound 
ALA 156 HA 4.78 1 4.77 1 
ALA 156 CB 23.38 1 23.37 1 
ALA 156 HB 0.84 1 0.84 1 
ALA 156 C 174.81 1 
  PHE 157 N 115.41 1 115.45 1 
PHE 157 HN 8.45 1 8.45 1 
PHE 157 CA 56.77 1 56.66 1 
PHE 157 HA 5.47 1 5.45 1 
PHE 157 CB 42.15 1 42.13 1 
PHE 157 HB2/HB3 2.93/2.74 2 2.92/2.75 2 
PHE 157 CD1/CD2 131.83 3 131.80 3 
PHE 157 HD1/HD2 7.20 3 7.20 3 
PHE 157 CE1/CE2 131.45 3 131.61 3 
PHE 157 HE1/HE2 7.38 3 7.38 3 
PHE 157 C 175.45 1 
  VAL 158 N 124.31 1 124.33 1 
VAL 158 HN 8.90 1 8.90 1 
VAL 158 CA 61.68 1 61.64 1 
VAL 158 HA 4.09 1 4.09 1 
VAL 158 CB 33.50 1 33.44 1 
VAL 158 HB 1.44 1 1.43 1 
VAL 158 CG1/CG2 20.89/20.29 2 20.77/20.20 2 
VAL 158 HG1/HG2 0.13/0.04 2 0.13/0.04 2 
VAL 158 C 173.34 1 
  GLU 159 N 126.97 1 126.89 1 
GLU 159 HN 8.66 1 8.64 1 
GLU 159 CA 54.24 1 54.23 1 
GLU 159 HA 5.01 1 5.01 1 
GLU 159 CB 32.03 1 32.05 1 
GLU 159 HB2/HB3 1.69/2.04 2 1.68/2.03 2 
GLU 159 CG 36.77 1 36.72 1 
GLU 159 HG2/HG3 2.03 2 2.02 2 
GLU 159 C 175.75 1 
  TYR 160 N 125.60 1 125.58 1 
TYR 160 HN 8.94 1 8.94 1 
TYR 160 CA 58.67 1 58.57 1 
TYR 160 HA 5.11 1 5.11 1 
TYR 160 CB 42.94 1 42.83 1 
TYR 160 HB2/HB3 3.13/2.77 2 3.12/2.76 2 
TYR 160 CD1/CD2 132.69 3 132.63 3 
TYR 160 HD1/HD2 6.81 3 6.81 3 
TYR 160 HE1/HE2 
  
6.35 3 
TYR 160 HH 9.40 1 9.37 1 
TYR 160 C 175.86 1 
  GLU 161 N 114.56 1 114.54 1 
GLU 161 HN 8.71 1 8.74 1 
GLU 161 CA 58.37 1 58.16 1 
GLU 161 HA 4.21 1 4.20 1 
GLU 161 CB 31.90 1 31.83 1 
GLU 161 HB2/HB3 1.98/2.24 2 1.98/2.22 2 
GLU 161 CG 37.40 1 37.42 1 
GLU 161 HG2/HG3 2.27 2 2.25 2 
GLU 161 C 175.97 1 
  VAL 162 N 108.38 1 108.40 1 
VAL 162 HN 6.85 1 6.85 1 
VAL 162 CA 57.07 1 56.98 1 
VAL 162 HA 4.86 1 4.86 1 
VAL 162 CB 34.81 1 34.81 1 
VAL 162 HB 2.19 1 2.20 1 
VAL 162 CG1/CG2 22.74/19.76 2 22.67/19.80 2 
VAL 162 HG1/HG2 1.06/0.76 2 1.06/0.78 2 
PRO 163 CA 65.21 1 65.06 1 
PRO 163 HA 4.15 1 4.14 1 
PRO 163 CB 32.41 1 32.44 1 
PRO 163 HB2/HB3 1.70/2.14 2 1.70/2.13 2 
PRO 163 CG 27.73 1 27.60 1 
PRO 163 HG2/HG3 2.00/1.88 2 1.99/1.88 2 
PRO 163 CD 51.13 1 50.99 1 
PRO 163 HD2/HD3 4.02/3.59 2 4.02/3.61 2 
PRO 163 C 178.72 1 
  GLU 164 N 122.28 1 122.22 1 
GLU 164 HN 9.45 1 9.48 1 
GLU 164 CA 62.07 1 61.90 1 
GLU 164 HA 3.31 1 3.30 1 
GLU 164 CB 28.25 1 28.25 1 
GLU 164 HB2/HB3 0.74 2 0.77 2 
GLU 164 HG2/HG3 2.63/2.37 2 
  GLU 164 C 176.87 1 
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ALA 165 N 118.62 1 118.53 1 
ALA 165 HN 6.33 1 6.31 1 
ALA 165 CA 54.35 1 54.40 1 
ALA 165 HA 3.65 1 3.63 1 
ALA 165 CB 19.97 1 19.92 1 
ALA 165 HB 0.66 1 0.65 1 
ALA 165 C 177.15 1 
  
ALA 166 N 117.01 1 116.95 1 
ALA 166 HN 5.94 1 5.92 1 
ALA 166 CA 54.38 1 54.41 1 
ALA 166 HA 3.66 1 3.64 1 
ALA 166 CB 18.62 1 18.62 1 
ALA 166 HB 1.47 1 1.46 1 
ALA 166 C 178.14 
   GLN 167 N 115.49 1 115.53 1 
GLN 167 HN 7.38 1 7.41 1 
GLN 167 CA 58.32 1 58.23 1 
GLN 167 HA 3.72 1 3.69 1 
GLN 167 CB 27.46 1 
  GLN 167 HB2/HB3 1.98 2 1.95 2 
GLN 167 CG 32.61 1 32.43 1 
GLN 167 HG2/HG3 2.18/2.35 2 2.16/2.33 2 
GLN 167 NE2 113.15 1 113.20 1 
GLN 167 HE21/HE22 6.71/8.04 2 6.71/8.02 2 
GLN 167 C 177.48 1 
  
LEU 168 N 117.01 1 116.87 1 
LEU 168 HN 7.47 1 7.46 1 
LEU 168 CA 57.68 1 57.61 1 
LEU 168 HA 4.03 1 4.02 1 
LEU 168 CB 42.89 1 42.76 1 
LEU 168 HB2/HB3 1.55/1.87 2 1.53/1.87 2 
LEU 168 CG 26.65 1 26.78 1 
LEU 168 HG 1.89 1 1.90 1 
LEU 168 CD1/CD2 24.13/26.52 2 24.00/26.41 2 
LEU 168 HD1/HD2 0.91/1.03 2 0.90/1.01 2 
LEU 168 C 178.23 1 
  
ALA 169 N 121.42 1 121.45 1 
ALA 169 HN 7.73 1 7.71 1 
ALA 169 CA 55.19 1 55.09 1 
ALA 169 HA 2.38 1 2.39 1 
ALA 169 CB 18.31 1 18.22 1 
ALA 169 HB 1.35 1 1.34 1 
ALA 169 C 179.51 1 
  
LEU 170 N 117.01 1 117.04 1 
LEU 170 HN 8.00 1 8.00 1 
LEU 170 CA 58.37 1 58.30 1 
LEU 170 HA 3.74 1 3.74 1 
LEU 170 CB 42.10 1 42.07 1 
LEU 170 HB2/HB3 1.57/1.79 2 1.58/1.77 2 
LEU 170 CG 26.92 1 26.88 1 
LEU 170 HG 1.72 1 1.71 1 
LEU 170 CD1/CD2 24.89/25.30 2 24.92/25.38 2 
LEU 170 HD1/HD2 0.81/0.80 2 0.80/0.79 2 
LEU 170 C 179.21 1 
  GLU 171 N 116.11 1 116.04 1 
GLU 171 HN 7.60 1 7.59 1 
GLU 171 CA 58.60 1 58.65 1 
GLU 171 HA 4.04 1 4.03 1 
GLU 171 CB 30.76 1 30.70 1 
GLU 171 HB2/HB3 2.19/2.06 2 2.17/2.05 2 
GLU 171 CG 36.83 1 36.83 1 
GLU 171 HG2/HG3 2.27/2.66 2 2.23/2.65 2 
GLU 171 C 179.25 1 
  GLN 172 N 114.55 1 114.52 1 
GLN 172 HN 8.16 1 8.18 1 
GLN 172 CA 57.72 1 57.46 1 
GLN 172 HA 4.46 1 4.45 1 
GLN 172 CB 29.61 1 29.50 1 
GLN 172 HB2/HB3 2.37/1.75 2 2.38/1.75 2 
GLN 172 CG 34.83 1 34.78 1 
GLN 172 HG2/HG3 2.41/2.77 2 2.39/2.77 2 
GLN 172 NE2 110.05 1 110.25 1 
GLN 172 HE21/HE22 7.75/6.90 2 7.76/6.86 2 
GLN 172 C 178.02 1 
  
MET 173 N 115.39 1 115.23 1 
MET 173 HN 8.09 1 8.10 1 
MET 173 CA 54.02 1 53.93 1 
MET 173 HA 5.04 1 5.04 1 
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MET 173 CB 31.12 1 31.02 1 
MET 173 HB2/HB3 1.94/2.14 2 1.91/2.13 2 
MET 173 CE 16.42 1 16.31 1 
MET 173 HE 1.39 1 1.38 1 
MET 173 C 176.54 1 
  ASN 174 N 116.23 1 116.13 1 
ASN 174 HN 7.22 1 7.19 1 
ASN 174 CA 55.93 1 55.83 1 
ASN 174 HA 4.48 1 4.46 1 
ASN 174 CB 39.01 1 38.98 1 
ASN 174 HB2/HB3 2.88/2.97 2 2.88/2.96 2 
SER 175 CA 59.98 1 59.96 1 
SER 175 HA 
  
4.34 1 
SER 175 CB 63.13 1 62.94 1 
SER 175 HB2/HB3 
  
4.02/4.05 2 
SER 175 C 174.05 1 
  VAL 176 N 120.71 1 120.60 1 
VAL 176 HN 7.40 1 7.38 1 
VAL 176 CA 62.66 1 62.56 1 
VAL 176 HA 4.06 1 4.04 1 
VAL 176 CB 32.86 1 32.80 1 
VAL 176 HB 2.08 1 2.07 1 
VAL 176 CG1/CG2 22.01/21.06 2 21.94/21.05 2 
VAL 176 HG1/HG2 1.03/0.90 2 1.02/0.89 2 
VAL 176 C 174.84 1 
  
MET 177 N 123.11 1 123.10 1 
MET 177 HN 8.27 1 8.26 1 
MET 177 CA 55.20 1 54.95 1 
MET 177 HA 4.62 1 4.59 1 
MET 177 CB 33.36 1 33.29 1 
MET 177 HB2/HB3 1.92/1.79 2 1.91/1.79 2 
MET 177 CG 32.26 1 32.29 1 
MET 177 HG2/HG3 2.32/2.28 2 2.29/2.28 2 
MET 177 CE 16.98 1 16.97 1 
MET 177 HE 1.93 1 1.91 1 
MET 177 C 175.49 1 
  
LEU 178 N 126.36 1 126.52 1 
LEU 178 HN 8.54 1 8.54 1 
LEU 178 CA 54.40 1 54.16 1 
LEU 178 HA 4.65 1 4.63 1 
LEU 178 CB 44.74 1 44.67 1 
LEU 178 HB2/HB3 1.58/1.42 2 1.57/1.41 2 
LEU 178 CD1/CD2 24.60 2 24.71 2 
LEU 178 HD1/HD2 0.82 2 0.82 2 
GLY 180 CA 45.21 1 45.09 1 
GLY 180 C 173.59 1 
  ARG 181 N 118.87 1 118.84 1 
ARG 181 HN 7.41 1 7.39 1 
ARG 181 CA 54.43 1 54.29 1 
ARG 181 CB 33.38 1 
  
ARG 181 HB2/HB3 1.90/1.77 2 1.87/1.78 2 
ARG 181 CG 27.05 1 26.93 1 
ARG 181 HG2/HG3 1.54 2 1.54 2 
ARG 181 CD 43.37 1 43.21 1 
ARG 181 HD2/HD3 3.01 2 3.01 2 
ARG 181 C 174.24 1 
  
ASN 182 N 120.54 1 120.43 1 
ASN 182 HN 8.34 1 8.34 1 
ASN 182 CA 54.24 1 54.08 1 
ASN 182 HA 4.86 1 4.85 1 
ASN 182 CB 39.72 1 39.56 1 
ASN 182 HB2/HB3 2.52 2 2.50 2 
ASN 182 C 175.28 1 
  ILE 183 N 118.06 1 118.09 1 
ILE 183 HN 8.34 1 8.34 1 
ILE 183 CA 60.99 1 60.77 1 
ILE 183 HA 4.65 1 4.65 1 
ILE 183 CB 40.34 1 40.22 1 
ILE 183 HB 2.02 1 2.02 1 
ILE 183 CG1 25.22 1 25.15 1 
ILE 183 HG12/HG13 1.50 2 1.50 2 
ILE 183 CG2 19.17 1 19.19 1 
ILE 183 HG2 0.95 1 0.94 1 
ILE 183 CD1 14.80 1 14.83 1 
ILE 183 HD1 0.87 1 0.87 1 
ILE 183 C 175.31 1 
  LYS 184 N 121.34 1 121.35 1 
LYS 184 HN 7.97 1 7.96 1 
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LYS 184 CA 54.25 1 54.21 1 
LYS 184 HA 4.95 1 4.95 1 
LYS 184 CB 35.15 1 35.10 1 
LYS 184 HB2/HB3 1.60/1.74 2 1.59/1.74 2 
LYS 184 CG 24.75 1 24.69 1 
LYS 184 HG2/HG3 1.45/1.36 2 1.44/1.36 2 
LYS 184 CD 29.24 1 29.03 1 
LYS 184 HD2/HD3 1.73 2 1.73 2 
LYS 184 CE 41.70 1 41.88 1 
LYS 184 HE2/HE3 3.02 2 2.99 2 
LYS 184 C 175.30 1 
  VAL 185 N 121.79 1 121.77 1 
VAL 185 HN 8.60 1 8.60 1 
VAL 185 CA 60.25 1 60.09 1 
VAL 185 HA 5.36 1 5.36 1 
VAL 185 CB 34.58 1 34.46 1 
VAL 185 HB 1.90 1 1.88 1 
VAL 185 CG1/CG2 22.42 2 22.49 2 
VAL 185 HG1/HG2 1.00 2 0.99 2 
VAL 185 C 175.53 1 
  GLY 186 N 112.45 1 112.53 1 
GLY 186 HN 9.00 1 8.99 1 
GLY 186 CA 44.99 1 44.81 1 
GLY 186 HA2/HA3 4.50/3.93 2 4.48/3.89 2 
ARG 187 CA 
  
53.75 1 
ARG 187 HA 
  
4.84 1 
SER 189 CA 
  
58.25 1 
SER 189 HA 
  
4.45 1 
SER 189 CB 
  
62.91 1 
SER 189 HB2/HB3 
  
4.74 2 
ASN 190 CA 52.87 1 52.74 1 
ASN 190 HA 4.77 1 4.75 1 
ASN 190 CB 36.70 1 36.54 1 
ASN 190 HB2/HB3 2.74/2.99 2 2.73/2.98 2 
ILE 191 HN 
  
7.59 1 
ILE 191 CA 62.35 1 62.26 1 
ILE 191 HA 4.02 1 4.02 1 
ILE 191 CB 38.92 1 38.63 1 
ILE 191 HB 1.88 1 1.88 1 
ILE 191 CG1 28.55 1 28.51 1 
ILE 191 HG12/HG13 1.24/1.43 2 1.24/1.43 2 
ILE 191 CG2 18.12 1 18.09 1 
ILE 191 HG2 0.89 1 0.88 1 
ILE 191 CD1 14.88 1 14.89 1 
ILE 191 HD1 0.85 1 0.85 1 
GLY 192 N 109.86 1 109.84 1 
GLY 192 HN 8.52 1 8.52 1 
GLY 192 CA 47.13 1 47.05 1 
GLN 193 CA 57.59 1 57.42 1 
GLN 193 HA 4.19 1 4.17 1 
GLN 193 CB 28.42 1 28.41 1 
GLN 193 HB2/HB3 2.17/2.09 2 2.15/2.06 2 
GLN 193 CG 34.09 1 33.93 1 
GLN 193 HG2/HG3 2.43 2 2.41 2 
ALA 194 N 118.98 1 118.99 1 
ALA 194 HN 7.71 1 7.66 1 
ALA 194 CA 52.02 1 51.80 1 
ALA 194 HA 4.51 1 4.49 1 
ALA 194 CB 19.80 1 19.69 1 
ALA 194 HB 1.44 1 1.43 1 
GLN 195 N 120.89 1 120.88 1 
GLN 195 HN 7.77 1 7.76 1 
GLN 195 CA 60.19 1 60.17 1 
GLN 195 CG 33.35 1 33.36 1 
GLN 195 HG2/HG3 2.38 2 2.37 2 
GLN 195 NE2 114.96 1 114.98 1 
GLN 195 HE21/HE22 6.56/7.91 2 6.57/7.90 2 
PRO 196 CA 66.45 1 66.25 1 
PRO 196 HA 4.44 1 4.43 1 
PRO 196 CB 31.16 1 31.09 1 
PRO 196 HB2/HB3 1.76/2.39 2 1.75/2.38 2 
PRO 196 CG 28.55 1 28.57 1 
PRO 196 HG2/HG3 2.08/2.00 2 2.06/1.99 2 
PRO 196 CD 50.02 1 50.02 1 
PRO 196 HD2/HD3 3.51/3.69 2 3.50/3.68 2 
PRO 196 C 179.60 1 
  ILE 197 N 116.68 1 116.75 1 
ILE 197 HN 7.15 1 7.14 1 
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ILE 197 CA 62.89 1 62.79 1 
ILE 197 HA 3.89 1 3.88 1 
ILE 197 CB 37.09 1 37.05 1 
ILE 197 HB 2.00 1 1.99 1 
ILE 197 CG1 28.54 1 28.54 1 
ILE 197 HG12/HG13 1.33/1.47 2 1.32/1.46 2 
ILE 197 CG2 18.49 1 18.45 1 
ILE 197 HG2 0.88 1 0.87 1 
ILE 197 CD1 11.80 1 11.75 1 
ILE 197 HD1 0.79 1 0.80 1 
ILE 197 C 177.55 1 
  ILE 198 N 123.20 1 123.13 1 
ILE 198 HN 7.97 1 7.97 1 
ILE 198 CA 66.62 1 66.39 1 
ILE 198 HA 3.55 1 3.55 1 
ILE 198 CB 37.66 1 37.69 1 
ILE 198 HB 2.00 1 1.99 1 
ILE 198 CG1 28.38 1 28.30 1 
ILE 198 HG12/HG13 1.22/1.63 2 1.23/1.61 2 
ILE 198 CG2 16.37 1 16.31 1 
ILE 198 HG2 0.93 1 0.92 1 
ILE 198 CD1 13.97 1 13.88 1 
ILE 198 HD11 0.74 1 0.73 1 
ILE 198 C 179.21 1 
  
ASP 199 N 119.81 1 119.82 1 
ASP 199 HN 8.65 1 8.64 1 
ASP 199 CA 57.43 1 57.29 1 
ASP 199 HA 4.40 1 4.38 1 
ASP 199 CB 39.90 1 39.82 1 
ASP 199 HB2/HB3 2.68/2.70 2 2.65/2.69 2 
ASP 199 C 179.12 1 
  GLN 200 N 122.15 1 122.15 1 
GLN 200 HN 7.65 1 7.65 1 
GLN 200 CA 59.24 1 59.14 1 
GLN 200 HA 4.14 1 4.12 1 
GLN 200 CB 28.48 1 28.51 1 
GLN 200 HB2/HB3 2.26/2.20 2 2.25/2.19 2 
GLN 200 CG 33.52 1 33.39 1 
GLN 200 HG2/HG3 2.56/2.35 2 2.55/2.34 2 
GLN 200 NE2 111.17 1 111.26 1 
GLN 200 HE21/HE22 6.68/7.65 2 6.69/7.65 2 
GLN 200 C 178.58 1 
  
LEU 201 N 120.44 1 120.37 1 
LEU 201 HN 8.64 1 8.63 1 
LEU 201 CA 58.44 1 58.28 1 
LEU 201 HA 3.98 1 3.96 1 
LEU 201 CB 41.91 1 41.80 1 
LEU 201 HB2/HB3 1.43/2.15 2 1.45/2.14 2 
LEU 201 CG 27.32 1 27.39 1 
LEU 201 HG 1.86 1 1.86 1 
LEU 201 CD1/CD2 26.71/24.08 2 26.71/24.00 2 
LEU 201 HD1/HD2 0.80/0.81 2 0.79/0.81 2 
LEU 201 C 178.56 1 
  ALA 202 N 120.94 1 120.86 1 
ALA 202 HN 8.00 1 7.98 1 
ALA 202 CA 55.12 1 55.00 1 
ALA 202 HA 3.94 1 3.92 1 
ALA 202 CB 17.88 1 17.82 1 
ALA 202 HB 1.57 1 1.56 1 
ALA 202 C 180.80 
   GLU 203 N 119.76 1 119.72 1 
GLU 203 HN 7.81 1 7.80 1 
GLU 203 CA 59.20 1 59.16 1 
GLU 203 HA 4.07 1 4.06 1 
GLU 203 CB 29.00 1 29.17 1 
GLU 203 HB2/HB3 2.18 2 2.18 2 
GLU 203 CG 36.00 1 35.81 1 
GLU 203 HG2/HG3 2.32/2.30 2 2.31/2.30 2 
GLU 203 C 180.10 1 
  GLU 204 N 120.61 1 120.57 1 
GLU 204 HN 8.48 1 8.47 1 
GLU 204 CA 59.20 1 59.21 1 
GLU 204 HA 4.06 1 4.05 1 
GLU 204 CB 30.34 1 30.18 1 
GLU 204 HB2/HB3 2.07/2.15 2 2.07/2.15 2 
GLU 204 CG 36.76 1 36.65 1 
GLU 204 HG2/HG3 2.30/2.67 2 2.30/2.66 2 
GLU 204 C 179.76 1 
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ALA 205 N 119.03 1 119.07 1 
ALA 205 HN 8.23 1 8.20 1 
ALA 205 CA 54.64 1 54.59 1 
ALA 205 HA 3.87 1 3.87 1 
ALA 205 CB 18.54 1 18.49 1 
ALA 205 HB 1.15 1 1.14 1 
ALA 205 C 179.50 1 
  
ARG 206 N 116.58 1 116.51 1 
ARG 206 HN 7.48 1 7.47 1 
ARG 206 CA 59.17 1 59.05 1 
ARG 206 HA 4.20 1 4.19 1 
ARG 206 CB 30.47 1 30.38 1 
ARG 206 HB2/HB3 1.99 2 1.99 2 
ARG 206 CG 27.97 1 27.93 1 
ARG 206 HG2/HG3 2.01/1.76 2 2.00/1.75 2 
ARG 206 CD 43.87 1 43.67 1 
ARG 206 HD2/HD3 3.28 2 3.26 2 
ARG 206 C 177.20 1 
  
ALA 207 N 118.65 1 118.62 1 
ALA 207 HN 7.31 1 7.30 1 
ALA 207 CA 53.29 1 53.17 1 
ALA 207 HA 4.12 1 4.12 1 
ALA 207 CB 18.64 1 18.65 1 
ALA 207 HB 1.16 1 1.15 1 
ALA 207 C 176.56 1 
  
PHE 208 N 114.60 1 114.62 1 
PHE 208 HN 7.71 1 7.70 1 
PHE 208 CA 57.46 1 57.33 1 
PHE 208 HA 4.48 1 4.49 1 
PHE 208 CB 41.43 1 
  
PHE 208 HB2/HB3 3.02/2.93 2 3.00/2.93 2 
PHE 208 CD1/CD2 132.25 3 132.38 3 
PHE 208 HD1/HD2 7.39 3 7.40 3 
PHE 208 CE1/CE2 131.81 3 131.75 3 
PHE 208 HE1/HE2 7.37 3 7.37 3 
ASN 209 CA 52.65 1 52.39 1 
ASN 209 HA 4.91 1 4.88 1 
ASN 209 CB 37.36 1 37.15 1 
ASN 209 HB2/HB3 2.65/3.57 2 2.67/3.57 2 
ASN 209 ND2 
  
113.48 1 
ASN 209 HD21/HD22 6.62 2 6.62 2 
ASN 209 C 174.55 1 
  
ARG 210 N 119.71 1 119.62 1 
ARG 210 HN 8.24 1 8.28 1 
ARG 210 CA 55.09 1 55.07 1 
ARG 210 HA 5.74 1 5.73 1 
ARG 210 CB 34.55 1 34.34 1 
ARG 210 HB2/HB3 1.63/1.87 2 1.65/1.85 2 
ARG 210 CG 29.12 1 29.05 1 
ARG 210 HG2/HG3 1.48/1.73 2 1.47/1.71 2 
ARG 210 HD2/HD3 3.18 2 3.16 2 
ARG 210 C 176.11 1 
  ILE 211 N 118.56 1 118.69 1 
ILE 211 HN 9.51 1 9.53 1 
ILE 211 CA 59.36 1 59.20 1 
ILE 211 HA 5.08 1 5.08 1 
ILE 211 CB 40.99 1 40.94 1 
ILE 211 HB 1.99 1 1.99 1 
ILE 211 CG1 26.74 1 26.74 1 
ILE 211 HG12/HG13 1.07/1.26 2 1.03/1.24 2 
ILE 211 CG2 19.24 1 19.15 1 
ILE 211 HG2 0.97 1 0.96 1 
ILE 211 CD1 15.34 1 15.16 1 
ILE 211 HD1 0.75 1 0.74 1 
ILE 211 C 172.15 1 
  TYR 212 N 124.92 1 124.94 1 
TYR 212 HN 9.16 1 9.16 1 
TYR 212 CA 55.65 1 55.65 1 
TYR 212 HA 4.72 1 4.72 1 
TYR 212 CB 42.75 1 42.65 1 
TYR 212 HB2/HB3 2.34/2.53 2 2.32/2.50 2 
TYR 212 CD1/CD2 133.19/132.65 3 133.02/132.65 3 
TYR 212 HD1/HD2 6.46/5.99 3 6.46/5.95 3 
TYR 212 CE1/CE2 116.56/118.16 3 116.55/118.11 3 
TYR 212 HE1/HE2 6.56/6.30 3 6.56/6.32 3 
TYR 212 HH 9.08 1 9.09 1 
TYR 212 C 172.36 1 
  VAL 213 N 124.11 1 123.77 1 
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VAL 213 HN 7.69 1 7.64 1 
VAL 213 CA 59.03 1 58.94 1 
VAL 213 HA 4.57 1 4.59 1 
VAL 213 CB 34.57 1 34.60 1 
VAL 213 HB 1.25 1 1.22 1 
VAL 213 CG1/CG2 21.37/20.82 2 21.12/20.85 2 
VAL 213 HG1/HG2 0.38/0.44 2 0.35/0.40 2 
VAL 213 C 171.69 1 
  
ALA 214 N 126.77 1 126.60 1 
ALA 214 HN 8.98 1 8.93 1 
ALA 214 CA 50.20 1 50.15 1 
ALA 214 HA 5.10 1 5.10 1 
ALA 214 CB 22.50 1 22.59 1 
ALA 214 HB 1.27 1 1.27 1 
ALA 214 C 176.84 1 
  SER 215 N 111.09 1 111.09 1 
SER 215 HN 8.29 1 8.25 1 
SER 215 CA 60.80 1 60.70 1 
SER 215 HA 3.85 1 3.85 1 
SER 215 CB 63.48 1 63.06 1 
SER 215 HB2/HB3 4.44/4.27 2 4.45/4.19 2 
SER 215 C 174.43 1 
  VAL 216 N 118.70 1 118.51 1 
VAL 216 HN 8.07 1 8.11 1 
VAL 216 CA 62.34 1 62.42 1 
VAL 216 HA 3.54 1 3.45 1 
VAL 216 CB 31.73 1 31.87 1 
VAL 216 HB 1.29 1 1.28 1 
VAL 216 CG1/CG2 21.76/21.40 2 21.69/21.42 2 
VAL 216 HG1/HG2 0.67/0.38 2 0.67/0.37 2 
VAL 216 C 176.50 1 
  
HIS 217 N 131.87 1 131.60 1 
HIS 217 HN 9.10 1 8.92 1 
HIS 217 CA 59.94 1 59.81 1 
HIS 217 HA 3.90 1 3.89 1 
HIS 217 CB 31.61 1 31.59 1 
HIS 217 HB2/HB3 2.84/3.09 2 2.79/3.07 2 
HIS 217 CD2 118.36 1 118.10 1 
HIS 217 HD2 6.96 1 7.04 1 
HIS 217 CE1 138.97 1 138.82 1 
HIS 217 HE1 7.71 1 7.78 1 
HIS 217 C 176.62 1 
  GLN 218 N 125.42 1 126.03 1 
GLN 218 HN 7.93 1 8.07 1 
GLN 218 CA 58.47 1 58.34 1 
GLN 218 HA 3.63 1 3.63 1 
GLN 218 CB 29.33 1 29.30 1 
GLN 218 HB2/HB3 1.83/1.78 2 1.85/1.79 2 
GLN 218 CG 33.47 1 33.39 1 
GLN 218 HG2/HG3 2.19/2.07 2 2.21/2.11 2 
GLN 218 NE2 113.01 1 113.03 1 
GLN 218 HE21/HE22 7.40/6.71 2 7.40/6.72 2 
GLN 218 C 176.20 1 
  ASP 219 N 121.44 1 121.76 1 
ASP 219 HN 10.83 1 11.16 1 
ASP 219 CA 55.69 1 55.49 1 
ASP 219 HA 4.73 1 4.75 1 
ASP 219 CB 40.59 1 40.88 1 
ASP 219 HB2/HB3 2.72/2.87 2 2.72/2.88 2 
ASP 219 C 177.10 1 
  
LEU 220 N 121.23 1 120.37 1 
LEU 220 HN 7.92 1 7.87 1 
LEU 220 CA 54.47 1 54.06 1 
LEU 220 HA 4.63 1 4.60 1 
LEU 220 CB 43.04 1 43.01 1 
LEU 220 HB2/HB3 2.00/1.28 2 1.99/1.28 2 
LEU 220 CG 27.36 1 27.49 1 
LEU 220 HG 1.67 1 1.60 1 
LEU 220 CD1/CD2 22.86/26.98 2 23.43/27.19 2 
LEU 220 HD1/HD2 0.80/0.93 2 0.69/0.91 2 
LEU 220 C 176.09 1 
  SER 221 N 116.03 1 115.92 1 
SER 221 HN 9.47 1 9.36 1 
SER 221 CA 56.07 1 55.84 1 
SER 221 HA 4.77 1 4.77 1 
SER 221 CB 67.11 1 67.04 1 
SER 221 HB2/HB3 3.99/4.21 2 3.95/4.20 2 
SER 221 C 175.39 1 
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ASP 222 N 118.44 1 118.22 1 
ASP 222 HN 9.19 1 9.26 1 
ASP 222 CA 57.74 1 57.47 1 
ASP 222 HA 3.74 1 3.70 1 
ASP 222 CB 39.62 1 39.21 1 
ASP 222 HB2/HB3 2.61 2 2.63/2.59 2 
ASP 222 C 178.08 1 
  
ASP 223 N 116.07 1 115.97 1 
ASP 223 HN 8.31 1 8.27 1 
ASP 223 CA 57.20 1 57.14 1 
ASP 223 HA 4.40 1 4.36 1 
ASP 223 CB 40.44 1 40.56 1 
ASP 223 HB2/HB3 2.65/2.51 2 2.60/2.50 2 
ASP 223 C 178.67 1 
  
ASP 224 N 120.87 1 121.86 1 
ASP 224 HN 7.62 1 7.63 1 
ASP 224 CA 57.51 1 57.45 1 
ASP 224 HA 4.41 1 4.36 1 
ASP 224 CB 41.98 1 41.76 1 
ASP 224 HB2/HB3 2.99/2.68 2 3.00/2.51 2 
ASP 224 C 178.68 1 
  ILE 225 N 117.30 1 117.02 1 
ILE 225 HN 7.35 1 7.33 1 
ILE 225 CA 61.50 1 61.95 1 
ILE 225 HA 3.95 1 3.83 1 
ILE 225 CB 35.92 1 35.71 1 
ILE 225 HB 1.89 1 1.83 1 
ILE 225 CG1 27.10 1 27.19 1 
ILE 225 HG12/HG13 1.06/1.51 2 1.03/1.52 2 
ILE 225 CG2 18.34 1 18.21 1 
ILE 225 HG2 0.64 1 0.62 1 
ILE 225 CD1 10.76 1 10.67 1 
ILE 225 HD1 0.63 1 0.63 1 
ILE 225 C 177.57 1 
  LYS 226 N 123.48 1 123.11 1 
LYS 226 HN 8.47 1 8.37 1 
LYS 226 CA 61.06 1 60.86 1 
LYS 226 HA 3.70 1 3.67 1 
LYS 226 CB 32.79 1 32.85 1 
LYS 226 HB2/HB3 1.99/2.02 2 1.98 2 
LYS 226 CG 25.52 1 25.29 1 
LYS 226 HG2/HG3 1.26/1.39 2 1.19/1.34 2 
LYS 226 CD 29.72 1 29.55 1 
LYS 226 HD2/HD3 1.68 2 1.64 2 
LYS 226 CE 42.08 1 41.68 1 
LYS 226 HE2/HE3 2.86 2 2.84 2 
LYS 226 C 177.72 1 
  SER 227 N 110.69 1 111.71 1 
SER 227 HN 7.82 1 7.92 1 
SER 227 CA 61.77 1 61.90 1 
SER 227 HA 4.24 1 4.21 1 
SER 227 CB 63.25 1 63.29 1 
SER 227 HB2/HB3 4.01 2 4.11/4.02 2 
SER 227 C 176.78 1 
  VAL 228 N 117.13 1 118.16 1 
VAL 228 HN 7.19 1 7.27 1 
VAL 228 CA 64.82 1 66.36 1 
VAL 228 HA 3.93 1 3.57 1 
VAL 228 CB 32.28 1 32.40 1 
VAL 228 HB 2.09 1 2.07 1 
VAL 228 CG1/CG2 21.90/21.72 2 22.81/21.68 2 
VAL 228 HG1/HG2 1.05/0.67 2 0.98/0.47 2 
VAL 228 C 177.93 1 
  PHE 229 N 117.02 1 114.78 1 
PHE 229 HN 8.27 1 8.32 1 
PHE 229 CA 62.13 1 62.54 1 
PHE 229 HA 4.41 1 4.18 1 
PHE 229 CB 37.91 1 37.53 1 
PHE 229 HB2/HB3 3.53/2.83 2 3.47/2.81 2 
PHE 229 CD1/CD2 132.46 3 132.08 3 
PHE 229 HD1/HD2 7.78 3 7.68 3 
PHE 229 CE1/CE2 130.18 3 129.94 3 
PHE 229 HE1/HE2 6.82 3 6.76 3 
PHE 229 CZ 128.72 1 128.90 1 
PHE 229 HZ 6.90 1 6.87 1 
PHE 229 C 179.49 1 
  GLU 230 N 126.27 1 126.36 1 
GLU 230 HN 8.76 1 8.91 1 
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GLU 230 CA 58.22 1 57.93 1 
GLU 230 HA 4.87 1 5.05 1 
GLU 230 CB 28.89 1 28.73 1 
GLU 230 HB2/HB3 2.31/2.11 2 2.29/2.08 2 
GLU 230 CG 37.62 1 37.98 1 
GLU 230 HG2/HG3 2.54 2 2.56 2 
GLU 230 C 177.08 1 
  
ALA 231 N 121.44 1 122.64 1 
ALA 231 HN 7.08 1 7.46 1 
ALA 231 CA 54.23 1 54.60 1 
ALA 231 HA 3.91 1 3.87 1 
ALA 231 CB 17.99 1 18.37 1 
ALA 231 HB 0.80 1 0.93 1 
ALA 231 C 178.45 1 
  
PHE 232 N 111.24 1 109.82 1 
PHE 232 HN 6.88 1 7.09 1 
PHE 232 CA 58.50 1 58.74 1 
PHE 232 HA 4.39 1 4.25 1 
PHE 232 CB 39.28 1 39.36 1 
PHE 232 HB2/HB3 3.48/2.65 2 3.44/2.72 2 
PHE 232 CD1/CD2 131.56 3 131.54 3 
PHE 232 HD1/HD2 7.24 3 7.35 3 
PHE 232 CE1/CE2 131.41 3 131.39 3 
PHE 232 HE1/HE2 7.37 3 7.05 3 
PHE 232 C 175.32 1 
  GLY 233 N 108.64 1 108.81 1 
GLY 233 HN 7.62 1 7.61 1 
GLY 233 CA 44.25 1 44.29 1 
GLY 233 HA2/HA3 3.89/4.50 2 3.89/4.53 2 
GLY 233 C 170.49 1 
  
LYS 234 N 116.61 1 116.52 1 
LYS 234 HN 8.05 1 8.04 1 
LYS 234 CA 57.65 1 57.82 1 
LYS 234 HA 4.30 1 4.26 1 
LYS 234 CB 32.93 1 32.99 1 
LYS 234 HB2/HB3 1.78 2 1.78 2 
LYS 234 CG 24.96 1 24.99 1 
LYS 234 HG2/HG3 1.48 2 1.48/1.38 2 
LYS 234 CD 29.14 1 28.91 1 
LYS 234 HD2/HD3 1.72/1.60 2 1.72/1.59 2 
LYS 234 C 177.59 1 
  ILE 235 N 128.28 1 128.25 1 
ILE 235 HN 9.11 1 9.28 1 
ILE 235 CA 61.96 1 61.90 1 
ILE 235 HA 4.03 1 4.06 1 
ILE 235 CB 40.36 1 40.35 1 
ILE 235 HB 1.64 1 1.61 1 
ILE 235 CG1 29.98 1 30.12 1 
ILE 235 HG12/HG13 0.18/1.96 2 0.03/1.93 2 
ILE 235 CG2 18.05 1 18.14 1 
ILE 235 HG2 0.58 1 0.58 1 
ILE 235 CD1 14.66 1 14.78 1 
ILE 235 HD1 0.70 1 0.68 1 
ILE 235 C 176.00 1 
  
LYS 236 N 128.21 1 128.04 1 
LYS 236 HN 9.10 1 9.00 1 
LYS 236 CA 57.76 1 57.84 1 
LYS 236 HA 4.31 1 4.29 1 
LYS 236 CB 33.80 1 33.84 1 
LYS 236 HB2/HB3 1.72/1.47 2 1.69/1.49 2 
LYS 236 CG 24.92 1 24.90 1 
LYS 236 HG2/HG3 1.36 2 1.35 2 
LYS 236 HE2/HE3 2.97 2 2.96 2 
LYS 236 C 176.44 1 
  SER 237 N 110.95 1 110.95 1 
SER 237 HN 7.45 1 7.44 1 
SER 237 CA 57.70 1 57.57 1 
SER 237 HA 4.48 1 4.50 1 
SER 237 CB 65.08 1 
  CYS 238 CA 58.38 1 58.09 1 
CYS 238 HA 4.76 1 4.77 1 
CYS 238 CB 26.72 1 26.52 1 
CYS 238 HB2/HB3 2.35/1.84 2 2.32/2.80 2 
CYS 238 C 172.14 1 
  
THR 239 N 121.56 1 121.81 1 
THR 239 HN 8.16 1 8.18 1 
THR 239 CA 60.44 1 60.23 1 
THR 239 HA 4.86 1 4.87 1 
201 
Residue 
name 
Residue 
number Atom name 
Chemical 
shift [ppm] Ambiguity 
Chemical 
shift [ppm] Ambiguity 
FIR RRM1-RRM2 free FIR RRM1-RRM2 bound 
THR 239 CB 72.12 1 71.79 1 
THR 239 HB 3.95 1 3.93 1 
THR 239 CG2 21.80 1 21.75 1 
THR 239 HG2 1.18 1 1.17 1 
THR 239 C 173.89 1 
  LEU 240 N 126.89 1 126.87 1 
LEU 240 HN 8.62 1 8.61 1 
LEU 240 CA 53.57 1 53.26 1 
LEU 240 HA 4.57 1 4.58 1 
LEU 240 CB 41.56 1 41.45 1 
LEU 240 HB2/HB3 0.80/1.49 2 0.76/1.47 2 
LEU 240 CG 27.01 1 26.94 1 
LEU 240 HG 1.16 1 1.13 1 
LEU 240 CD1/CD2 24.68/21.59 2 24.61/21.47 2 
LEU 240 HD1/HD2 -0.05/0.11 2 -0.09/0.08 2 
LEU 240 C 176.73 1 
  ALA 241 N 127.79 1 127.75 1 
ALA 241 HN 8.45 1 8.36 1 
ALA 241 CA 52.47 1 52.42 1 
ALA 241 HA 4.14 1 4.13 1 
ALA 241 CB 19.18 1 19.30 1 
ALA 241 HB 0.78 1 0.78 1 
ALA 241 C 177.27 1 
  ARG 242 N 120.89 1 120.88 1 
ARG 242 HN 8.46 1 8.47 1 
ARG 242 CA 54.87 1 54.71 1 
ARG 242 HA 4.73 1 4.71 1 
ARG 242 CB 33.34 1 33.22 1 
ARG 242 HB2/HB3 1.62/1.37 2 1.62/1.36 2 
ARG 242 CG 27.26 1 27.20 1 
ARG 242 HG2/HG3 1.59/1.34 2 1.58/1.33 2 
ARG 242 CD 42.94 1 42.81 1 
ARG 242 HD2/HD3 2.96/3.04 2 2.96/3.03 2 
ARG 242 C 175.48 1 
  ASP 243 N 123.72 1 123.65 1 
ASP 243 HN 8.44 1 8.43 1 
ASP 243 CA 51.01 1 50.90 1 
ASP 243 HA 4.92 1 4.91 1 
ASP 243 CB 42.76 1 42.68 1 
ASP 243 HB2/HB3 3.16/2.41 2 3.16/2.40 2 
PRO 244 CA 64.36 1 64.26 1 
PRO 244 HA 4.39 1 4.38 1 
PRO 244 CB 32.34 1 32.27 1 
PRO 244 HB2/HB3 2.36/2.03 2 2.34/2.03 2 
PRO 244 CG 27.20 1 27.11 1 
PRO 244 HG2/HG3 2.07 2 2.06 2 
PRO 244 CD 51.25 1 51.18 1 
PRO 244 HD2/HD3 4.00/4.08 2 3.99/4.07 2 
PRO 244 C 177.87 1 
  
THR 245 N 112.89 1 112.84 1 
THR 245 HN 8.43 1 8.43 1 
THR 245 CA 64.86 1 64.84 1 
THR 245 HA 4.23 1 4.22 1 
THR 245 CB 68.91 1 68.85 1 
THR 245 HB 4.28 1 4.27 1 
THR 245 CG2 22.14 1 22.00 1 
THR 245 HG2 1.24 1 1.23 1 
THR 245 C 176.05 1 
  THR 246 N 109.19 1 109.14 1 
THR 246 HN 7.65 1 7.63 1 
THR 246 CA 61.90 1 61.73 1 
THR 246 HA 4.43 1 4.43 1 
THR 246 CB 71.36 1 71.13 1 
THR 246 HB 4.28 1 4.27 1 
THR 246 CG2 21.12 1 21.09 1 
THR 246 HG2 1.20 1 1.19 1 
THR 246 C 176.50 1 
  GLY 247 N 111.01 1 110.98 1 
GLY 247 HN 8.42 1 8.42 1 
GLY 247 CA 45.77 1 45.67 1 
GLY 247 HA2/HA3 3.77/4.23 2 3.77/4.23 2 
GLY 247 C 173.96 1 
  
LYS 248 N 121.11 1 121.11 1 
LYS 248 HN 7.93 1 7.93 1 
LYS 248 CA 55.67 1 55.44 1 
LYS 248 HA 4.43 1 4.42 1 
LYS 248 CB 33.37 1 33.27 1 
LYS 248 HB2/HB3 1.63/1.83 2 1.61/1.83 2 
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LYS 248 CG 24.98 1 24.87 1 
LYS 248 HG2/HG3 1.36 2 1.35 2 
LYS 248 CD 29.13 1 28.93 1 
LYS 248 HD2/HD3 1.60 2 1.59 2 
LYS 248 HE2/HE3 2.95 2 2.93 2 
LYS 248 C 176.79 1 
  
HIS 249 N 120.09 1 120.10 1 
HIS 249 HN 8.51 1 8.50 1 
HIS 249 CA 55.55 1 55.42 1 
HIS 249 HA 5.37 1 5.37 1 
HIS 249 CB 32.12 1 32.11 1 
HIS 249 HB2/HB3 3.28/2.59 2 3.27/2.58 2 
HIS 249 CD2 119.78 1 119.73 1 
HIS 249 HD2 7.07 1 7.07 1 
HIS 249 CE1 139.39 1 139.20 1 
HIS 249 HE1 7.42 1 7.42 1 
HIS 249 C 176.57 1 
  LYS 250 N 118.23 1 118.17 1 
LYS 250 HN 8.61 1 8.62 1 
LYS 250 CA 56.41 1 56.42 1 
LYS 250 HA 4.43 1 4.42 1 
LYS 250 CB 34.41 1 34.33 1 
LYS 250 HB2/HB3 1.36/2.46 2 1.36/2.44 2 
LYS 250 CG 25.96 1 25.83 1 
LYS 250 HG2/HG3 1.35/1.48 2 1.35/1.48 2 
LYS 250 CD 30.08 1 29.81 1 
LYS 250 HD2/HD3 1.74/1.81 2 1.75/1.81 2 
LYS 250 CE 
  
41.63 1 
LYS 250 HE2/HE3 
  
3.01/2.95 2 
LYS 250 C 177.99 1 
  GLY 251 N 114.40 1 114.30 1 
GLY 251 HN 11.23 1 11.21 1 
GLY 251 CA 45.79 1 45.67 1 
GLY 251 HA2/HA3 4.30/4.19 2 4.31/4.13 2 
GLY 251 C 172.40 1 
  TYR 252 N 112.78 1 112.77 1 
TYR 252 HN 7.14 1 7.13 1 
TYR 252 CA 54.66 1 54.64 1 
TYR 252 HA 5.62 1 5.61 1 
TYR 252 CB 41.28 1 41.28 1 
TYR 252 HB2/HB3 2.76/3.02 2 2.76/3.01 2 
TYR 252 CD1/CD2 133.71 3 133.74 3 
TYR 252 HD1/HD2 6.81 3 6.82 3 
TYR 252 CE1/CE2 118.05 3 118.02 3 
TYR 252 HE1/HE2 6.81 3 6.81 3 
TYR 252 C 172.69 1 
  GLY 253 N 106.02 1 105.97 1 
GLY 253 HN 8.81 1 8.77 1 
GLY 253 CA 45.63 1 45.65 1 
GLY 253 HA2/HA3 4.04/4.07 2 4.02/4.08 2 
GLY 253 C 183.54 1 
  PHE 254 N 113.11 1 113.01 1 
PHE 254 HN 7.81 1 7.80 1 
PHE 254 CA 56.51 1 56.35 1 
PHE 254 HA 5.77 1 5.73 1 
PHE 254 CB 44.55 1 44.51 1 
PHE 254 HB2/HB3 2.76 2 2.73/2.75 2 
PHE 254 CD1/CD2 132.30 3 132.27 3 
PHE 254 HD1/HD2 7.27 3 7.26 3 
PHE 254 CE1/CE2 130.94 3 131.05 3 
PHE 254 HE1/HE2 7.33 3 7.34 3 
PHE 254 C 175.87 1 
  
ILE 255 N 122.97 1 122.97 1 
ILE 255 HN 8.73 1 8.77 1 
ILE 255 CA 59.97 1 59.84 1 
ILE 255 HA 4.59 1 4.55 1 
ILE 255 CB 41.53 1 41.60 1 
ILE 255 HB 1.23 1 1.23 1 
ILE 255 CG1 28.34 1 28.34 1 
ILE 255 HG12/HG13 1.05/0.59 2 1.05/0.58 2 
ILE 255 CG2 17.94 1 18.18 1 
ILE 255 HG2 0.23 1 0.22 1 
ILE 255 CD1 14.23 1 14.22 1 
ILE 255 HD1 -0.13 1 -0.13 1 
ILE 255 C 173.90 1 
  GLU 256 N 125.76 1 125.75 1 
GLU 256 HN 8.78 1 8.83 1 
GLU 256 CA 54.54 1 54.55 1 
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GLU 256 HA 5.04 1 5.03 1 
GLU 256 CB 32.76 1 32.54 1 
GLU 256 HB2/HB3 2.17/1.78 2 2.17/1.77 2 
GLU 256 CG 36.57 1 36.55 1 
GLU 256 HG2/HG3 2.28/2.16 2 2.23/2.16 2 
GLU 256 C 175.96 1 
  
TYR 257 N 125.34 1 125.57 1 
TYR 257 HN 8.84 1 8.83 1 
TYR 257 CA 59.10 1 59.19 1 
TYR 257 HA 4.95 1 4.85 1 
TYR 257 CB 41.41 1 41.10 1 
TYR 257 HB2/HB3 2.77/3.58 2 2.74/3.56 2 
TYR 257 CD1/CD2 133.27 3 133.49 3 
TYR 257 HD1/HD2 6.96 3 6.96 3 
TYR 257 CE1/CE2 117.73 3 117.59 3 
TYR 257 HE1/HE2 6.67 3 6.66 3 
TYR 257 HH 8.80 1 8.77 1 
TYR 257 C 176.01 1 
  GLU 258 N 119.59 1 119.56 1 
GLU 258 HN 8.27 1 8.29 1 
GLU 258 CA 59.80 1 59.97 1 
GLU 258 HA 4.11 1 4.08 1 
GLU 258 CB 30.48 1 30.37 1 
GLU 258 HB2/HB3 2.22/1.97 2 2.20/1.95 2 
GLU 258 CG 36.90 1 36.92 1 
GLU 258 HG2/HG3 2.24/2.14 2 2.21/2.12 2 
GLU 258 C 176.91 1 
  LYS 259 N 116.19 1 116.15 1 
LYS 259 HN 8.76 1 8.80 1 
LYS 259 CA 54.57 1 54.34 1 
LYS 259 HA 4.74 1 4.73 1 
LYS 259 CB 35.02 1 34.84 1 
LYS 259 HB2/HB3 2.02/1.90 2 2.00/1.89 2 
LYS 259 CG 25.12 1 25.02 1 
LYS 259 HG2/HG3 1.58/1.49 2 1.58/1.48 2 
LYS 259 CD 29.25 1 29.17 1 
LYS 259 HD2/HD3 1.76 2 1.76 2 
LYS 259 CE 42.29 1 42.02 1 
LYS 259 HE2/HE3 3.05 2 3.04 2 
ALA 260 CA 55.21 1 55.02 1 
ALA 260 HA 3.94 1 3.91 1 
ALA 260 CB 18.52 1 18.29 1 
ALA 260 HB 1.44 1 1.42 1 
GLN 261 CA 58.65 1 58.57 1 
GLN 261 CB 28.26 1 
  GLN 261 C 177.18 1 
  SER 262 N 112.33 1 112.38 1 
SER 262 HN 6.86 1 6.83 1 
SER 262 CA 61.95 1 62.02 1 
SER 262 HA 4.01 1 4.00 1 
SER 262 CB 63.11 1 63.01 1 
SER 262 HB2/HB3 3.48/2.78 2 3.48/2.86 2 
SER 262 C 174.15 1 
  SER 263 N 113.62 1 113.58 1 
SER 263 HN 6.93 1 6.88 1 
SER 263 CA 61.17 1 60.96 1 
SER 263 HA 3.72 1 3.68 1 
SER 263 CB 62.88 1 62.63 1 
SER 263 HB2/HB3 3.84/3.74 2 3.81/3.76 2 
SER 263 C 175.48 1 
  GLN 264 N 121.16 1 121.53 1 
GLN 264 HN 7.31 1 7.40 1 
GLN 264 CA 58.67 1 58.62 1 
GLN 264 HA 3.94 1 3.93 1 
GLN 264 CB 28.32 1 28.26 1 
GLN 264 HB2/HB3 2.09 2 2.09 2 
GLN 264 CG 33.73 1 33.70 1 
GLN 264 HG2/HG3 2.38 2 2.36 2 
GLN 264 C 171.68 
   ASP 265 N 121.20 1 121.48 1 
ASP 265 HN 8.20 1 8.32 1 
ASP 265 CA 57.04 1 57.17 1 
ASP 265 HA 4.26 1 4.24 1 
ASP 265 CB 40.31 1 40.48 1 
ASP 265 HB2/HB3 2.75/2.72 2 2.74/2.72 2 
ASP 265 C 178.07 1 
  ALA 266 N 122.41 1 122.67 1 
ALA 266 HN 7.94 1 7.92 1 
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ALA 266 CA 55.00 1 55.10 1 
ALA 266 HA 2.34 1 2.40 1 
ALA 266 CB 19.70 1 19.26 1 
ALA 266 HB 1.34 1 1.25 1 
ALA 266 C 179.51 1 
  VAL 267 N 116.40 1 116.66 1 
VAL 267 HN 7.55 1 7.71 1 
VAL 267 CA 66.44 1 66.14 1 
VAL 267 HA 3.44 1 3.47 1 
VAL 267 CB 31.59 1 31.50 1 
VAL 267 HB 2.06 1 2.06 1 
VAL 267 CG1/CG2 21.88/23.41 2 21.82/23.58 2 
VAL 267 HG1/HG2 0.97/1.01 2 0.96/0.99 2 
VAL 267 C 177.72 1 
  SER 268 N 112.11 1 112.13 1 
SER 268 HN 7.65 1 7.74 1 
SER 268 CA 61.03 1 60.75 1 
SER 268 HA 4.20 1 4.21 1 
SER 268 CB 63.47 1 63.55 1 
SER 268 HB2/HB3 3.94 2 3.95/3.93 2 
SER 268 C 176.28 1 
  SER 269 N 112.86 1 112.55 1 
SER 269 HN 7.50 1 7.36 1 
SER 269 CA 60.98 1 60.48 1 
SER 269 HA 4.58 1 4.57 1 
SER 269 CB 65.21 1 65.61 1 
SER 269 HB2/HB3 3.75/3.49 2 3.70/3.52 2 
SER 269 C 175.61 1 
  MET 270 N 115.02 1 115.41 1 
MET 270 HN 7.85 1 7.75 1 
MET 270 CA 54.05 1 54.34 1 
MET 270 HA 4.88 1 4.94 1 
MET 270 CB 32.03 1 31.63 1 
MET 270 HB2/HB3 1.85/1.98 2 1.94/2.07 2 
MET 270 CG 33.48 1 33.81 1 
MET 270 HG2/HG3 1.64/1.86 2 1.61/1.96 2 
MET 270 CE 16.05 1 15.35 1 
MET 270 HE 0.60 1 0.19 1 
MET 270 C 176.76 1 
  ASN 271 N 117.81 1 118.36 1 
ASN 271 HN 7.50 1 7.83 1 
ASN 271 CA 56.75 1 57.06 1 
ASN 271 HA 4.44 1 4.46 1 
ASN 271 CB 39.08 1 39.28 1 
ASN 271 HB2/HB3 2.86/2.97 2 2.83/2.91 2 
ASN 271 ND2 113.21 1 113.40 1 
ASN 271 HD21/HD22 7.84/6.43 2 7.89/6.54 2 
ASN 271 C 175.90 1 
  
LEU 272 N 123.66 1 123.40 1 
LEU 272 HN 9.17 1 9.23 1 
LEU 272 CA 57.24 1 57.16 1 
LEU 272 HA 3.90 1 3.88 1 
LEU 272 CB 38.48 1 38.40 1 
LEU 272 HB2/HB3 1.54/2.03 2 1.54/2.03 2 
LEU 272 CG 27.15 1 27.11 1 
LEU 272 HG 1.51 1 1.52 1 
LEU 272 CD1/CD2 24.94/22.23 2 24.98/22.18 2 
LEU 272 HD1/HD2 0.81/0.71 2 0.80/0.70 2 
LEU 272 C 174.43 1 
  PHE 273 N 121.19 1 120.99 1 
PHE 273 HN 7.71 1 7.59 1 
PHE 273 CA 58.71 1 58.72 1 
PHE 273 HA 4.36 1 4.29 1 
PHE 273 CB 41.71 1 41.47 1 
PHE 273 HB2/HB3 3.16/3.01 2 3.31/2.97 2 
PHE 273 CD1/CD2 132.34 3 132.84 3 
PHE 273 HD1/HD2 7.11 3 7.17 3 
PHE 273 CE1/CE2 130.98 3 130.29 3 
PHE 273 HE1/HE2 7.26 3 6.92 3 
PHE 273 C 175.06 1 
  ASP 274 N 126.85 1 127.06 1 
ASP 274 HN 7.73 1 7.91 1 
ASP 274 CA 53.60 1 53.70 1 
ASP 274 HA 4.34 1 4.31 1 
ASP 274 CB 40.71 1 40.72 1 
ASP 274 HB2/HB3 2.10/2.45 2 2.21/2.46 2 
ASP 274 C 173.99 1 
  LEU 275 N 128.64 1 128.83 1 
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LEU 275 HN 8.35 1 8.49 1 
LEU 275 CA 53.91 1 53.58 1 
LEU 275 HA 4.71 1 4.77 1 
LEU 275 CB 44.47 1 43.88 1 
LEU 275 HB2/HB3 1.46/2.01 2 1.46/2.09 2 
LEU 275 CG 27.64 1 27.54 1 
LEU 275 HG 1.57 1 1.58 1 
LEU 275 CD1/CD2 24.02/27.33 2 24.38/27.14 2 
LEU 275 HD1/HD2 1.09/0.98 2 1.04/0.97 2 
LEU 275 C 176.49 1 
  GLY 276 N 114.43 1 114.25 1 
GLY 276 HN 8.85 1 9.06 1 
GLY 276 CA 46.44 1 46.37 1 
GLY 276 HA2/HA3 3.66 2 3.67/3.62 2 
GLY 276 C 174.29 1 
  GLY 277 N 106.30 1 106.93 1 
GLY 277 HN 8.37 1 8.46 1 
GLY 277 CA 45.07 1 45.01 1 
GLY 277 HA2/HA3 3.60/4.07 2 3.57/4.06 2 
GLY 277 C 174.04 1 
  GLN 278 N 117.95 1 117.60 1 
GLN 278 HN 7.21 1 7.11 1 
GLN 278 CA 53.94 1 53.74 1 
GLN 278 HA 4.38 1 4.33 1 
GLN 278 CB 32.17 1 31.81 1 
GLN 278 HB2/HB3 1.99/2.13 2 1.94/2.13 2 
GLN 278 CG 34.48 1 34.25 1 
GLN 278 HG2/HG3 2.28/2.37 2 2.25/2.33 2 
GLN 278 NE2 109.67 1 109.78 1 
GLN 278 HE21/HE22 6.92/6.79 2 6.91/6.73 2 
GLN 278 C 173.13 1 
  
TYR 279 N 120.05 1 120.84 1 
TYR 279 HN 8.15 1 8.24 1 
TYR 279 CA 56.60 1 55.97 1 
TYR 279 HA 4.78 1 4.81 1 
TYR 279 CB 38.12 1 38.06 1 
TYR 279 HB2/HB3 2.56/2.74 2 2.54/2.73 2 
TYR 279 CD1/CD2 132.81 3 132.72 3 
TYR 279 HD1/HD2 6.99 3 6.98 3 
TYR 279 CE1/CE2 118.42 3 118.26 3 
TYR 279 HE1/HE2 6.77 3 6.76 3 
TYR 279 C 175.87 1 
  
LEU 280 N 123.80 1 123.46 1 
LEU 280 HN 9.16 1 9.24 1 
LEU 280 CA 55.61 1 55.32 1 
LEU 280 HA 4.46 1 4.47 1 
LEU 280 CB 43.59 1 43.52 1 
LEU 280 HB2/HB3 1.37/2.31 2 1.35/2.26 2 
LEU 280 CG 26.61 1 26.64 1 
LEU 280 HG 2.24 1 2.25 1 
LEU 280 CD1/CD2 26.85/23.25 2 26.89/23.30 2 
LEU 280 HD1/HD2 1.06/0.87 2 1.04/0.87 2 
LEU 280 C 177.27 1 
  ARG 281 N 119.40 1 119.43 1 
ARG 281 HN 7.76 1 7.76 1 
ARG 281 CA 52.83 1 52.62 1 
ARG 281 HA 5.25 1 5.27 1 
ARG 281 CB 31.42 1 31.42 1 
ARG 281 HB2/HB3 1.76 2 1.74 2 
ARG 281 CG 27.13 1 27.26 1 
ARG 281 HG2/HG3 1.54/1.02 2 1.53/0.98 2 
ARG 281 CD 42.40 1 42.22 1 
ARG 281 HD2/HD3 3.18/3.12 2 3.16/3.11 2 
ARG 281 C 174.71 1 
  VAL 282 N 122.11 1 121.52 1 
VAL 282 HN 8.76 1 8.68 1 
VAL 282 CA 60.17 1 59.98 1 
VAL 282 HA 5.39 1 5.37 1 
VAL 282 CB 36.16 1 36.16 1 
VAL 282 HB 1.81 1 1.78 1 
VAL 282 CG1/CG2 23.07/23.46 2 22.97 2 
VAL 282 HG1/HG2 1.01/1.04 2 0.99 2 
VAL 282 C 174.41 1 
  GLY 283 N 110.74 1 110.40 1 
GLY 283 HN 9.05 1 9.02 1 
GLY 283 CA 45.09 1 45.03 1 
GLY 283 HA2/HA3 4.60/4.03 2 4.57/4.03 2 
GLY 283 C 171.89 1 
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Residue 
name 
Residue 
number Atom name 
Chemical 
shift [ppm] Ambiguity 
Chemical 
shift [ppm] Ambiguity 
FIR RRM1-RRM2 free FIR RRM1-RRM2 bound 
LYS 284 N 119.20 1 119.29 1 
LYS 284 HN 8.60 1 8.60 1 
LYS 284 CA 57.01 1 56.94 1 
LYS 284 HA 4.44 1 4.41 1 
LYS 284 CB 33.19 1 33.24 1 
LYS 284 HB2/HB3 1.85/2.00 2 1.83/1.98 2 
LYS 284 CG 25.32 1 25.26 1 
LYS 284 HG2/HG3 1.54 2 1.54 2 
LYS 284 CD 29.53 1 29.41 1 
LYS 284 HD2/HD3 1.74 2 1.73 2 
LYS 284 CE 42.16 1 42.03 1 
LYS 284 HE2/HE3 3.00 2 2.99 2 
LYS 284 C 176.34 1 
  
ALA 285 N 121.04 1 120.97 1 
ALA 285 HN 7.76 1 7.71 1 
ALA 285 CA 52.56 1 52.41 1 
ALA 285 HA 4.75 1 4.75 1 
ALA 285 CB 19.69 1 19.53 1 
ALA 285 HB 1.53 1 1.52 1 
ALA 285 C 178.18 1 
  VAL 286 N 114.62 1 114.72 1 
VAL 286 HN 9.84 1 9.85 1 
VAL 286 CA 60.76 1 60.41 1 
VAL 286 HA 4.52 1 4.50 1 
VAL 286 CB 31.94 1 31.78 1 
VAL 286 HB 2.38 1 2.36 1 
VAL 286 CG1/CG2 21.59/19.06 2 21.42/19.07 2 
VAL 286 HG1/HG2 0.79/0.56 2 0.78/0.55 2 
VAL 286 C 173.13 1 
  THR 287 N 108.36 1 108.29 1 
THR 287 HN 7.24 1 7.22 1 
THR 287 CA 58.08 1 57.87 1 
THR 287 HA 4.67 1 4.65 1 
THR 287 CB 70.25 1 70.01 1 
THR 287 HB 4.21 1 4.20 1 
THR 287 CG2 23.57 1 23.04 1 
THR 287 HG2 1.09 1 1.08 1 
PRO 288 CA 61.54 1 61.50 1 
PRO 288 HA 4.36 1 4.34 1 
PRO 288 CB 30.43 1 30.27 1 
PRO 288 HB2/HB3 2.00/1.88 2 2.06/1.87 2 
PRO 288 CG 26.18 1 26.13 1 
PRO 288 HG2/HG3 2.32/1.76 2 2.31/1.75 2 
PRO 288 CD 50.18 1 50.20 1 
PRO 288 HD2/HD3 3.54/3.93 2 3.53/3.92 2 
PRO 291 CA 63.71 1 63.63 1 
LEU 292 N 120.02 1 120.10 1 
LEU 292 HN 8.18 1 8.17 1 
LEU 292 CA 55.00 1 
  
LEU 292 CB 41.91 1 
  
LEU 293 N 121.89 1 121.69 1 
LEU 293 HN 7.87 1 7.85 1 
LEU 293 CA 55.02 1 55.01 1 
LEU 293 CB 42.47 1 
  
THR 294 N 116.94 1 116.96 1 
THR 294 HN 7.95 1 7.95 1 
THR 294 CA 59.62 1 59.51 1 
THR 294 CB 69.83 1 
  PRO 295 CA 63.28 1 63.21 1 
PRO 295 CB 32.21 1 
  
ALA 296 N 125.00 1 124.97 1 
ALA 296 HN 8.32 1 8.30 1 
ALA 296 CA 52.63 1 52.54 1 
ALA 296 HA 4.37 1 4.42 1 
ALA 296 CB 19.38 1 19.41 1 
ALA 296 HB 1.40 1 1.46 1 
ALA 296 C 176.99 1 
  
THR 297 N 118.44 1 118.41 1 
THR 297 HN 7.64 1 7.66 1 
THR 297 CA 63.05 1 62.97 1 
THR 297 CB 70.90 1 
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Residue 
name 
Residue 
number Atom name 
Chemical 
shift [ppm] Ambiguity 
Chemical 
shift [ppm] Ambiguity 
FBP Nbox free FBP Nbox bound 
GLY 22 CA 43.42 1 
  
ALA 23 N 123.85 1 
  
ALA 23 HN 8.59 1 
  
ALA 23 CA 52.73 1 
  ALA 23 HA 4.37 1 
  ALA 23 CB 19.46 1 
  ALA 23 HB 1.39 1 
  
MET 24 N 119.74 1 
  
MET 24 HN 8.47 1 
  
MET 24 CA 55.65 1 55.59 1 
MET 24 HA 4.47 1 4.49 1 
MET 24 CB 32.92 1 32.56 1 
MET 24 HB2/HB3 2.06/1.99 2 2.07/2.00 2 
MET 24 CG 32.00 1 32.47 1 
MET 24 HG2/HG3 2.60/2.55 2 2.61/2.55 2 
MET 24 CE 
  
17.05 1 
MET 24 HE 
  
2.10 1 
GLY 25 N 109.93 1 
  GLY 25 HN 8.32 1 
  GLY 25 CA 45.36 1 45.35 1 
GLY 25 HA2/HA3 3.90 2 3.91 2 
TYR 26 N 120.22 1 
  TYR 26 HN 8.02 1 
  TYR 26 CA 57.93 1 58.07 1 
TYR 26 HA 4.59 1 4.59 1 
TYR 26 CB 39.00 1 38.65 1 
TYR 26 HB2/HB3 3.01/2.96 2 3.03 2 
TYR 26 HD1/HD2 
  
7.12 3 
TYR 26 HE1/HE2 
  
6.85 3 
VAL 27 N 122.41 1 
  VAL 27 HN 8.00 1 
  VAL 27 CA 62.29 1 62.78 1 
VAL 27 HA 4.04 1 3.99 1 
VAL 27 CB 33.01 1 32.70 1 
VAL 27 HB 2.00 1 2.02 1 
VAL 27 CG1/CG2 20.81 2 21.06 2 
VAL 27 HG1/HG2 0.88 2 0.89 2 
ASN 28 N 122.08 1 
  
ASN 28 HN 8.32 1 
  
ASN 28 CA 53.40 1 53.86 1 
ASN 28 HA 4.65 1 4.65 1 
ASN 28 CB 39.16 1 38.98 1 
ASN 28 HB2/HB3 2.83/2.77 2 2.90 2 
ASP 29 N 121.69 1 
  
ASP 29 HN 8.29 1 
  
ASP 29 CA 54.87 1 56.61 1 
ASP 29 HA 4.54 1 4.48 1 
ASP 29 CB 41.25 1 40.92 1 
ASP 29 HB2/HB3 2.64 2 2.75/2.67 2 
ALA 30 N 123.63 1 
  
ALA 30 HN 8.19 1 
  
ALA 30 CA 53.68 1 54.77 1 
ALA 30 HA 4.17 1 4.10 1 
ALA 30 CB 18.79 1 18.79 1 
ALA 30 HB 1.27 1 1.20 1 
PHE 31 N 118.11 1 
  
PHE 31 HN 8.08 1 
  
PHE 31 CA 58.46 1 61.04 1 
PHE 31 HA 4.54 1 4.24 1 
PHE 31 CB 39.04 1 39.57 1 
PHE 31 HB2/HB3 3.22/3.08 2 3.22 2 
PHE 31 HD1/HD2 
  
7.22 3 
PHE 31 HE1/HE2 
  
7.52 3 
LYS 32 N 118.11 1 
  LYS 32 HN 7.95 1 
  LYS 32 CA 57.83 1 59.78 1 
LYS 32 HA 4.12 1 3.84 1 
LYS 32 CB 32.85 1 32.15 1 
LYS 32 HB2/HB3 1.81 2 1.92 1 
LYS 32 CG 24.78 1 25.43 1 
LYS 32 HG2/HG3 1.44/1.38 2 1.47/1.67 2 
LYS 32 CD 29.19 1 29.28 1 
LYS 32 HD2/HD3 1.68 2 1.73 2 
LYS 32 CE 
  
41.88 1 
LYS 32 HE2/HE3 3.00 2 3.01 2 
ASP 33 N 120.12 1 
  ASP 33 HN 8.17 1 
  ASP 33 CA 55.32 1 56.74 1 
ASP 33 HA 4.52 1 4.47 1 
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shift [ppm] Ambiguity 
Chemical 
shift [ppm] Ambiguity 
FBP Nbox free FBP Nbox bound 
ASP 33 CB 41.28 1 41.13 1 
ASP 33 HB2/HB3 2.70 2 2.79/2.76 2 
ALA 34 N 123.28 1 
  
ALA 34 HN 8.09 1 
  ALA 34 CA 54.35 1 54.53 1 
ALA 34 HA 4.14 1 3.92 1 
ALA 34 CB 18.75 1 
  
ALA 34 HB 1.45 1 1.30 1 
LEU 35 N 119.46 1 
  
LEU 35 HN 8.04 1 
  LEU 35 CA 56.69 1 58.45 1 
LEU 35 HA 4.20 1 3.95 1 
LEU 35 CB 41.90 1 42.19 1 
LEU 35 HB2/HB3 1.73/1.60 2 1.71/1.47 2 
LEU 35 CG 27.08 1 26.46 1 
LEU 35 HG 1.62 1 1.34 1 
LEU 35 CD1/CD2 24.57/23.68 2 25.45/24.19 2 
LEU 35 HD1/HD2 0.90/0.86 2 0.83/0.78 2 
GLN 36 N 119.12 1 
  GLN 36 HN 8.04 1 
  GLN 36 CA 57.39 1 59.04 1 
GLN 36 HA 4.16 1 4.07 1 
GLN 36 CB 28.70 1 28.02 1 
GLN 36 HB2/HB3 2.13/2.10 2 2.27/2.29 2 
GLN 36 CG 33.87 1 33.63 1 
GLN 36 HG2/HG3 2.43/2.38 2 2.49/2.53 2 
ARG 37 N 120.16 1 
  
ARG 37 HN 8.08 1 
  ARG 37 CA 57.61 1 
  ARG 37 HA 4.17 1 
  ARG 37 CB 30.47 1 
  
ARG 37 HB2/HB3 1.83 2 1.89 2 
ARG 37 CG 27.43 1 
  
ARG 37 HG2/HG3 1.65 2 1.65/1.88 2 
ARG 37 CD 43.42 1 43.57 1 
ARG 37 HD2/HD3 3.19 2 2.95/3.47 2 
ALA 38 N 122.58 1 
  
ALA 38 HN 8.00 1 
  
ALA 38 CA 53.53 1 55.26 1 
ALA 38 HA 4.24 1 3.97 1 
ALA 38 CB 18.78 1 
  ALA 38 HB 1.45 1 1.62 1 
ARG 39 N 118.79 1 
  
ARG 39 HN 8.02 1 
  
ARG 39 CA 57.10 1 59.09 1 
ARG 39 HA 4.23 1 4.06 1 
ARG 39 CB 30.63 1 29.82 1 
ARG 39 HB2/HB3 1.88/1.83 2 2.00/1.94 2 
ARG 39 CG 27.24 1 27.86 1 
ARG 39 HG2/HG3 1.66 2 1.91/1.69 2 
ARG 39 CD 43.54 1 43.47 1 
ARG 39 HD2/HD3 3.20 2 3.19 2 
GLN 40 N 120.57 1 
  GLN 40 HN 8.14 1 
  GLN 40 CA 56.66 1 58.50 1 
GLN 40 HA 4.29 1 4.14 1 
GLN 40 CB 29.22 1 28.42 1 
GLN 40 HB2/HB3 2.11/2.06 2 2.21/2.26 2 
GLN 40 CG 33.92 1 34.00 1 
GLN 40 HG2/HG3 2.41/2.37 2 2.44/2.55 2 
ILE 41 N 121.18 1 
  
ILE 41 HN 8.04 1 
  
ILE 41 CA 61.87 1 63.73 1 
ILE 41 HA 4.09 1 3.87 1 
ILE 41 CB 38.73 1 37.99 1 
ILE 41 HB 1.88 1 1.98 1 
ILE 41 CG1 27.45 1 28.69 1 
ILE 41 HG12/HG13 1.50/1.20 2 1.70/1.37 2 
ILE 41 CG2 17.42 1 18.65 1 
ILE 41 HG2 0.92 1 0.96 1 
ILE 41 CD1 12.89 1 13.56 1 
ILE 41 HD1 0.86 1 0.98 1 
ALA 42 N 126.53 1 
  
ALA 42 HN 8.14 1 
  
ALA 42 CA 52.82 1 53.97 1 
ALA 42 HA 4.29 1 4.17 1 
ALA 42 CB 19.16 1 18.40 1 
ALA 42 HB 1.40 1 1.48 1 
ALA 43 N 122.60 1 
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ALA 43 HN 8.04 1 
  
ALA 43 CA 52.74 1 53.98 1 
ALA 43 HA 4.28 1 4.17 1 
ALA 43 CB 19.27 1 18.44 1 
ALA 43 HB 1.40 1 1.48 1 
LYS 44 N 120.19 1 
  LYS 44 HN 8.10 1 
  
LYS 44 CA 56.39 1 57.47 1 
LYS 44 HA 4.32 1 4.23 1 
LYS 44 CB 32.93 1 32.45 1 
LYS 44 HB2/HB3 1.84/1.77 2 1.95 1 
LYS 44 CG 24.75 1 24.85 1 
LYS 44 HG2/HG3 1.45/1.39 2 1.51/1.55 2 
LYS 44 CD 29.17 1 29.34 1 
LYS 44 HD2/HD3 1.68 2 1.73 2 
LYS 44 CE 
  
41.81 1 
LYS 44 HE2/HE3 3.00 2 3.00 2 
ILE 45 N 122.14 1 
  ILE 45 HN 8.15 1 
  
ILE 45 CA 61.40 1 62.18 1 
ILE 45 HA 4.19 1 4.10 1 
ILE 45 CB 38.76 1 38.18 1 
ILE 45 HB 1.88 1 1.90 1 
ILE 45 CG1 27.39 1 27.51 1 
ILE 45 HG12/HG13 1.50/1.20 2 1.46/1.09 2 
ILE 45 CG2 17.42 1 17.38 1 
ILE 45 HG2 0.92 1 0.79 1 
ILE 45 CD1 12.87 1 
  ILE 45 HD1 0.86 1 
  GLY 46 N 112.86 1 
  GLY 46 HN 8.46 1 
  GLY 46 CA 45.43 1 
  GLY 46 HA2/HA3 3.96/4.05 2 
  GLY 47 N 108.74 1 
  GLY 47 HN 8.22 1 
  GLY 47 CA 45.43 1 
  GLY 47 HA2/HA3 3.98 2 
  
ASP 48 N 120.40 1 
  
ASP 48 HN 8.29 1 
  
ASP 48 CA 54.42 1 54.27 1 
ASP 48 HA 4.62 1 4.63 1 
ASP 48 CB 41.48 1 41.54 1 
ASP 48 HB2/HB3 2.65/2.69 2 2.63/2.70 2 
ALA 49 N 124.29 1 
  
ALA 49 HN 8.31 1 
  
ALA 49 CA 52.93 1 52.68 1 
ALA 49 HA 4.34 1 4.35 1 
ALA 49 CB 19.26 1 19.37 1 
ALA 49 HB 1.42 1 1.41 1 
GLY 50 N 107.80 1 
  GLY 50 HN 8.39 1 
  GLY 50 CA 45.58 1 45.40 1 
GLY 50 HA2/HA3 4.03 2 4.01 2 
THR 51 N 112.90 1 
  THR 51 HN 7.98 1 
  
THR 51 CA 61.73 1 61.60 1 
THR 51 HA 4.44 1 4.45 1 
THR 51 CB 70.18 1 70.07 1 
THR 51 HB 4.32 1 4.32 1 
THR 51 CG2 21.39 1 21.49 1 
THR 51 HG2 1.20 1 1.21 1 
SER 52 N 123.42 1 
  SER 52 HN 8.00 1 
  SER 52 CA 60.19 1 60.11 1 
SER 52 HA 4.31 1 4.31 1 
SER 52 CB 65.06 1 64.83 1 
SER 52 HB2/HB3 3.87 2 3.87 2 
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Appendix VI Inter-molecular restraints used during structure calculations of FIR 
RRM1-RRM2 – FBP Nbox complex. 
 
No. FIR RRM1-RRM2 
atom(s) 
FBP Nbox peptide atom(s) Upper bound [Å] 
1 F232 HA A30 QB 3.5 
2 V228 QG1 L35 QQD 3.5 
3 A231 QB A30 QB 5.0 
4 A231 QB D33 HB2 3.5 
5 A231 QB D33 HB3 3.5 
6 D224 HB2 I41 QG2/I41 QD1 5.0 
7 D224 HB3 I41 QG2/I41 QD1 5.0 
8 V228 QG1 I41 QG2/I41 QD1 2.8 
9 V228 QG2 I41 QG2/I41 QD1 5.0 
10 L220 QD1 I41 QG2/I41 QD1 3.5 
11 L220 QD2 I41 QG2/I41 QD1 3.5 
12 L275 QD1 I41 QG2/I41 QD1 2.8 
13 S269 HB2 V27 QQG 5.0 
14 S269 HB3 V27 QQG 5.0 
15 S269 HA V27 QQG 5.0 
16 S227 HB2 L35 QQD 5.0 
17 S227 HB3 L35 QQD 5.0 
18 D265 HA V27 QQG 5.0 
19 D265 HB2 V27 QQG 5.0 
20 D265 HB3 V27 QQG 5.0 
21 L220 QD1 R39 HG2 5.0 
22 L220 QD1 R39 HG3 5.0 
23 A231 QB R37 HD2 6.0 
24 A231 QB R37 HD3 6.0 
25 S269 HB2 F31 QD 5.0 
26 S269 HB3 F31 QD 5.0 
27 S227 HB2 I41 QG2/I41 QD1 5.0 
28 S227 HB3 I41 QG2/I41 QD1 5.0 
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No. FIR RRM1-RRM2 
atom(s) 
FBP Nbox peptide atom(s) Upper bound [Å] 
29 L275 QD2 I41 QG2/I41 QD1 3.5 
30 V228 QG1 A34 HA/L35 HA/A38 HA 2.8 
31 V228 QG1 R37 HB2/ R37 HB3/I41 HB 3.5 
32 V228 QG1 A38 QB 3.5 
33 V228 QG1 I41 HG12 5.0 
34 V228 QG2 A34 HA/L35 HA 5.0 
35 V228 QG2 R37 HB2/ R37 HB3/I41 HB 5.0 
36 V228 QG2 A38 QB 3.5 
37 V228 QG2 A34 QB 5.0 
38 A231 QB A30 HA/A34 HA 2.8 
39 A231 QB F31 QB 6.0 
40 A231 QB R37 HB2 5.0 
41 A231 QB R37 HB3 5.0 
42 A231 QB A34 QB 5.0 
43 F232 HA A34 QB 5.0 
44 L275 QD1 I41 HB 5.0 
45 L275 QD1 A38 QB 3.5 
46 F232 QD A30 QB 5.0 
47 F232 QE A30 QB 5.0 
48 F273 QE I41 QG2 5.0 
49 F273 QE I41 QD1 5.0 
50 F273 QD I41 QD1 5.0 
51 F232 QE A34 HA 3.5 
52 F273 QD A38 HA 5.0 
53 F273 QE A38 HA 3.5 
54 F273 QD L35 HG 5.0 
55 F232 QD V27 QQG 5.0 
56 F232 QE V27 QQG 5.0 
57 F232 QD F31 HA 2.8 
58 V228 QG1 F31 QD 3.5 
59 V228 QG1 F31 QE 3.5 
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No. FIR RRM1-RRM2 
atom(s) 
FBP Nbox peptide atom(s) Upper bound [Å] 
60 L220 QD1 K44 QE 5.0 
61 D219 HB2 I45 HA 5.0 
62 D219 HB3 I45 HA 5.0 
63 L220 QD1 I41 HB 5.0 
64 L220 QD1 A38 QB 5.0 
65 V228 HA R37 HB2/R37 HB3 5.0 
66 A231 QB D33 HA 5.0 
67 A231 QB R37 QG 5.0 
68 M270 QE A38 QB 6.0 
69 M270 QE A34 QB 6.0 
70 L275 QD1 A38 HA/L35 HA/R39 HA 3.5 
71 L275 QD1 A42 QB 5.0 
72 D224 HA I41 QG2/I41 QD1 3.5 
 
